Characterization of renal CD133+ cells and their therapeutic efficacy in a model of acute kidney injury by Santeramo, I
 
 
 
 
CHARACTERIZATION OF RENAL CD133+ 
CELLS AND THEIR THERAPEUTIC EFFICACY IN A 
MODEL OF ACUTE KIDNEY INJURY 
 
 
 
 
 
 
 
Thesis submitted in accordance with the requirements of the University of 
Liverpool for the degree of Doctor in Philosophy 
 
By 
 
 
Ilaria Santeramo 
September 2016 
 
 
 
  
i 
 
DECLARATION 
I hereby declare that except where specific reference is made to the work of 
others, the contents of this dissertation are original and have not been submitted in 
whole or in part for consideration for any other degree or qualification in this, or any 
other university. This dissertation is my own work and contains nothing which is the 
outcome of work done in collaboration with others except as specified in the text. This 
dissertation contains fewer than 65,000 words including bibliography, footnotes, 
tables and equations and has fewer than 70 figures. 
 
 
Ilaria Santeramo 
September 2016 
 
  
ii 
 
iii 
 
ABSTRACT 
Renal ‘progenitor’ cells expressing CD133 have been proposed as cellular 
therapeutics for treating patients with kidney disease. In the literature, CD133+ cells 
isolated from adult kidneys showed the expression of nephron progenitor markers 
(Pax2), and broad differentiation plasticity, being able to differentiate towards 
epithelial cells and podocytes. Most importantly, when injected into preclinical models 
of kidney injury, CD133+ cells integrated into damaged renal tissue and improved renal 
health. Nevertheless, the evidence for CD133 being a bona fide renal progenitor 
marker is conflicting.  
In this study, five renal biopsies belonging to children (from 6 months to 10 years 
old) were used. The localization of CD133 was consistent with previous studies, as the 
expression of CD133 was demonstrated on the cells of the Bowman’s capsule and in 
scattered tubular cells. From each sample, a bulk renal population was isolated and 
was initially characterized for the presence of the CD133 marker. Once placed in 
culture, most of the renal cells started expressing CD133. A further phenotypical 
characterization revealed that the vast majority of the cells expressed epithelial 
(EpCam, E-Cadherin, CD24), and some mesenchymal (CD73, CD44) markers. Also, the 
CD133+ population appeared heterogeneous for the expression of other markers. 
Most notably, CD13, a marker of fully differentiated tubular cel ls, was found to be 
significantly expressed in part of the CD133+ cells, suggesting that either fully 
differentiated cells started expressing CD13 de novo, or the CD133+ were committed 
towards a tubular fate. 
The bulk population was sorted by FACS into CD133+ and CD133- sub-populations 
which were compared in additional experiments to explore the progenitor-like 
features of the CD133+ cells.  
iv 
 
First, the ability of both CD133+ and CD133- sub-populations to differentiate 
towards podocytes in vitro was investigated. Both sub-populations were found to 
express the podocyte markers, nephrin and podocin, to a similar extent following 
stimulation with retinoic acid. However, the assay did not prove to be consistent and it 
was not used any further.  
Secondly, the potential of both CD133+ and CD133- sub-populations to integrate 
into ex vivo reaggregated mouse kidney rudiments was determined. Surprisingly, the 
majority of both cell types died in the chimeric rudiments within two days in culture. 
Neither the surviving CD133+ nor the CD133- cells showed any propensity to integrate 
into developing renal structures. Unexpectedly, the CD133+ cells were found to clump 
on top of the rudiment and had a negative impact on the developing rudiment, 
whereas the CD133- cells did not. Alongside with the test of the human cells in the 
chimeric rudiments, the assay itself was modified to suit the imaging of the rudiments 
in a Light-sheet fluorescent microscope (LSFM). 3D embryonic renal organoids were 
efficiently produced and the development of their structures could be successfully 
monitored through the LSFM in proof-of-concept experiments. 
The final aim of this work was to assess the therapeutic efficacy of the CD133+ and 
CD133- sub-populations in a rat model of cisplatin-induced acute kidney injury. The 
renal function was monitored using a non-invasive transcutaneous device that 
measures the half-life of an exogenously administered renal marker, FITC-Sinistrin, 
alongside to the measurement of conventional biomarkers, serum creatinine, and 
urea. Following intravenous (IV) injection, both CD133+ and CD133- cells ameliorated 
renal function and preserved renal histology. The data suggest that the human cells 
passed through the lungs, and probably reached the kidneys. However, no cells were 
alive at the end of the study (14 days), but traces of PKH26 were retrieved in lungs 
and, to a lesser extent, in the kidneys, suggesting the possible involvement of 
paracrine mechanisms, possible through extracellular vesicles in the observed 
functional amelioration.  
Additional biodistribution studies showed that soon after the IV injection the 
human cells were identified in the lungs of the animals, but not in the kidneys. 
Phagocytic cells, identified through the marker CD68, were observed around the 
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human cells in the lungs as early as 1 hour after the injection. By 24 hours, clusters of 
CD68+ cells could be found, but not human cells. Therefore, the data suggest that the 
human cells die in the lungs and that the macrophages might play an active role in the  
disappearance.  
Taken together, this work shows that the expression of CD133 does not confer any 
advantage to the nephrogenic potential ex vivo or to the therapeutic efficacy in vivo. 
Moreover, since the cells were shown to be entrapped in the lungs, the renal repair is 
probably mediated by cell-derived factors, rather than by CD133+ cells homing to the 
kidneys and generating specialised renal cells. The role of macrophages in the 
resolution or regenerative mechanisms should be considered and further examined in 
future preclinical studies of cellular therapies for kidney diseases. 
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1 INTRODUCTION     
1.1 KIDNEY STRUCTURE AND MAJOR COMPONENTS 
The kidneys are highly complex organs designated for the maintenance of the 
homeostasis of ions and pH in the body. Moreover, the kidneys have the crucial role of 
eliminating small molecules, proteins, and toxins from the blood creating urine that 
will be excreted from the body. Both kidneys account for 0.5% of the total body mass 
and receive approximately 20% of the cardiac output (Hallgrímsson et al., 2003). 
The functional renal units are called nephrons (Figure 1.1). It has been estimated 
that an adult human kidney contains an average of 1 million nephrons (Puelles et al., 
2011). Each nephron is a complex tridimensional ensemble constituted by the renal 
corpuscle and a series of renal tubules. The renal tubule begins at the urinary pole of 
the Bowman’s capsule as the proximal convoluted tubule (PT cells), continues through 
a hairpin loop, the loop of Henle, and turns into a distal convoluted tubule (DT cells) 
before reaching the collecting duct (CD). The whole unit counts several types of cells, 
unique in their properties (Hallgrímsson et al., 2003).  
The renal corpuscle consists of the Bowman’s capsule, a parietal epithelial layer of 
cells surrounding the glomerulus that contains the capillary tuft. In the glomerulus, a 
high-volume, acellular, almost protein-free filtrate of the blood plasma is formed. The 
blood flows into the glomerulus through the afferent arterioles, is filtered through the 
glomerular filtration barrier (GFB) and drains through the efferent arteriole. The GFB is 
a complex structure based on the cross-talk of three crucial components: endothelial 
cells, podocytes, and the glomerular basement membrane (GBM) (Haraldsson et al., 
2008) (Figure 1.1).  
The glomerular endothelial cells are flattened and extensively fenestrated, 
without a diaphragm. These features allow a high permeability of water and small 
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solutes in the glomerulus. The fenestrae represent circa 20% of the endothelial 
surface and would be big enough (60nm) to let proteins such as albumin (3.6 nm) pass 
through. However, the endothelial cell is coated on its luminal side with an endothelial 
cell surface layer (ESL), made of negatively charged glycoproteins and 
glycosaminoglycans (GAGs), which accumulate within the fenestrae making them less 
narrow. Therefore, the endothelial cells represent the first layer of the high 
permselectivity of the glomerular wall, defined as the selective permeation of certain 
ionic species through the wall (Haraldsson et al., 2008; Jarad and Miner, 2009; Scott 
and Quaggin, 2015).  
The podocytes are visceral epithelial cells that face the primary urine in the 
Bowman’s space and embrace the capillary coils. They are characterized by a quite 
large and arborized cell body from which foot processes protrude, interdigitating 
cytoplasmic protrusions separated from each other by slit diaphragm (SD) 
(Brinkkoetter et al., 2013). Nephrin, podocin, and podocalyxin are instrumental in 
maintaining the structural integrity of the SD and participate in impeding the high-
molecular-weight plasma components to end up in the urine (Scott and Quaggin, 
2015). Podocytes participate in the secretion of proteins found in the GBM and ensure 
the survival of endothelial cells, secreting the vascular endothelial growth factor-A 
(VEGF-A) and angiopoietin-1 (Haraldsson et al., 2008).  
Both podocytes and endothelial cells secrete essential components of the GBM. 
The GBM is twice as thick as any other basement membrane in the body (Hallgrímsson 
et al., 2003). The GBM is a fibrous mix of IV collagen, laminin β2, entactin, together 
with glycoproteins and sulphated proteoglycans. Proteoglycans consist of protein 
cores with attached heparan sulfate and GAGs side chains, contributing to the 
negative charge of the basement membrane. The network of fibres alone, however, is 
not sufficient for the permselectivity of the glomerulus (Camici, 2005). 
In its entirety, the GFB prevents the passage of exogenous and endogenous 
macromolecules from the blood into the urine based on their size, shape and charge 
(Brinkkoetter et al., 2013). Water and small solutes (urea, glucose, amino acids, and 
mineral ions) can pass undisturbed through the GFB. However, circulating cells 
(erythrocytes) and high-molecular-weight plasma proteins and anionic 
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macromolecules, such as albumin are retained in the glomerular capillaries. Generally 
speaking, the more positive the molecular charge of the solute, the more it will 
penetrate through the GFB. In fact, in diseases where the GFB is compromised, the 
primary outcome is represented by the presence of bulk proteins in the urine, a 
condition called proteinuria or, when albumin is measured, albuminuria (Brinkkoetter 
et al., 2013). 
The glomerular filtration is determined by the equilibrium between the hydrostatic 
pressure (HP) that drives the fluids out of the capillary lumen, led by the blood 
pressure and the oncotic pressure (OP), exerted by colloids in the plasma, such as 
proteins, which pull fluids inside the capillaries. The net filtration pressure (NFP) is 
equal to the difference between HP and OP and it is optimal to filter 125 ml/min/1.73 
m2 of glomerular fluid from the glomerular capillaries into the Bowman’s capsule 
(glomerular filtration rate, GFR). Autoregulatory pathways are activated when one of 
the pressures above changes to maintain the GFR constant, mainly because 
reabsorption of water and solutes depends on how quickly the filtrate flows through 
the tubules (Hallgrímsson et al., 2003).  
The GFR highly depends on age, sex and body size as well as on the physiological 
status that might affect the nephrons (e.g. pregnancy, protein intake). The GFR is 
indirectly calculated through the clearance of a filtration marker in the plasma or 
urine. The ideal filtration marker would be freely filtered across the GBM, would not 
be bound by plasma proteins and would not be reabsorbed or secreted by the 
proximal tubule cells. Also, the marker should be physiologically inert (Stevens and 
Levey, 2005). Inulin, a 5200 Da protein, is an inert uncharged polymer of fructose and 
represents the best candidate. However, the methods available to measure urinary or 
plasma clearance of inulin are invasive for the patients, require a bolus administration 
of the marker and necessitate accurate sampling times. Moreover, inulin is challenging 
to handle and expensive, so it is not the best option for the clinical practice (Lopez-
Giacoman and Madero, 2015). Therefore, the GFR is estimated from prediction 
equations that exploit endogenous markers, such as creatinine and Cystatin C (Stevens 
and Levey, 2009). This topic will be further discussed on page 13. 
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Once in the Bowman’s capsule space, the filtrate drains to the urinary pole and 
enters the tubule. From the proximal tubular cells to the collecting ducts, there is a 
continuum of specialized cells with a unique range of ion exchangers, cotransporters 
and channels that will reabsorb all organic nutrients and water. Each cell type has 
different absorptive capabilities, with the PTC being the most active in reabsorption. 
The most abundant cation in the filtrate is the Na+. Proximal tubule cells reabsorb the 
Na+ from the luminal filtrate, alongside with water. The first level of transcellular 
absorption of Na+ occurrs actively through the Na+-K+ ATPase. This pump creates a 
concentration gradient that drives the Na+ entry through the apical membrane. 
Organic nutrients, such as glucose, amino acids, vitamins and most cations are then 
actively co-transported with the Na+. Water is reabsorbed by osmosis through 
aquaporins. Finally, negatively charged ions are passively reabsorbed coupled with the 
active gradient of Na+.  
Finally, the kidney is one of the master regulators of the arterial blood pressure, 
through the activation of the Renin-Angiotensin-Aldosterone System (RAAS). The 
cascade starts with the release of the enzyme Renin in the intravascular space by 
juxtaglomerular cells located close to the afferent arterioles. The secretion of renin is 
positively regulated by the decrease of blood pressure, and by the levels of sodium 
chloride to the thick ascending limb of the loop of Henle and by the activation of the 
sympathetic nervous system. Renin is the key enzyme that initiates the cascade 
formation of Angiotensin II (ANG II). ANG II is responsible for vasoconstriction, through 
the contraction of the mesangial cells and, therefore, for a reduction in the GFR. It also 
stimulates the reabsorption of water and NaCl in the proximal tubule cells, and the 
production of the hormone aldosterone in the adrenal glands which stimulate water 
and NaCl reabsorption in the distal tubule cells (Harrison-Bernard, 2009).  
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FIGURE 1.1 SCHEMATIC REPRESENTATION OF THE STRUCTURE OF THE KIDNEY, NEPHRON AND 
GLOMERULUS 
The kidney is made of thousands of functional units, the nephrons. Each nephron is 
composed of a series of convoluted tubuli and the glomerulus. Within the glomerulus, the 
blood gets filtered and the waste, toxins, and ions end up in the urine. Within the tubule, the 
urine gets concentrated, and relevant nutrients are picked up by tubular cells. Finally, the 
urine reach the collecting ducts that end up in the ureter. The image was adapted from "The 
Kidneys and Osmoregulatory Organs” Source: Boundless. “Kidney Structure.” Boundless 
Biology. Boundless, OpenStax College. 
1.1.1 RENAL DEVELOPMENT: AN OVERVIEW 
The mature mammalian kidney, the metanephros, originates from the 
intermediate mesoderm (IM). From the IM, the Wolffian duct (WD) gives rise to the 
ureteric bud (UB) and the metanephric mesenchyme (MM). The UB forms the 
collecting ducts, whereas the MM the nephrons. The two populations secrete 
reciprocal inductive signals so that the ureteric bud sprouts from the caudal portion of 
the Wolffian ducts into the metanephric mesenchyme (E10.5 – Figure 1.2 A) (Reidy 
and Rosenblum, 2009; Vize, 2003). In turn, the cells of the MM send signals to the UB 
to regulate its invasion and branching in the MM. A subset of the MM cells, the cap 
6 
 
mesenchyme, condensates around the tip of the ureteric bud (Figure 1.2B). Studies in 
mouse embryos have shown that this population expresses some transcription factors 
necessary for nephrogenesis (reviewed in (Vainio and Lin, 2002), including Six2, Pax2, 
and Wt1. Pax2 (paired box gene 2) is expressed by both the ureteric bud and early 
MM condensate. Wt1 (Wilms tumor gene 1) and Six2 (Sine Oculis Homeobox Homolog 
2) are required for nephron formation and prevent apoptosis in MM during growth. 
Notably, Six2 defines the cap mesenchyme as multipotent progenitor population. 
From E11.5, the ureteric bud starts to branch and the cap mesenchyme population 
undergoes a mesenchymal-to-epithelial transition to give rise to the nephron by 
forming renal vesicles (Figure 1.2C), comma-shaped bodies (Figure 1.2D) and S-shaped 
bodies (Figure 1.2E) and, ultimately, glomeruli (Figure 1.2F) (Rak-Raszewska et al., 
2015; Vainio and Lin, 2002; Vize, 2003). 
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FIGURE 1.2 SCHEMATIC REPRESENTATION OF THE RENAL DEVELOPMENT FROM E10.5 TO THE 
FORMATION OF THE NEPHRON 
Adapted from (Rak-Raszewska et al., 2015; Vainio and Lin, 2002). In the mouse, at E10.5, 
the outgrowth of the UB from the Wolffian duct is orchestrated by essential developmental 
genes, such as Osr1, Wt1, Pax2, and Sall1. As a result, there is an upregulation of the GDNF 
production in the MM. GDNF binds the receptor Ret and induces budding of the ureteric 
bud. (B) After the invasion into the MM, the UB branches following induction from several 
growth factors, one of which is GDNF. The MM condenses around the ureteric tip. Pax2 is 
expressed in both components, whereas the expression of Wt1, Six2 and Cited1 is exclusive 
for the MM. (C) From E11.5, the nephron forms through the sequential shaping of the 
condensed metanephric mesenchyme: (C) renal vesicles (RV), (D) Comma shaped bodies, 
(E) S-Shaped bodies, and, finally, (F) the glomerulus. 
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1.1.2 POSTNATAL DEVELOPMENT OF THE KIDNEY 
In an adult kidney, the number of nephrons is stable for the whole lifespan, and it 
is determined during the gestation period. Therefore, any episode happening during 
the early steps of development will have tremendous consequences for the individual. 
For example, preterm infants (born before the 37th week of gestation) born with a 
lower number of nephrons, have a higher risk of developing CKD in their life (Fanos et 
al., 2015). The functionality of the nephron is achieved by the 32nd gestational week 
with nearly 1 million nephrons, but it reaches the adult levels by two years of age 
(Sulemanji and Vakili, 2013). As opposed to rodents where nephrogenesis continues 
until the second week after birth, in humans, nephrogenesis ceases before the 36th 
week of gestation. At birth, the cortex is already mature. However, the glomeruli 
occupy a higher volume of the cortex in the first two months after birth (18%) 
compared to adulthood (8.6%). During the first years after birth, the nephron grows, 
and the tubule elongate. The dimensions of the kidney will grow during childhood and 
adolescence, reaching a size of about 12 cm in the adult, but the functionality and 
anatomically maturation is reached during the first year of age (Cukuranovic, 2005; 
Marchal et al., 1986). However, which cells contribute to the growth of the glomerulus 
or tubular elongation is not completely understood.  
1.2 ACUTE KIDNEY INJURY 
Acute kidney injury (AKI) is defined as a rapid decline in the GFR (Edelstein, 2008). 
It refers to a complex condition that encloses different clinical manifestations ranging 
from an increase in serum creatinine levels to renal failure. Several risk factors can 
play a role in the development of AKI, which in turn might lead to increased mortality. 
As an example, 30% of patients who undergo cardiac surgery are affected by 
postoperative AKI that increases their mortality risk after the surgery (Ricci et al., 
2008; Ricci et al., 2011).  
Before 2004, a clear consensus on the definition of AKI was missing, making direct 
comparisons between studies problematic. As a matter of fact, AKI has been reported 
to have an incidence between 1% and 25% of intensive care unit (ICU) patients and to 
have a mortality rate ranging from 15 to 80% (Chawla and Kimmel, 2012; Singbartl and 
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Kellum, 2012). The RIFLE criteria were therefore introduced to facilitate and uniform a 
clinical diagnosis of AKI. They provide a list of severity classes, namely Risk, Injury and 
Failure and, consequently, the possible outcomes, Loss, and ESRD. The assessment of 
those criteria is based on two parameters: change in blood creatinine levels and GFR 
from baseline and the urine output per kilogram of body weight in a set period (Ricci 
et al., 2011). The RIFLE criteria were applied to a cohort of critically ill patients, and 
the results revealed that the criteria are unambiguous and able to distinguish between 
functional (vasoconstriction) and structural (acute tubular necrosis) renal dysfunction 
(Van Biesen et al., 2006). However, several limitations of this model were raised, 
mostly about the use of serum creatinine or urine output to infer the extent of the 
tubular injury. Another major drawback of the RIFLE criteria is represented by the 
necessity to benchmark the creatinine or GFR values against the baseline values, in 
some cases not available. Even if there are several methods to retrospectively 
estimate serum creatinine and GFR, none of them appears to be accurate (Ricci et al., 
2008; Ricci et al., 2011). 
In 2007, the RIFLE criteria were refined by the AKI Network and named AKIN 
criteria. Besides a change in the name of the risk categories  (now divided in stages, 
from 1 to 3), a subtle, yet important note was added: an absolute change in creatinine 
of minimum 0.3 mg/dl within 48 hours is sufficient to assign the patient to the first 
stage. This cut-off was found in previous studies as associated with a higher mortality 
risk in patients after cardiac surgery (Lassnigg et al., 2004). Also, the two outcome 
categories have been eliminated; patients in need of a replacement therapy are 
grouped in stage three, regardless of the creatinine levels or urine output. Those 
improvements, however, did not change the sensitivity, predictive accuracy, and 
specificity of the classification of patients with AKI (Ricci et al., 2008; Ricci et al., 2011). 
In 2012, the KDIGO (Kidney Disease Improving Global Outcomes) guidelines were 
published giving precise recommendations to clinicians about the initial classifications 
of the patients and the management of AKI depending on the stage the patient is in 
(2012).  
In the past, it was believed that patients surviving from AKI would entirely recover 
the renal function. However, several pieces of evidence point towards the 
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bidirectional relationships between acute kidney injury and chronic kidney diseases 
(CKD). AKI was identified as risk factor for the incidence of CKD; patients who 
experienced AKI once and fully recovered the renal function were more likely to 
develop CKD than patients who did not experience AKI (Bucaloiu et al., 2012; Leung et 
al., 2013). Also, the severity of the injury and the frequency of AKI are essential factors 
that determine the progression to CKD and ESRD and determine higher mortality rates 
(Chawla et al., 2011). The duration of the AKI episode, instead, was more linked to 
long-term mortality rate together with the severity of the insult (Chawla and Kimmel, 
2012). 
Therefore, the paradigm by which patients with AKI do return to the pre-morbid 
renal function values might be overrated. The KDIGO guidelines advice the physicians 
to evaluate patients who experienced AKI 3 months after their discharge to better 
monitor the recovery, onset, and development of CKD or the worsening of pre-existing 
CKD (Chawla et al., 2014; Chawla and Kimmel, 2012; 2012; Palevsky, 2012). 
1.3 CHRONIC KIDNEY DISEASES AND END STAGE RENAL DISEASE 
CKD was defined by the National Kidney Foundation in 2002 as an impairment of 
the renal function and renal damage. Functionally, the loss of kidney function is 
characterized by a decrease in the GFR levels to a value lower than 60 mL/min/1.73 m2 
with or without kidney damage. On the other hand, the renal damage is identified 
through pathologic abnormalities or increase in urinary sediment and proteinuria for 
more than three months. Importantly, the CKD has been subcategorized in 5 stages, 
according to the GFR levels. CKD5 represents the level where the GFR is so low (<15 
ml/min/1.73 m2) that the renal failure is established.  
The stratification of the progression of the disease is essential to identify the 
window of opportunity for therapeutic intervention to slow down the progression of 
CKD and reduce complications associated with the outcomes, such as ESRD, 
cardiovascular risk and, most importantly, life quality and survival. CKD takes a long 
time to develop, and it is asymptomatic until later stages. However, urinary and serum 
biomarkers available are a fundamental tool to detect the disease (Fink et al., 2012).  
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1.4 THE END POINT: ALTERNATIVES FOR ESRD PATIENTS 
GFR and albuminuria are two strong independent risk factors for ESRD 
progression. Once the patient reaches the ESRD, the kidney is unable to perform all 
physiological tasks and requires an external intervention, in the form of dialysis or 
renal transplantation, referred as Renal Replacement Therapies (RRT). Both 
alternatives extend the life expectancy of the patients, but they are also associated 
with higher costs for the society (Vanholder et al., 2015). It has been estimated that 
transplantation confers an incremental gain in the life expectancy of 3 to 15 years 
when compared to dialysis, depending on the waiting list time and donor and 
recipient-specific factors, such as age at transplantation (Wong et al., 2012). 
Additionally, RRT-related expenses are even greater in the elderly population, who 
often present co-morbidities and a higher prevalence of CKD than the general 
population.  
1.4.1 TRANSPLANTATION 
Between the two options, transplantation is the most cost-effective choice. 
However, the waiting lists are getting longer and longer as the number of candidates 
in need of a transplanted kidney greatly exceeds the number of available kidneys. 
Figure 1.3 depicts a summary of transplant activity for the UK over the last ten years. 
More than 2000 patients per year are destined to start dialysis while waiting for a 
kidney.  
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FIGURE 1.3 OVERVIEW OF THE NUMBER OF PATIENTS ON THE TRANSPLANT LIST AND THE NUMBER OF 
AVAILABLE KIDNEYS IN THE UK 
The data refer to the last decade from the 1st of April 2005 up to the 31st of March 2015, 
obtained from the Transplant activity report 2014-20151. The majority of the transplanted 
organs come from deceased donors. The rest might be supplied by familiars, as live donors.  
Another option that is being implemented is to broaden the criteria of the pool of 
donors, including ‘high risks’ individuals, such as hepatitis C and HIV-positive donors 
for acceptors with the same disease, or old donors with or without comorbidities 
(diabetes for example) (Vanholder et al., 2015). Nevertheless, it has still been 
estimated a gain of life in the acceptors of ‘high risk’ organs over patients on dialysis. 
A recent study analyzed rejection rates and grafts from subjects transplanted with 
organs coming from donors with severe AKI compared to subjects who received 
normal kidneys. They concluded that there were no differences between the two 
groups in the short-term (1 year) (Heilman et al., 2015). However, the real statistical 
evidence will be available in few years when the long-term survival and grafts data will 
be available. In any case, the higher costs associated with the comorbidities of the 
subjects who received high-risk organs will have to be taken into account (Schold and 
Segev, 2012).  
 
                                                 
1
 https://www.organdonation.nhs.uk/supporting-my-decision/statistics-about-organ-
donation/transplant-activity-report/ 
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1.4.2 DIALYSIS 
In case an organ is not available or the patient is not healthy (or well) enough to 
undergo major surgery, the last option is to start dialysis. In the UK, the NHS provides 
different options for dialysis, such as hemodialysis (HD) or peritoneal dialysis (PD) in 
hospitals, satellite units, or in the patients’ homes. Home-based options of both HD 
and PD are more cost-effective than the hospital-based ones (Baboolal et al., 2008). 
Hemodialysis involves the use of a machine that will clean the blood. It is a process 
that lasts few hours, and it needs to be done at least three times per week. Peritoneal 
dialysis uses the peritoneum as a filter: a catheter is inserted into the peritoneal 
cavity, a cleansing fluid is put in the cavity and after the filtration is over leaves the 
cavity through the catheter. By the end of the procedure, the fluid will contain all the 
waste and toxin normally removed by the kidneys. It takes approximately thi rty 
minutes, but it needs to be repeated four times per day. However, it can be done 
overnight while sleeping. Whichever method the patient is going to prefer, there are 
serious impairments associated such as impossibility to have a normal working or 
studying schedule, inability to exercise or go on holiday2.  
1.5 BIOMARKERS OF ACUTE KIDNEY INJURY 
A biomarker is an endogenous biomolecule that infers the disease status of a 
specific organ. In the kidney, the ideal biomarker would be i) able to solely identify 
renal damage, and, within the kidney, can pinpoint the site of damage (specificity); ii) 
it is sensitive, meaning that its levels need to resemble the onset, progression, and 
recovery from the damage (sensitivity); iii) it can be retrieved through non-invasive 
sampling or in readily available body fluids; iv) it is conserved in different species, to 
facilitate the interpretations of therapies in preclinical model. With those features, a 
good biomarker would help clinicians and researchers to make reasonable decisions 
on the drug regime to assign or to identify the risk/benefits ratio in preclinical models 
of renal injury (Bonventre et al., 2010). 
Serum creatinine and Blood Urea Nitrogen (BUN) are commonly used to assess the 
renal function in preclinical models and patients. 
                                                 
2
  http://www.nhs.uk/Conditions/Dialysis/Pages/Introduction.aspx 
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Creatinine is a breakdown product of creatine phosphate, released by the muscles 
into the plasma at a constant rate. Historically, serum creatinine has been used as a 
renal marker in clinical settings, simply because it is freely filtered by the glomerulus 
and it is not reabsorbed. However, it can be secreted at very low levels from the tubuli 
(Uchino, 2010).  
There is an increased awareness of the inappropriateness of serum creatinine to 
measure renal function for several reasons. Firstly, differences in age, sex, dietary 
intake, muscle mass, exercise levels do influence serum creatinine excretion. 
Specifically, muscle mass plays a central role in the creatinine measurements 
(Heymsfield et al., 1983). Secondly, serum creatinine levels do not reflect early 
changes in GFR. In fact, it has been estimated that between 10% and 40% of creatinine 
is cleared by tubular secretion into the urine and it is not accumulated in the blood 
(Ciarimboli et al., 2012). Lastly, several methods are used to measure serum 
creatinine: Jaffe method, enzymatic, HPLC. The Jaffe method is based on the reaction 
of creatinine with picric acid in an alkaline environment that produces a solution that 
can be measured at 420 nm. However, 20% of the colorimetric reaction outcome is 
due to noncreatinine chromogens, such as proteins and glucose. Therefore, there is 
often an overestimation of the creatinine concentrations (Delanghe and Speeckaert, 
2011). The enzymatic method is based on the conversion of creatinine and derived 
metabolites by the enzymes creatininase, creatinase and sarcosine oxidase. Hydrogen 
peroxide, generated by the reaction, is then measured. HPLC (High-performance 
Liquid Chromatography) is the gold standard to measure serum creatinine. However, 
is quite time-consuming mainly due to the deproteinization and preparation of the 
sample. Nevertheless, HPLC and the enzymatic method gave comparable results in 
mice and rats (Keppler et al., 2007). The three different methods have different costs 
and difficulties associated, with the Jaffe method being the simplest and less accurate 
and the HPLC being the most complicated and precise. Inevitably, the use of the 
various analytical methods to measure creatinine implies a lack of methodological 
standardization and the difficulties in comparing the results (Delanghe and 
Speeckaert, 2011).   
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In the clinic, the serum creatinine is exploited in estimating GFR (eGFR) through 
equations. Generally speaking, the following equations require stable levels of 
creatinine, which is not possible to have in subjects with AKI, making them inaccurate 
for some categories of patients. Over time, three equations have been developed and 
used in clinical settings, all with their advantages and drawbacks. They are: 
- Cockcroft-Gault equation (1976), estimates 24 hours creatinine clearance, not 
GFR; the variable ‘weight’ is part of the equation, without adjusting for body 
surface area; 
- MDRD equation (Modification of Diet in Renal Disease) (1999), estimates the 
actual GFR by measuring the urinary clearance of iothalamate; age, gender and 
ethnicity are incorporated into the equation, whereas weight is not since it is 
adjusted for body surface area; the equation was developed in CKD patients. 
Therefore, GFR in subjects at normal GFR levels is underestimated; 
- CKD-EPI (Chronic Kidney Disease – Epidemiology Collaboration) creatinine 
equation (2009), different coefficients are used depending on age, sex, 
ethnicity and creatinine condition, it outperforms the MRDR, but it still 
overestimates GFR for particular categories (Delanaye and Mariat, 2013). 
BUN is the other widely used renal biomarker. It is freely filtered by the 
glomerulus, but the urea is reabsorbed by other parts of the nephrons. A rise in BUN 
levels can be observed even in the absence of kidney injury, in cases of volume 
depletion and an increase of endogenous or exogenous protein load, which lead to the 
production of urea. It is not specific or sensitive (Bonventre et al., 2010). 
Despite all those considerations, both serum creatinine and BUN are still the first 
choices to evaluate renal function in clinical settings and preclinical models.  
1.6 NOVEL BIOMARKERS OF ACUTE KIDNEY INJURY 
More sensitive and accurate biomarkers of AKI have been identified and validated 
in preclinical models and the clinic as alternatives to creatinine and BUN. Some of 
them, such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury 
molecule (Kim-1) and IL18, allow an earlier recognition of tubular damage (from 2 
hours for NGAL and Kim-1 to 12 hours for IL18) in the urine that would not translate 
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into a change in GFR. Table 1.1 offers a summary of some of the emerging renal 
biomarkers for AKI [reviewed in (Vaidya and Bonventre, 2006) and (Vaidya et al., 
2008)]. Cystatin C and Kim-1 will be discussed in more detail.  
Cystatin C (Cys-C) is a low-molecular-weight protein (13 KDa) positively-charged 
and constantly excreted by most nucleated cells (Abrahamson et al., 1990). Cys-C is 
freely filtered by the glomerulus, reabsorbed by Megalin-mediated endocytosis in the 
tubular epithelial cells and catabolized (Tenstad et al., 1996). Serum Cys-C has been 
indicated as a suitable endogenous marker of GFR, being able to detect AKI 2 days 
earlier than serum creatinine (Van Biesen et al., 2006). In fact, in contrast to serum 
creatinine, serum Cystatin-C is unaffected by other non-GFR determinants, such as 
age, sex, race and muscle mass or change in diet (Baxmann et al., 2008). 
There is increasing evidence that urinary Cys-C can be used as a biomarker to 
detect AKI. In fact, following a tubular injury, the microvillus surface area of the brush 
border of the proximal tubular cells is compromised, as well as its reabsorptive 
capacity (Ferguson et al., 2008). Therefore, Cys-C, reabsorbed by the tubular 
epithelium in a healthy scenario, accumulates in the urine during tubular impairment. 
In fact, urinary Cystatin C was found elevated in subjects with tubular injuries and was 
even predictive of subsequent need for RRT (Conti et al., 2006; Herget-Rosenthal et 
al., 2004; Uchida and Gotoh, 2002).  
Kidney injury molecule (Kim-1) also known as T-cell immunoglobulin, mucin-1 
(TIM-1) is a type I cell membrane glycoprotein containing an immunoglobulin-like 
domain and a mucin domain in its extracellular region, identified through analysis of 
the gene expression of ischemic versus healthy kidney tissue (Ichimura et al., 1998). In 
situ hybridization showed high levels of Kim-1 mRNA in the post-ischemic kidney, and 
immunohistochemistry showed its colocalization with Vimentin on regenerating 
proximal tubular epithelial cells (Ichimura et al., 1998). High levels of Kim-1 have been 
reported in renal cell carcinoma (Han et al., 2005), where tubular epithelial cells 
become dedifferentiated, and in several nephropathies (reviewed in (Vaidya and 
Bonventre, 2006)). 
Specifically, Kim-1 has been validated in a rat model of ischemia/reperfusion and a 
rat model of cisplatin-induced acute kidney injury. In the latter, urinary Kim-1 was 
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detected as early as one day after induction of the damage (7.5 mg/kg), whereas BUN 
and creatinine were significantly elevated from day three onwards (Vaidya et al., 
2006). There is evidence that the ectodomain of Kim-1 is shed from injured proximal 
tubular cells in vitro, mediated by a metalloproteinase-dependent cleavage (Bailly et 
al., 2002). A further evidence of the release of Kim-1 following tubular injury comes 
from a study where the soluble Kim-1 was found detectable in individuals with 
ischemic Acute Tubular Necrosis (ATN) as higher than patients with other forms of 
renal damage and healthy controls (Han et al., 2002).   
Also, Kim-1 was compared with several other biomarkers for acute kidney injury. 
SD (Sprague Dawley®) rats were treated with 1mg/kg of Cisplatin for 1, 3, 5, 7 and 14 
days. Kim-1 was the only marker to show sensitivity, marking a significant increase 
from day five and correlating with the extent of the damage. Alongside, 
immunohistochemical staining for Kim-1 correlated to the urinary Kim-1 changes. 
From day 1, it was possible to appreciate an increase in the intensity of the staining 
and spread in the area stained, starting from the outer stripe of the medulla to the 
cortex. Of note, glomeruli did not show any staining, corroborating the specificity for 
tubular injuries (Vinken et al., 2012). 
The finding that Kim-1 is not detectable in healthy renal tissues and is sensitive to 
early changes in tubular injury makes it a suitable non-invasive biomarker to detect 
AKI. 
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TABLE 1.1 LIST OF SOME OF THE BIOMARKERS ALTERNATIVE TO CREATININE AND UREA FOR DETECTION OF AKI (BONVENTRE ET AL., 2010; VAIDYA AND BONVENTRE, 
2006; VAIDYA ET AL., 2008) 
Biomarker Type Produced by Advantages Disadvantages Correlation with diseases 
IL-18  
(interleukin-18) 
Cytokine 
Constitutively expressed by 
distal tubular epithelium. 
Observe in endothelium 
and leukocytes. 
Early marker of AKI, 
independent 
predictor of poor 
outcome 
Involved in several 
inflammatory 
diseases 
↑ AKI patients 
↑ delayed graft function 
↑ IRI/Cisplatin in mice 
NGAL  
(neutrophil 
gelatinase-
associated 
lipocalin) 
Protein 
Induced in epithelial cells 
during inflammation or 
malignancy. 
More sensitive than 
creatinine. Precedes 
creatinine by 1-3 
days. 
 
Not very specific. 
Found in other 
organs. 
↑IRI (few hours) mice 
↑Cisplatin (three hours) 
mice 
NAG 
(N-acetyl-β-
glucosaminidase) 
Enzyme 
Renal tubular epithelium 
 
Very sensitive, the 
amount of NAG 
shredded in the urine 
is proportional to the 
damage 
Not very specific. 
Inhibited by 
endogenous urea 
Urinary levels of 
NAG can be 
detected in non-AKI 
related pathologies 
↑ nephrotoxins damage 
↑ delayed graft function 
↑ diabetic nephropathy 
High levels correlate with 
poor outcome 
Clusterin 
Glyco-
protein 
Dedifferentiated tubular 
cells after injury. The 
secreted form is anti-
apoptotic and prosurvival 
Not very sensitive  
↑ cisplatin model (5 days 
after) 
↑ IRI 
β2 microglobulin Protein 
Cell surface of all nucleated 
cells. Filtered by the 
glomerulus and reabsorbed 
by the proximal tubule cells 
Very sensitive 
Unstable in urine, 
rapidly degraded in 
pH<6. 
↑ nephrotoxins damage 
↑renal transplantation 
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1.7  HUMAN KIDNEY STEM/PROGENITOR CELLS (HKSPCS): CD133+ CELLS 
Unlike the liver, the kidney does not repair itself after partial ablation. In humans, 
nephrogenesis is completed at the end of the 36th week of gestation. The number of 
nephrons is determined by the intrauterine environment during the gestation period, 
and de novo formation of nephrons has never been documented (Fanos et al., 2015; 
Little, 2006). Upon damage induced by ischemia or chemical compounds, the 
mammalian kidney can replenish cells lost and restore the tubular epithelium 
(Bonventre, 2003; Toback, 1992). In contrast, when the insult aggravates the 
glomerular compartment, a substantial loss of glomerular cells leads to progressive 
scarring and fibrosis and, ultimately, to a permanent loss of renal function. 
Several repair mechanisms have been proposed over time, from the recruitment 
of bone marrow stem cells to the dedifferentiation of resident proximal tubular cells 
to the involvement of a resident progenitor cell population capable of regenerating 
the damaged area. Over the last decade, however, there has been an inconclusive 
debate about whether a true progenitor population exists. Bussolati and colleagues 
were the first to describe a progenitor population in 2005, selecting CD133 (Prominin-
1) as a surface marker (Bussolati et al., 2005). The authors do not clearly indicate the 
rationale of their choice, but use CD133 since it is expressed by undifferentiated 
epithelial cells in the intestine. Using this marker, they identified interstitial cells in 
normal portions of cortical regions of kidneys surgically removed, which accounted for 
circa 0.8% of the total amount of the freshly isolated cells. Once in culture, CD133+ 
progenitor cells showed a high proliferative capacity and could be expanded up to 
eight/nine passages, consistent with a limited life-span of progenitor cells. The 
phenotypical analysis showed the absence of hematopoietic markers (CD34, CD45), 
the presence of mesenchymal markers (CD29, CD73 and CD44) and, most importantly,  
the expression of Pax2, marker of the metanephric mesenchyme. Moreover, CD133+ 
clones could be successfully isolated, cultured and differentiated towards epithelial 
and endothelial cells, losing the expression of CD133 upon differentiation but 
retaining the expression of Pax2 (Bussolati et al., 2005). Most importantly, this study 
investigated the potential of this novel progenitor population to ameliorate a severe 
compromised immunodeficient (SCID) mouse model of glycerol-induced acute kidney 
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injury. HLA staining and PKH2 staining were identified in the kidney on cells expressing 
markers of fully differentiated renal epithelia. The authors explained this co-
localization by speculating the engraftment and subsequent differentiation of the 
CD133+ into the tubular epithelium (Bussolati et al., 2005).  
This study paved the way to further investigations on the existence and the nature 
of renal progenitor cells as therapeutics for regenerative medicine. The Romagnani 
group has given the major contribution to unraveling the properties of renal 
progenitor cells. They showed that cells expressing both CD133 and CD24, defined as 
Parietal Epithelial Cells (PEC), were identified in the Bowman’s capsule (BC) of human 
kidneys (healthy portions coming from patients with localized renal tumours). Virtually 
100% of the glomerular outgrowth was shown to be positive for CD133, CD24, CD106, 
CD105 and CD44 and negative for proximal and distal tubular markers . Stem cell 
markers, such as Oct4 and Bmi1 were also expressed by double positive, but not 
double negative cells (Sagrinati et al., 2006). CD133+CD24+, but not CD133-CD24- cells 
were clonogenic and showed an exceptional plasticity, being able to give rise to 
tubular epithelial cells, osteoblasts, adipocytes and neural cells. Furthermore, PKH26-
labelled double positive cells engrafted and differentiated into the tubules of a mouse 
model of glycerol-induced acute kidney injury, ameliorated the BUN levels and 
improved renal structure (Sagrinati et al., 2006).  
The PEC lie on the BC as a continuum: from undifferentiated cells at the urinary 
pole, expressing only CD133+ and CD24+ to pre-committed podocytes progenitors, 
expressing the two markers and podocalyxin (PDX), to fully differentiated podocytes 
on the vascular pole, expressing only PDX (Figure 1.4). To corroborate the finding that 
double positive cells are progenitors, CD133+CD24+PDX- were shown to be able to 
differentiate toward tubular epithelial cells and podocytes upon appropriate stimuli  in 
vitro. The counterpart CD133+CD24+PDX+, in contrast, did not differentiate, indicating 
a predetermined commitment to the podocytic compartment (Ronconi et al., 2009). 
CD133+CD24+PDX- cells were then injected in a mouse model of Adriamycin-induced 
chronic kidney injury. As shown by PKH26 staining and HLA staining, the 
CD133+CD24+PDX- cells were found in the glomeruli (11% ca.) and the tubules (8%) 
after three days from the second injection (Ronconi et al., 2009). Proliferative 
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CD133+CD24+ cells, but not CD133+CD24+PDX- cells populate crescents in collapsing 
glomerulopathy and crescentic glomerulonephritis in human biopsies  (Smeets et al., 
2009). However, it cannot be excluded that fully differentiated podocytes 
dedifferentiate giving rise to the crescentic lesions, acquiring CD133 and CD24 as 
markers.  
 
FIGURE 1.4 SCHEMATIC REPRESENTATION OF THE LOCALIZATION OF THE POPULATIONS OF PUTATIVE 
PROGENITOR CELLS ON THE BOWMAN’S CAPSULE 
The putative progenitor cells were localized on the BC of the glomerulus: undifferentiated 
cells, expressing CD133, CD24 and CD106 are confined to the urinary pole of the BC, whereas 
fully differentiated podocytes expressing PDX, but not CD133 and CD24 are present on the 
vascular pole. Between these two populations, lies a podocyte-committed cell population 
with an intermediate phenotype. In the tubuli, a scattered progenitor popul ation was 
identified, lacking the expression of CD106. The graphic was inspired by (Angelotti et al., 
2012) 
The researchers went then a step further, comparing the gene expression profile 
of CD133+CD24+ cells isolated from the glomerulus to CD133+CD24+ cells isolated from 
the tubuli. VCAM-1 (CD106) was found to be differentially expressed at the urinary 
pole of the BC. Hence, a new population, expressing CD133+CD24+CD106- was 
proposed as tubular progenitor population, scattered in the proximal and distal tubule 
(called ‘scattered tubular cells’ STCs) (Figure 1.4). Accordingly, CD133+CD24+CD106- 
cells were able to transdifferentiate in vivo into tubular cells (proximal and distal), but 
not into podocytes. Conversely, CD133+CD24+CD106+ cells were able to differentiate 
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into both, in vitro and in vivo (Angelotti et al., 2012). This scattered population was 
observed in the tubuli of patients with ATN and found to express Ki67, Vimentin, and 
Pax2 (Smeets et al., 2013). The number of proliferative progenitor cells expressing 
Pax2 was found to correlate positively with the patient outcome (Ye et al., 2011).  
Subsequently, the group of Camussi dissected the different parts of the nephron 
for the presence of CD133+ cells and focused on the CD133+ cells found in the inner 
medulla of the papilla (named pCD133+ from now on). Marker profile of pCD133+ cells 
shows a corresponding pattern to cortical CD133+ cells (nestin, vimentin, Pax2), but 
mCD133+ expressed Six1 and Six2 also. Moreover, Oct4A isoform, involved in 
stemness, was upregulated in pCD133+ cells. Progenitor properties were maintained 
and fostered in hypoxic conditions, so was the expression of Oct4 isoforms (Bussolati 
et al., 2012). pCD133+/CD73+ cells can produce and release erythropoietin that 
regulates blood red cells production (Bussolati et al., 2013). mCD133+ cells were 
tested for their regenerative potential in a glycerol-induced acute kidney injury model. 
Biodistribution data at 48 hours post IV injection revealed that CD133+ cells 
preferentially homed to the damaged kidneys. Comparatively, small quantities were 
found in lungs, liver and spleen. Conversely, a larger proportion of the MSCs was 
found in the same organs. Despite the renal localization, the human CD133+ cells 
(identified by HLA staining) were mostly found in the interstitial space in a not 
proliferative phase, and they did not differentiate in epithelial cells. In the attempt to 
define the mechanisms of action of the renal CD133 in the AKI model, the cytokine 
profile from both MSCs and CD133+ cells was investigated in conditioned medium. 
Among them, IL15 was found to be exclusively released by the mCD133+ cells in vitro, 
factor involved in the maintenance of the renal epithelium (Grange et al., 2014a). 
1.8 CD133 AS A MARKER OF STEM CELLS 
Prominin-1 (CD133) was identified in 1997 on murine neuroepithelial stem cells 
and named after its location on the protrusion of the apical plasma membrane 
(Weigmann et al., 1997). In the same year, the human Prominin-1 (CD133) was 
identified on hematopoietic stem cells from blood and bone marrow and fetal liver 
cells expressing CD34 (Yin et al., 1997).  The gene is located on chromosome 4 in 
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humans or chromosome 5 in mice, and the protein consists of an extracellular N-
domain and five transmembrane domains with two extracellular loops which carry N-
linked glycosylation sites and a cytoplasmic C-tail (Shmelkov et al., 2005). It is 
important to highlight that the human prominin-1 is expressed in many cell types, 
epithelial and non-epithelial, such as rod photoreceptor cells and bone marrow-
derived CD34+ cells (Corbeil et al., 2010; Fargeas, 2006; Mizrak et al., 2008).  
Interestingly, the biological role of CD133/Prominin-1 is still partially elusive. What 
it is known is that CD133 is located on the apical plasma membrane in microdomains, 
also called lipid rafts, often enriched in cholesterol and sphingolipids. Also, the 
transmembrane domains are unusually long and might increase the thickness of the 
membrane to increase interactions with lipids. Therefore, it was suggested that it is 
implicated in the shaping and organization of the plasma membranes (Bauer et al., 
2008; Fargeas, 2006).  
Although many cell types express CD133, stem/progenitor cells share a distinct 
glycosylation pattern on the CD133 protein (Yin et al., 1997). The second extracellular 
loop, in particular, is subjected to glycosylation. AC133 and 293C2 (Miltenyi Biotech) 
are the specific monoclonal antibodies able to identify the glycosylated version of 
CD133 on stem/progenitor cells. CD133 was used to identify endothelial cells, liver 
stem cells, prostatic epithelial stem cells, pancreatic ductal progenitor cells (Fargeas, 
2006). 
Karbanova and colleagues derived a different monoclonal antibody (80B258) and 
showed expression of Prominin-1 in several glandular epithelia in the adult liver, 
pancreas and uterus (Karbanova et al., 2008). Instead, when using the conventional 
AC133, the signal is hard to identify or very weak. The authors point out the technical 
difficulties on using AC133 for immunohistochemistry (IHC). Conventional antigen 
retrieval procedure and the lipidic environment where CD133 usually resides might 
not unmask the glycosylated epitopes and make problematic to define its localization. 
Hence, AC133 might identify a subset of CD133+ cells, with features commonly 
ascribed to stem/progenitor cells (Karbanova et al., 2008).  
In the adult human pancreas, AC133 was found in the lumen of ductal epithelia 
together with markers of fully differentiated and specialized cells (CA-II). Similarly to 
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the kidney, the AC133+ might identify a facultative progenitor population that 
undergoes dedifferentiation in the case of injury or regeneration (Lardon et al., 2008). 
In the normal adult colon, AC133 was expressed on fully differentiated epithelial cells 
and completely overlapped with EpCam (Epithelial cell adhesion molecule), 
corroborating its epithelial origin (Shmelkov et al., 2008). 
Since Prominin-1 or CD133, but not AC133 is expressed in a wide range of tissues, 
the activity of its promoter and the relative amount of AC133+ cells were investigated 
in colon cancer stem cells during differentiation (Kemper et al., 2010). Upon 
differentiation, the levels of the transcript and the protein CD133 did not change. 
Instead, the number of cells that presented the glycosylated epitopes AC133 and 293C 
decreased, suggesting that the protein might undergo a conformational change in the 
folding that would mask the glycosylated epitope on the membrane (Kemper et al., 
2010).  
In the kidney, Prominin-1 was identified in all proximal tubule cells on the apical 
surface in the study that introduced CD133 for the first time. The antibody used (mAb 
13A4), though, was not specifically tested against the glycosylated epitope (Weigmann 
et al., 1997).  
Due to its location, Prominin-1 can be easily released in the extracellular space as 
membrane vesicles of 50-80 nm, defined prominosomes. In fact, Prominin-1 has been 
detected in external body fluids in the adult, including saliva, urine, seminal and 
lacrimal fluid (Bauer et al., 2008; Fargeas, 2006; Florek et al., 2007).  Also, to 
complement its role as stem/progenitor marker, CD133 allowed the isolation of 
several cancer stem cells from solid tumours, such as breast, colon, liver, lung, 
melanoma, ovarian, pancreatic and prostate cancer and glioma (Medema, 2013).  
To conclude, having a marker with such a broad expression with an unknown 
biological role is not ideal to isolate progenitor cells or cancer stem cells. However, 
other markers or different approaches have been employed.  
1.8.1 PHYSIOLOGICAL ROLE OF CD133 
In the previous paragraph, CD133 was introduced as a ubiquitous marker for stem 
cells, progenitor cells, and cancer stem cells. However, its specific role remains largely 
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elusive. Nevertheless, this transmembrane protein has been shown to be involved in 
several processes, including cell self-renewal, tumorigenesis, metastasis, resistance, 
metabolism, differentiation, autophagy, apoptosis, and regeneration. In this 
paragraph, some evidences of the role of CD133 in the context of some of these 
processes will be briefly presented. 
Tumorigenesis and self-renewal: CD133+ cells  isolated from colon cancer and 
gliomas were capable of initiating tumors when transplanted in immunocompromised 
xenotransplantation models. Importantly, this capacity was maintained when the cells 
were serially transplanted, highlighting the ability of the CD133+ cell to self-renew. 
Both processes were shown to be mediated by the activation of the PI3K/Akt and 
MAPK pathways (Wang et al., 2010). As a proof that the tumorigenicity and self-
renewal depend on the expression of CD133, the silencing of the gene led to a 
decreased both properties in cancer cells (Neuzil et al., 2007), and the expression of 
CD133 in HEK293 cells led to an acquisition of both properties (Canis et al., 2013). 
However, it needs to be mentioned that even the CD133- cells from colon cancer were 
able to form tumours in vivo, leading to believe that CD133 is not the exclusive factor 
that confers this capacity to cells (Shmelkov et al., 2008). 
Metabolism: as mentioned in the previous paragraph, CD133 is a membrane 
protein that interacts with cholesterol and sphingolipids on the apical plasma 
membrane in microdomains, also called lipid rafts. The unusually long transmembrane 
domains might increase the thickness of the membrane to increase interactions with 
lipids. Therefore, it was suggested that it is implicated in the shaping and organization 
of the plasma membranes (Bauer et al., 2008; Fargeas, 2006). Also, CD133 has been 
reported to be involved in the maintenance of the iron homeostasis though 
downregulation of transferrin (Bourseau-Guilmain et al., 2011), and of the glucose 
metabolism. Regarding the latter, the expression and activity levels of the enzyme 
hexokinase II were found to be lower in CD133+ hepatocarcinoma cells (Gong et al., 
2012), although the relationship between the 2 proteins has not been uncovered yet.  
Apoptosis: CD133+ liver cancer cells were shown to be resistant to TRAIL (TGFβ and 
TNF-related apoptosis-inducing ligand)-induced apoptosis through the high expression 
of FLIP (FLICE-like inhibitory protein) (Zobalova et al., 2008). 
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Regeneration: CD133+ cells mainly from bone marrow, cord blood and peripheral 
blood have been tested in pre-clinical models and are currently used in clinical trials as 
a regenerative tool. As an example, bone marrow-derived CD133+ cells proved to be 
efficacious in a mouse spinal cord injury model, improving angiogenesis, axon growth 
and functional recovery (Kamei et al., 2013); in a muscle injury rat model, they 
differentiated into endothelial and myogenic lineages (Shi et al., 2009); in a myocardial 
infarction model, they improved cardiac function (Ahmadi et al., 2007).  
The properties of CD133 have been studied in a wide range of cell types, including 
primary tumours, opening to the possibility that the involvement of CD133 in a 
specific mechanism might be cell type-dependant. However, the different pieces of 
this puzzle certainly point towards a pivotal role of CD133 in a large variety of 
processes, that are under intense investigation. 
1.9 OTHER MARKERS USED TO ISOLATE HKSPCS 
The fetal kidney contains pools of stem cells that can be isolated and studied. Since 
the cells from the MM give rise to the whole nephron during renal development, they 
have been proposed for regenerative medicine purposes (Pleniceanu et al., 2010; 
Reidy and Rosenblum, 2009).  
Wilms’ tumors (WT) are classified as a heterogeneous combination of fully 
differentiated cells, stromal cells and embryonic cells that closely resemble the MM. 
Taking advantage of this congruence, Dekel and colleagues investigated by gene 
expression profile the differences among adult human kidneys (HAK), human fetal 
kidneys (HFK), Wilms’ tumor and renal cell carcinoma (RCC) (Dekel et al., 2006). Genes 
upregulated in the HFK and WT would represent genes preferentially expressed during 
development from embryonic renal stem cells. Among the genes, several transcription 
factors well known to be expressed in the MM were identified (Wt1, Pax2, Lim1, Six1, 
Eya1, Sall1, Cited1). However, for isolation purposes, surface markers are more 
convenient. NCAM1 (Neural Cell Adhesion molecule - CD56) emerged as a good 
candidate for a progenitor population due to its location in the nephrogenic zone (in 
the condensed mesenchyme and renal vesicles, comma and S-shaped bodies), 
overlapping with Six2. The expression of NCAM, analysed in conjunction with EpCAM, 
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marker of epithelial cells, and several transcription factors (Six2, Cited1, Sall1, Wt1, 
Pax2) led to the conclusion that NCAM1+ cells represent an MM-derived progenitor 
population. Interestingly, EpCAMbright cells, considered to be the tubular epithelial 
cells, expressed the largest amount of CD133 and CD24-positive cells, whereas only 
20% of NCAM1 positive cells expressed CD133 (Metsuyanim et al., 2009). 
In the perspective of a controlled expansion in view of a cell therapy transplatable 
for the clinic, NCAM1+ cells were expanded in serum free medium (SFM) or serum-
containing medium (SCM). In SFM, NCAM1+ cells presented a more epithelial profile, 
upregulating Pax2, Sall1 and E-Cadherin. Next, NCAM1+ cells were compared to 
NCAM1- cells for clonogenic efficiency, scoring 8% and less than 1%, respectively. The 
cloning efficiency of NCAM1+ cells was annulled when a specific antibody-drug 
conjugate (ADC). Also, CAM (chorioallantoic membrane) grafts with NCAM1+, but not 
with NCAM1- cells showed tubular epithelial structures expressing markers of all 
tubular segments. Finally, the NCAM1+ cells engrafted into tubuli of in vivo in a chronic 
kidney injury model (5/6 Nephrectomy) and improved renal function, by ameliorating 
the creatinine clearance (Harari-Steinberg et al., 2013).  
The expression of NCAM1 was evaluated also in the adult kidney: approximately 
15% of the cells in culture expressed NCAM1. NCAM1+ cells tick all the boxes for a 
progenitor/stem population: had a higher clonogenic capacity and proliferation 
capacity than their counterpart, could differentiate into adipocytes and osteocytes 
and preferentially form spheroids when cultured in the appropriate environment. 
Microarray analysis suggests that NCAM1+ cells undergo first epithelial 
dedifferentiation and then epithelial-to-mesenchymal transition (EMT), such as 
downregulation of E-Cadherin and upregulation of Vimentin. Interestingly, they 
expressed a range of transporters and ion channels proper of proximal tubule cells, 
suggesting that NCAM1+ cells descend from the tubular compartment. Even more 
interestingly, though, both NCAM1+ and NCAM1- cells could ameliorate a glycerol-
induced mouse model of acute kidney injury. Following intravenous administration, 
NCAM1+ cells were mainly found in the kidneys and lungs, but by 72 hours, the 
number of human cells in the kidneys decreased (Buzhor et al., 2013). 
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 Also, Tra-1-60, a marker of pluripotent stem cells, was proposed as putative 
progenitor marker in the kidney, since it was observed in Pax-2 expressing cells in the 
nephrogenic zone in fetal kidneys. In the adult human kidney, it was identified in 
scattered cells in the epithelial membrane antigen (EMA) positive cells, representing 
distal tubules. ATN biopsies were studied and an increase of the Tra-1-60 positive 
cells, also positive for EMA. Also, these cells were proliferating as indicated by the Ki67 
staining and expressed Pax2. However, Tra-1-60 positive cells were not the only cells 
that expressed Pax2 and proliferated in damaged tubuli (Fesenko et al., 2010). What is 
still missing is a canonical proof-of-concept that the Tra-1-60+ cells have a high 
proliferative, differentiation, and clonogenic potential. Even more importantly, they 
have not been tested in vivo. Hence, definite conclusions cannot be drawn.  
1.10 OTHER APPROACHES USED TO IDENTIFY HKSPCS 
Different functional approaches have been used to isolate a population with 
progenitor properties, an alternative to the use of defined surface markers.  
Adult stem cells have been identified in other organs for their feature of being 
quiescent or slow cycling. In fact, quiescent cells would retain labelled thymidine 
analogues for longer. Hence, such cells are defined “label-retaining cells” (LRCs) 
(Carlone and Breault, 2012; Fuchs, 2009). This strategy allowed the identification of 
LRCs in the papilla of the adult kidneys of rats that received BrdU few days after birth. 
Specifically, the vast majority of BrdU-positive cells were observed in the outer papilla. 
Three weeks after induction of an ischemic injury, the BrdU signal in the papilla was 
markedly reduced, suggesting that these cells participated in the regeneration 
process. In a slightly different experimental set-up, BrdU was administered 36 hours 
after IRI and chased for 1 hour. Proliferating cells were mainly present in the outer 
papilla. It was postulated that from the papilla, this putative stem cells population 
would migrate into the medulla to counteract the cell loss due to ischemia (Oliver et 
al., 2004). These proliferating papillary cells were also identified using CldU pulse by 
Humphreys and colleagues. However, in contrast to the study of Oliver at al., LRCs 
cells in the mouse papilla did not proliferate, nor migrated into the cortex following 
ischemia/reperfusion (Humphreys et al., 2011). Cells expressing higher levels of 
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Telomerase were identified in the papilla of mTert-GFP mice. These cells, however, did 
not increase in number following ischemia-reperfusion, nor migrated towards the 
outer medulla. Instead, they proliferated following osmotic shock, suggesting a pivotal 
role in the homeostasis of the papilla (Song et al., 2011). 
The enzyme Aldehyde dehydrogenase (ALDH), responsible for aldehydes oxidation, 
has been used to isolate a wide number of normal and cancer stem cells, due to its 
involvement in stem cells maintenance, regarding protection against cytotoxic drugs, 
expansion and differentiation (Ma and Allan, 2011). Lindgren and colleagues used the 
Aldefluor® assay on freshly isolated tubular renal cells (Lindgren et al., 2011). ALDHhigh 
cells, accounting for 7% of the total population, when compared to ALDH low by 
microarray, were found to be enriched in anti-apoptotic genes and genes involved in 
migration and adherence. Instead, the upregulation of HNF1A and HNF1B, 
transcription factors expressed in fully differentiated renal epithelial cells, in ALDH low 
cells confirmed the tubular origin of the cellular suspension. CD133 (Prominin-1) and 
CD24, but also Vimentin were found to be upregulated in ALDHhigh cells and their 
expression in scattered cells in the PT was confirmed by immunohistochemistry. Renal 
biopsies of patients with ATN in remission were stained as well. Regenerating tubuli 
showed apical staining of CD133 and basal staining of Vimentin, as will be shown by 
Smeets and colleagues few years later (Lindgren et al., 2011; Smeets et al., 2013).  
Bombelli and colleagues used sphere-forming assays to isolate quiescent cells from 
primary renal cultures that would retain PKH26 (Bombelli et al., 2013). Cells within the 
spheres appeared quite heterogeneous, with a PKH26+ core in the centre. Cells 
expressing Pax2, epithelial markers, distal and proximal tubular markers as well as 
Synaptopodin were observed in the spheres. Interestingly, cells isolated from the 
nephrospheres showed a higher ALDH activity and an upregulation of genes involved 
in pluripotency, ECM formation, and Notch pathway when compared to primary renal 
cultures in 2D. The PKH26high-sorted cells were the only cells able to create clonal 
nephrospheres and to differentiate into the epithelial, endothelial and podocytic 
lineage. In regards to the expression of CD133, both PKH26high and PKH26low cells have 
a high expression of CD133, accounting for approximately 70% and 55% respectively. 
Even 40% of the PKH26neg cells expressed CD133. In contrast, only 18% of the primary 
 30 
 
renal cultures in 2D expressed CD133. Interestingly, CD24 was not highly expressed in 
nephrospheres or primary cultures (Bombelli et al., 2013). This finding is in contrast 
with previous studies outlined at the beginning of this paragraph where in vivo and in 
vitro renal progenitor/stem cells express both CD133 and CD24. Those differences 
were attributed to the different culture conditions used in the study (Romagnani and 
Remuzzi, 2014).  
Buzhor and colleagues applied the same approach using adult kidney epithelial 
cells. The spheres were not monoclonal but presented a good expression profile 
regarding nephron progenitor genes. Flow cytometry revealed that the majority of the  
cells in the spheroids are phenotypically EpCAM+CD24+CD133+CD44+ and express 
higher levels of genes involved in cell–cell adhesion/ECM/cell recognition, ion 
transport, and regulation of cellular component biogenesis, whereas downregulated 
genes were related to cell growth/mitosis/cell cycle and cell locomotion. Using this 
system, the group showed that consistent results can be obtained even culturing the 
cells for a long time before inducing nephrosphere formation (Buzhor et al., 2011).  
All the studies presented so far indicate that a progenitor population might exist. 
However, genetic lineage tracing would be the most powerful tool to help to elucidate 
the origin of putative progenitor populations in the kidney and the dynamics that lead 
to the response of the tubular epithelia to injury. Rinkevic and colleagues exploited 
the so-called ‘rainbow’ mouse to analyse the presence of stem or progenitor cells in 
kidneys in homeostasis and after injury (Rinkevich et al., 2011). A multicolour (yellow, 
green, red, blue) Cre-dependent construct in the ROSA26 locus was crossed with an 
inducible Cre-ER protein under the Actin promoter. Tuning the recombination 
frequency, this model allows the lineage tracing of single cells labelled with different 
Cre-dependent reporter constructs regardless of putative markers in the kidney 
(Rinkevich et al., 2014). By doing so, the group observed that even one single cell can 
generate clones composed of several cells  during the first seven months of the mice 
life, initiating tubulogenesis. The clone-initiating cells were confined to specific 
segments of the nephron and did not show any plasticity in the differentiation. The 
population involved in tubulogenesis appears to be tissue-specific with progenitor 
characteristics. Upon ischemic and glycerol-induced damage, segment-specific clones 
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were identified in the kidney cortex, medulla, and papilla. Even when labelled single 
cells were tested for their potential in vitro to generate organoids, they showed a 
consistent staining for single segment-specific markers. The authors reason this 
finding with a culture condition that might support all fates, so they did not exclude 
the possibility that a multipotent population was present. However, the system labels 
single cells randomly, so fully differentiated cells would be labelled as well, 
maintaining open the possibility that fully differentiated cells might re-enter the cell 
cycle in case of tissue maintenance and, most importantly, repair (Rinkevich et al., 
2014).   
1.11 THE OTHER SIDE OF THE SPECTRUM: THE DEDIFFERENTIATION THEORY 
Several studies argue against the existence of a predetermined stem/progenitor 
population in the adult kidney. In acute kidney injury, it is not uncommon to observe a 
regenerative process. In this context, several groups advanced the hypothesis that the 
regeneration is driven by injured fully differentiated proximal tubule cells. Following 
injury, these cells would dedifferentiate and proliferate to replenish the lost 
epithelium.  
The Bonventre group tackled the question using a combination of DNA-analogues 
pulse to track cell division in the renal epithelium after IRI. CldU (5-Chloro-2′-
deoxyuridine) was injected 24 hours after the ischemia/reperfusion injury (IRI), 
whereas IdU (5-Iodo-2′-deoxyuridine) was injected at 45 hours after injury, 3 hours 
before sacrificing the animals. Progenitor cells would display both DNA-analogues in 
case they are the unique population able to counteract the PTC loss. In contrast, 
randomly expanding differentiated tubular epithelial cells would have a very low 
amount of cells labelled with both analogues and a high percentage of single-labelled 
cells. Indeed, the results showed that replication of PTC after the injury occurs 
stochastically (Humphreys, 2014; Humphreys et al., 2011).  
Genetic approaches provided finer and unequivocal evidence for the theory. Using 
a more elegant genetic approach, Kusaba and colleagues labelled all fully 
differentiated proximal tubule cells using a Cre mouse SLC34a1-GFPCreERT2 crossed 
with an R26RtdTomato/+ mouse. Depending on the dose of tamoxifen used, bigenic mice 
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would have specifically few or all proximal tubule cells dTomato-labelled (Kusaba et 
al., 2014). Progenitor cells with a simplified morphology that do not express markers 
of fully differentiated epithelia would not have been labelled. Therefore, this system 
was meant to prove whether new epithelial cells after injury originate from fully 
differentiated PTCs or not. Some significant findings were shown in the study: i) fully 
differentiated PTCs upon mild or severe injury can undergo one or multiple cell 
divisions, respectively; ii) injured fully differentiated tubular epithelia do express 
markers attributed to putative progenitor/stem cells, including CD133, CD24, Pax2, 
Vimentin and markers of injury, such as Kim-1 (Corbeil et al., 2014; Humphreys, 2014; 
Kusaba and Humphreys, 2014; Kusaba et al., 2014). 
Berger and colleagues reached the same conclusion using a different transgenic 
mouse, the PEC-rtTA mouse. In this model, all Parietal Epithelial cells and scattered 
tubular cells (STC) are labelled upon administration of doxycycline. PEC-rtTA cells 
labelled up to 7 days before the IRI did not expand following injury. Instead, when the 
PEC-rtTA cells were labelled during the injury, a massive increase of labelled cells was 
observed (Berger et al., 2014).  
Of note, the two antibodies that detect the human glycosylated epitopes CD133\1 
and CD133\2 do not cross-react with mouse or rat, so it is difficult to establish 
whether the CD133+ population has an equivalent in rodents (Angelotti et al., 2010). 
Smeets and colleagues provided a link between the rodent and the human studies. 
They investigated the presence of a scattered CD133+CD24+ population in healthy 
human kidneys and kidneys from patients with acute kidney injury due to ischaemia–
reperfusion injury after transplantation (ATN) (Smeets et al., 2013). The kidneys from 
ATN patients present complete tubular cross-sections positive for CD24 (and, 
therefore, CD133) or foci of CD24+ cells to a larger extent than healthy kidneys. These 
cells were shown to express also Vimentin, marker of dedifferentiated cells, and Kim-
1, a marker of tubular injury. In rats, Vimentin was used to identify the equivalent 
CD24+ scattered population. Indeed, following unilateral ureteral obstruction (UUO), 
more Vimentin-positive cells were identifiable in the cortex. Conversely, kidneys from 
healthy rats do not show Vimentin or this scattered population even in old age. Both 
CD24+ cells in the human kidney and Vimentin+ cells in the rat kidney show virtually no 
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brush border, which, after injury, can be attributed to shedding and flattening of the 
epithelium that is undergoing repair. Altogether, these data indicate the presence of a 
de novo population that participates in the repair of the renal epithelium. 
Interestingly, the differences in the number of scattered CD24+ cells and Vimentin+ 
cells in healthy human and rat samples were attributed to the possibility that older 
patients might suffer from nephrosclerosis or mild tubular injury associated with the 
nephrectomy or adaptive responses to the homeostatic repair (Humphreys, 2014; 
Smeets et al., 2013).  
1.12 METHODS USED TO TEST THE POTENTIAL OF HKSPCS 
Once a putative progenitor population has been isolated, regardless of the 
approach used, it has to be tested for its potential. Usually, differentiation is the first 
characteristic that is investigated. Also, for the kidney, a kidney reaggregation assay 
can be used to explore the potential of the cell of interest to integrate into developing 
embryonic renal structures. 
1.12.1 DIFFERENTIATION ASSAYS  
The differentiation potential of putative human renal progenitor cells expressing 
CD133 into intra-lineage and extra-lineage cell types has been investigated by several 
groups.  
Bussolati and colleagues demonstrated the multipotent nature of the CD133+ 
population (isolated from cortex and papilla) by differentiating the cells into epithelial 
and endothelial cells. On the one hand, when cultured in the presence of HGF 
(hepatocyte growth factor) and FGF4 (Fibroblast growth factor-4), the cells became 
polarized and expressed markers of proximal and distal tubules  (Bussolati et al., 2005). 
On the other hand, when cultured with VEGF, the cells started expressing endothelial 
markers. Furthermore, both epithelial and endothelial differentiated cells were able to 
form tubular structures when embedded in Matrigel, suggesting that the 
differentiation potential can also be achieved in vivo (Bussolati et al., 2005; Bussolati 
et al., 2012; Ward et al., 2011). 
Romagnani and colleagues defined the CD133+/CD24+ population isolated from 
human kidneys as multipotent after showing that individual clones obtained from the 
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CD133+/CD24+ population could be differentiated into renal lineages, both tubular and 
podocytic, and into extra-renal lineages, such as neurogenic, osteogenic and 
adipogenic cells (Sagrinati et al., 2006). To drive the differentiation of the human 
progenitor cells into podocytes, CD133+/CD24+ cells were cultured in VRAD (Vitamin 
D3, All-trans-Retinoic Acid, DMEM/F12) medium for seven days (Ronconi et al., 2009). 
This medium was originally described as the optimum medium to maintain the 
expression of nephrin which is otherwise lost in a primary culture of podocytes 
(Takano et al., 2007). Specifically, both Retinoic Acid (All-trans-Retinoic Acid, ATRA), a 
derivative of Vitamin A, and Vitamin D3 induce the expression of nephrin by binding to 
the Retinoic Acid Receptor (RAR) and the Vitamin D Receptor (VDR) (Okamura et al., 
2009; Suzuki et al., 2003). Specifically, ATRA has also been shown to induce the 
formation of foot processes in vitro (Vaughan et al., 2005). 
1.12.2 KIDNEY REAGGREGATION ASSAY 
In the last century, the culture of the forming embryonic kidney ex vivo has been 
used as an experimental approach to investigate its development closely. Since then, 
the experimental set up has been refined to integrate the progress that the biological 
sciences were making alongside. In the original culture system, the whole kidney or its 
metanephric mesenchyme was grown on a surface at the air-medium interface, 
supported by the embryonic spinal cord, placed underneath the kidney but separated 
by a filter. The embryonic spinal cord allowed growth and development of the 
rudiment so that it can be studied in vitro (Rak-Raszewska et al., 2015). In 2010, 
Unbekandt and Davies modified the culture conditions of the assay, simplifying it and 
opening new avenues which not only enabled the analysis the developmental 
processes in the embryonic kidney in greater detail but also had considerable 
implications for tissue engineering and regenerative medicine (Unbekandt and Davies, 
2010). In this system, embryonic mouse kidneys at E11.5 post-fertilization were 
enzymatically dissociated. The single cell suspension was subsequently centrifuged to 
allow the formation of a pellet that is cultured at the air-medium interface. In this 
process, nephrogenesis is recapitulated, and both forming nephrons and ureteric buds 
can be observed. In the first 24 hours of the assay, the pellets are cultured in the 
presence of ROCK (Rho-associated protein kinase) inhibitor, which enhances survival 
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of the embryonic kidney cells, thus allowing the formation of epithelial structures that 
show branching and protein expression typical of ureteric bud in the renal organoids. 
Also, nephrons display the proper sequence of development, giving rise to renal 
vesicles, comma-shaped bodies, and S-shaped bodies. The developing nephrons 
express markers for distal (E-Cadherin) and proximal (megalin) tubules and for 
glomeruli (Wt1) (Ganeva et al., 2011; Unbekandt and Davies, 2010). One of the 
strengths of the assay is the ability to investigate the role of single proteins in renal 
development since siRNA approaches can be incorporated into specifically tailored 
loss-of-function analysis. For example, reaggregated kidney rudiments containing 
Wt1-knock-down cells displayed ureteric bud formation, but no nephron formation, 
suggesting that the genes/proteins in the reaggregated kidney behave as they would 
in vivo (Unbekandt and Davies, 2010). The kidney rudiment assay was further modified 
with the aim of achieving an accurate cortico-medullary specification and loop of 
Henle formation (Sebinger et al., 2010). 
Through the dissociation and re-aggregation steps, the assay provides a window of 
opportunity to manipulate the primary embryonic kidney cells; however, it also offers 
the possibility to introduce exogenous cells and test their engraftment potential in the 
developing structures of chimeric renal organoids. Stem or progenitor cells can, 
therefore, be tested to evaluate i) their role and contribution to the recapitulation of 
nephrogenesis, and ii) their potential to differentiate into specialized cells  (Wilm and 
Murray, 2015). Indeed, a broad range of cell types with different potencies have been 
mixed with embryonic renal cells at E11.5-E13.5 to test their nephrogenic potential, 
using ESCs and iPSCs (Takasato et al., 2014; Xia et al., 2013), nephron progenitor cells 
obtained from ESCs and iPSCs (Takasato et al., 2014; Xia et al., 2013), hMSCs (Kuzma-
Kuzniarska et al., 2012), Amniotic Fluid Stem cells (Siegel et al., 2010; Xinaris et al., 
2015) and iPSCs-derived podocytes (Song et al., 2012). Ratios and outcomes are 
summarized in Figure 1.5.  
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FIGURE 1.5 SUMMARY OF STUDIES THAT USED THE KIDNEY REAGGREGATION ASSAY TO VALIDATE THE 
NEPHROGENIC POTENTIAL OF DIFFERENT POPULATIONS OF HUMAN STEM CELLS, ORDERED BY THEIR 
POTENCY 
The kidney reaggregation assay was used to test the potential of various human cells of 
interest to integrate into disaggregated mouse rudiments. The human cells are mixed with 
the mouse embryonic cells to form a chimeric rudiment in precise ratios, presented in the 
table as a percentage of human cells per rudiment. The only cells to display a true 
engraftment were the nephron progenitor cells differentiated from ESCs or iPSCs. † In this 
paper, the authors injected 1500 CD133+ cells into an E12.5 embryo and cultured the whole 
organ for four days. The results of this study will be discussed in chapter 4.  
‡ In this paper, the authors mechanically disaggregated E13.5-E15.5 kidneys and mixed CFDA-
labelled cells into the chimeric rudiments.  
Importantly, in the reaggregated rudiments, the developed tubuli displayed the 
expression of some physiologically-relevant organic anionic and cationic transporters, 
which were able to selectively uptake their substrates (Lawrence et al., 2015).  
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One of the major drawbacks of the renal organoid system is the absence of a 
vascular network, thus preventing the full maturation of podocytes. Xinaris and 
colleagues circumvented this limitation by pre-treating the rudiment with VEGF and, 
after implantation under the kidney capsule, by regularly injecting VEGF into the 
animals. Subsequently, the rudiments developed a Bowman’s capsule that contained 
cells expressing the podocyte marker set, including Synaptopodin, CD2AP, and 
Nephrin (Xinaris et al., 2015; Xinaris et al., 2012).  
So far, the integration and differentiation potential of CD133+ cells has only been 
assessed in an alternative rudiment approach by Ward and colleagues. In their study, 
the authors did not use the aggregation-disaggregation assay. Instead, they injected a 
suspension of 1500 cortical or papillar CFDA-labeled CD133+ cells into the embryonic 
kidneys and evaluated the integration of the cells into tubular structures  after four 
days in culture. Both cortical and papillar CD133+ cells were shown to have integrated 
into developing tubules, whereas the unsorted population of kidney cells occupied the 
interstitium of the kidneys (Ward et al., 2011).  
The reaggregated rudiments are routinely imaged using confocal microscopy. The 
Light-sheet microscope can offer an alternative for a more gentle imaging method. 
1.12.3 THE LIGHT SHEET MICROSCOPE: PRINCIPLES AND ADVANTAGES 
The Light sheet fluorescent microscopy (LSFM) has been developed over the past 
15 years and demanded the efforts of a multi-disciplinary team due to its complexity. 
The novelty of the light sheet microscope also called selective plane illumination 
microscope (SPIM), resides in the presence of an illumination lens positioned 
orthogonally to the detection lens. This configuration allows the generation of sheets 
of light from the illumination lens to excite thin sections of the samples. The 
arrangement eliminates the light emitted from the out-of-focus areas of the sample, 
thus reducing the phototoxicity and photobleaching of the specimen. Furthermore, 
the sample is presented vertically, is moved through the light sheets and can be 
rotated freely. Hence, multiview imaging of live samples is possible (Reynaud et al., 
2015).  
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In the SPIM, a single exposure of milliseconds is enough to achieve the optical 
sectioning of the entire plane, and the image is recorded fast. Conversely, in a 
conventional laser-scanning confocal microscope, the laser beam needs to travel from 
one pixel to the other, thus maintaining a longer exposure on the whole sample and 
increasing the time necessary to acquire the images, which subsequently can lead to 
phototoxicity and photobleaching of the specimen. It is not surprising, therefore, that 
the light sheet microscope has been a very appealing tool for biologists aiming to 
image over days the developmental processes in Caenorhabditis elegans, zebrafish or 
Drosophila (Ebeling and Jorgensen, 2013).  
This technology enables a long-term gentle imaging of three-dimensional 
organoids; therefore, it might be a powerful tool to study the behaviour of 
progenitor/stem cell populations into a three-dimensional environment as it is the 
reaggregation assay described in the past paragraph. 
1.13 IN VIVO MODELS OF ACUTE KIDNEY INJURY  
Several models have been developed to study the onset of renal damage and to 
test pharmacological interventions to treat renal diseases. As far as AKI is concerned, 
the most used in vivo models can be categorized in toxic AKI, where the insult is 
represented by a nephrotoxin (Cisplatin, Gentamycin, Folic Acid), ischemic AKI, where 
the blood supply to the kidney is interrupted for a short period of time, and sepsis, 
where the renal damage is due to a massive inflammatory response, induced by a 
surgical procedure or injection of lipopolysaccharide (LPS). All these damages are 
relatively easy to induce. However, their simplicity often makes the models less 
clinically significant. For instance, Cisplatin is typically administered to cancer patients 
regularly. Therefore, the renal damage develops slowly. In animal models, a low dose 
of nephrotoxin (or a lower clamping time) can increase the variability of the outcome 
enormously. As a result, a single dose of the toxin, or longer times for clamping is 
preferred. Table 1.2 summarizes the most common in vivo models used to study AKI. 
The pathophysiology of the cisplatin-induced model of acute kidney injury will be 
discussed in more detail in the following paragraph (Heyman, 2010; Singh et al., 2012). 
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 TABLE 1.2 OVERVIEW OF THE IN VIVO MODELS USED TO STUDY ACUTE KIDNEY INJURY. 
Abbreviations: C – cortex; T – tubuli; PT – proximal tubular cells; M – medulla; OM – outer 
medulla; IM – inner medulla; IMu – intramuscular injection; IP – intraperitoneal injection; IV – 
intravenous injection; IR – ischemia reperfusion; LPS endotoxemia; CLP – Cecal Ligation and 
Puncture. Details are taken from (Singh et al., 2012, Heyman et al., 2010) 
Model 
type 
Agent inducing 
the damage 
Induction of 
damage 
(Route of 
administration) 
Localization 
of injury 
Clinical 
Relevance 
Toxic 
Gentamicin 
80-100 mg/kg 
(IP) 
C ++ 
Cisplatin 
M: 20-40 mg/kg 
R: 7 mg/Kg (IP) 
C (S3 - PT) +++ 
Folic Acid 
M/R: 250 
mg/kg (IV) 
C (T) ++ 
Glycerol 
8-10 ml/Kg 
(IMu) 
C (PT) +++ 
Hypoxic 
Warm IR 
20-45 min 
clamping 
OM +/- 
Cold IR 
20-45 min 
clamping 
IM ++++ 
Sepsis 
LPS 
2.5-15 mg/kg 
(IP) 
OM +/- 
CLP 
cecal ligation 
and puncture 
C, M +++ 
1.13.1 PATHOPHYSIOLOGY OF THE CISPLATIN-INDUCED INJURY 
Cisplatin (cis-diamminedichloroplatinum [II]) is a widely used platinum-based 
chemotherapy drug, highly effective against a wide range of solid tissue tumours 
(Hanigan and Devarajan, 2003). It has been used alone or as an adjuvant to other 
procedures, like surgery or radiotherapy (dos Santos et al., 2012). Nephrotoxicity, 
neurotoxicity, ototoxicity and emetogenicity (capacity to induce vomit) have been 
reported as side effects. Although nephrotoxicity can be managed through hydration 
and the use of diuretics, it still represents a dose-limiting factor for the success of the 
therapy (dos Santos et al., 2012; Wang and Lippard, 2005). Cisplatin-induced AKI is the 
major presentation of nephrotoxicity with a reduction of 20–40% of their GFR, 
increased serum BUN and creatinine levels as well as reduced concentrations of serum 
magnesium and potassium (Kintzel, 2001; Miller et al., 2010; Ries and Klastersky, 
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1986). Approximately, one-third of patients treated with cisplatin develop a renal 
impairment within days after the initial dose (Sahni et al., 2009). 
Cisplatin gets concentrated in the kidney during the excretion process. The primary 
targets of cisplatin are the renal proximal tubules, principally the epithelial tubular 
cells of the S-3 segment (Werner et al. 1995). In fact, it has been reported that the 
concentration of cisplatin in tubular epithelial cells is ﬁve-fold higher than in plasma 
therefore even nontoxic blood levels of cisplatin might reach toxic levels in kidneys 
(Ozkok and Edelstein, 2014). Subsequently, glomeruli and distal tubules can be 
affected. 
Ctr1 (high-affinity copper transporter) and OCT2 (organic cation transporter) are 
the transporters responsible for the uptake of cisplatin in mice, rats and human 
kidneys (Ciarimboli et al., 2010; Ciarimboli et al., 2005; Ishida et al., 2002; Ozkok and 
Edelstein, 2014). In fact, the knock-down of Ctr1 in yeast and mouse cells in vitro and 
OCT2 in vivo provides protection from the tubular damage induced by cisplatin 
(Ciarimboli et al., 2005; Ishida et al., 2002).  
Once inside the cell, the cisplatin is hydrolysed, and the chloride ions dissociate 
from the molecule due to low intracellular chloride concentrations (Miller et al., 
2010). The resulting positively charged cisplatin binds to a great variety of molecules, 
like RNA, DNA, and proteins. In the nucleus, it causes intra- and inter-strand cross-
linking events, causing disruptions in the replication, transcription, and repair of the 
DNA (Sanchez-Gonzalez et al., 2011).  
In addition to nuclear DNA damage, the positively charged platinum molecules 
accumulate into the negatively charged mitochondria, generating mitochondrial 
dysfunctions. It has been reported that Cisplatin inhibits the oxidation of fatty acids, 
impeding the activity of PPAR-α, resulting in a decreased energy production (Portilla et 
al., 2002). Also, a drop in the electrochemical membrane potential, the considerable 
decrease in mitochondrial calcium uptake as well as a disruption of mitochondrial 
respiratory complexes and function have been reported as consequences of 
accumulation of cisplatin in vitro (Miller et al., 2010).  
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Apoptosis plays a major role in the histological changes in the renal tissue 
associated with cisplatin damage, together with necrosis (Pabla and Dong, 2008). In 
vitro, the dose used defines the cut-off between the two types of cell death 
(Lieberthal et al., 1996). Also, their role in the development of cisplatin-induced AKI 
has been confirmed in vivo (Faubel et al., 2004; Ramesh and Reeves, 2003). 
 Apoptosis can be activated through different pathways, both caspase-dependent 
and -independent, including:  
- extrinsic pathways, initiated by the activation of Caspase-8 by the death-
cell receptors, such as Fas, and TNFR2 (TNFα Receptor), triggered by 
cisplatin (Kaushal et al., 2001; Pabla and Dong, 2008; Ramesh and Reeves, 
2003; Razzaque et al., 1999);  
- intrinsic pathways, or mitochondrial pathways; the cisplatin activates Bax, 
which in turn induces the release of Cytochrome C, prompting a caspase-
dependent apoptosis (Wei et al., 2007);  
- ER-stress pathway, through activation of caspase-12 (Pabla and Dong, 
2008).  
1.13.2 INFLAMMATION  
Inflammation is one of the major components of the pathophysiology of cisplatin-
induced AKI. The impairment of the integrity of the endothelial barrier, caused by 
nephrotoxic agents, facilitates the migration and infiltration of the immune response 
cells, initiating early inflammatory cascades (Akcay et al., 2009; Jang and Rabb, 2015).  
T cells have a pivotal role in the pathophysiology of cisplatin injury. An increase of 
infiltrated T cells was observed in mice within 1 hour from the cisplatin injection, 
peaked at 12 hours and declined by 24 hours. In the absence of T cells in a nu/nu 
mouse model, the amelioration of the renal function and histological damage was 
reported. And, when T cells were restored in nu/nu mice, a higher degree of damage 
was observed, but not comparable to the wild-type animals. Among the T cells, CD4+ 
cells were shown to be more detrimental in the cisplatin pathology, due to their 
secretion of pro-inflammatory cytokines, such as IL-12 and TNF-α (Yokota et al., 2003). 
Indeed, CD4-deficient mice produce less TNF-α in the kidney than wild-type and are 
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more protected from renal damage than the CD8- deficient mice (Liu et al., 2006). 
However, in the context of cisplatin injury, TNF-α is not only produced by immune 
cells but also by intrinsic renal cells, such as tubular epithelial cells in response to 
cisplatin in vivo and in vitro (Ramesh and Reeves, 2005; Zhang et al., 2007).  
TNF-α plays a major role in the development of the cisplatin-induced pathology. 
Cisplatin can specifically activate caspase 8, which in turn activates TNF-α. In fact, TNF-
α protein and mRNA were upregulated following cisplatin administration in serum, 
kidney tissue, and urine. Inhibition of TNF-α resulted in a downregulation of the IL-1β, 
RANTES, MIP-2, MCP-1, TGF- β, IP-10 transcripts and an amelioration of the renal 
function (Ramesh and Reeves, 2002, 2004). As a further piece of evidence, caspase-1 
deficient mice show a marked decreased secretion of IL-1β, IL-18, and IL-6. Notably, 
mice with singular KO for this three cytokine were not protected by cisplatin (Faubel 
et al., 2007). Hence, these cytokines/chemokines represent pro-inflammatory 
mediators that activate and recruit components of the innate and adaptive immune 
response from the circulation, leading to exacerbation of the ongoing kidney damage.  
On the other hand, anti-inflammatory cytokines are produced by the renal tissue 
to foster the remodelling of the injured tissue, such as IL-4, IL-13, TGF-β, and IL-10. IL-
10 is produced by Th-2, Treg cells, DC cells and macrophages. IL-10 KO mice treated 
with cisplatin show a significant rise in markers of renal function (creatinine and urea) 
when compared to the wild-type. Interestingly, the infiltration of neutrophils was 
largely increased in IL-10 KO mice treated with cisplatin suggesting a role as  an 
inhibitor of monocytes and neutrophils recruitment in the renal tissue (Tadagavadi 
and Reeves, 2010). In the same reports, the authors demonstrate a protective role for 
DC in the cisplatin nephrotoxicity, partially due to the secretion of IL-10 (Tadagavadi 
and Reeves, 2010). 
Neutrophils are the most abundant type of white blood cells that can be found in 
the bone marrow, spleen, liver, and lung, under physiological conditions. During acute 
inflammation, neutrophils are the first type of leukocytes to be attracted by 
chemotaxis in a damaged organ (Kolaczkowska and Kubes, 2013). The role of 
neutrophils has been studied in cisplatin-induced injury. In mice, the number of 
neutrophils increased by twenty-four hours of the injection of cisplatin in the blood 
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and by 48 hours in the kidney. Ablation of the neutrophils through specific antibodies 
did not induce an improvement in the renal function (Faubel et al., 2007; Tadagavadi 
et al., 2015). The role of neutrophils in AKI is still controversial.  
Macrophages are ‘professional’ phagocytic cells usually presents in healthy tissues. 
In vivo, upon injury or infection, resident tissue macrophages can easily switch 
phenotypes, depending on the stimuli from the local environment. Pan-macrophages 
markers include CD68 and F4/80. Once activated, mature macrophages can either 
exert a more phagocytic and pro-inflammatory role (so called, classically activated M1 
macrophages) or an anti-inflammatory and regenerative role (alternatively activated 
M2 macrophages). Major details are provided in Table 1.3. However, this 
categorization in M1 and M2 macrophages has been recently challenged, since it is 
believed that, due to the high diversity of the macrophage phenotypes, it is not 
possible to have a clear distinction in M1 and M2 only. Instead, it was proposed to 
refer to macrophages depending on the factors that activate them (Lee et al., 2006; 
Murray et al., 2014; Murray and Wynn, 2011).  
TABLE 1.3 CLASSIFICATION OF MACROPHAGES SUBTYPES IN REGENERATIVE MEDICINE BASED ON 
MARKER EXPRESSION. FROM (CAO ET AL., 2015; MURRAY AND WYNN, 2011) 
 
In the cisplatin nephrotoxicity, a positive correlation between the number of 
interstitial macrophages and the degree of kidney injury was identified, suggesting 
that kidney macrophages play a pathogenic role in the progression of the damage. 
Name Markers Role 
Subcateg
ories 
Markers Activated by 
M1 
MHC-II, 
CD86 
Pro-inflammatory, 
anti-microbial, 
anti-tumoral 
activity 
N/A 
MHC-II, 
CD86 
LPS or IFNγ 
M2 
Arg1, 
CD206 
Anti-inflammatory, 
wound healing 
M2a 
CD206, 
CD163 
IL-4 IL-13 
M2b 
MHC-II, 
CD86 
immune 
complexes, LPS, 
IL-1β 
M2c 
CD206, 
CD150 
IL-10, TGFβ, 
glucocorticoids, 
apoptotic cells 
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Cisplatin induces an increase of the infiltrating macrophages  as early as 24 hours in 
mice, as shown by the increase of the F4/80 positive cells and up to at least 72 hours. 
Inhibitors of the TNF-α and NF-κB reduced the extent of the macrophage infiltration 
and led to an amelioration of the renal function. Once again, TNF-α has been shown to 
be the responsible for the macrophages infiltration and, therefore, for the 
exacerbation of the renal function. Depletion of macrophages, achieved using 
liposome-encapsulated clodronate (LEC), did not restore completely renal function 
upon cisplatin damage (Lee et al., 2006).  
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2 MATERIALS AND METHODS 
2.1 CELL CULTURE PROCEDURES 
Cell culture procedures were performed under sterile conditions in a Laminar Flow 
Cabinet safety class II. All surfaces, materials, and mediums in direct or indirect 
contact with the working area were either sterile or disinfected with 70% ethanol. All 
solutions were pre-warmed to 37˚C before use. 
2.1.1 ISOLATION OF HUMAN RENAL CELLS 
The samples employed in this study were identified with hK# (human Kidney 
#number) and listed on page 73. All biopsy tissues were obtained from anonymised 
donors, previous informed consent from donor families. The samples were obtained 
from Mr. Simon Kenny, a renal urologist at the Alder Hey Hospital (Liverpool, UK). hK2, 
the only healthy kidney in the cohort, was collected from the Royal University Hospital 
(Liverpool, UK). The study received full approval from the NHSBT (National Health 
Service Blood and Transfusion), and it is registered in the UK Clinical Research 
Network Study Portfolio (ID 6403). 
Upon reception, the tissue fragments were rinsed few times with cold PBS 
(Dulbecco’s Phosphate Buffered Saline, Sigma, D8537) to remove external blood. 
Where necessary, fatty tissue was removed using a forceps. The tissue was dissected 
in a 10 cm dish placed in a bucket of ice; pieces of approximately 2 mm2 were 
obtained using a surgical blade (size 22, 0108, Swann-Morton, UK) in sterile 
conditions. The pieces were digested using Collagenase I (1mg/mL, C0130, Sigma) for 1 
hour and 30 minutes at 37˚C. During this incubation period, the tubes were agitated 
by inversion every ten minutes to avoid the deposition of the tissue at the bottom of 
the tube. At the end of the incubation period, the solution was centrifuged at 1500 
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rpm for 5 minutes and washed with cold PBS once. The pellet still comprising some 
fragments was then resuspended in DMEM/F12 containing Deoxyribonuclease I (1%) 
(DNAse I, D4263, Sigma) and incubated for 15 minutes at room temperature. The 
solution was centrifuged at 1500 rpm for 5 minutes, and the pellet was washed with 
cold PBS twice. The suspension was passed through a 70 µm and a 40 µm sterile sieve 
(352350, 352340, respectively, Corning) to obtain a single cell suspension. The pellet 
was plated in the Human renal progenitor cell (HRPC) medium used for fetal 
progenitor cells (Price et al., 2007). For the media protocols, please consult page 67. 
The following day the medium was collected, centrifuged and the pellet was replated 
in HRPC medium. Fresh HRPC medium was added to the original plates. The medium 
was changed every two days until the cells reached confluence.  
2.1.2 ROUTINE CELL CULTURE PROCEDURES 
Cells were grown at 37°C in a humidified incubator supplied with 5% CO2 and 
passaged when at 80%/90% confluence. For subculturing, the culture medium was 
discarded, the cells were firstly washed with PBS, and the cells were detached from 
the dish by incubating the cells at 37°C with Trypsin/EDTA (Sigma, 59427C) for 2-3 
minutes. The detachment was monitored under the inverted microscope to avoid 
excessive exposure to Trypsin. At the end of the incubation period, double the trypsin 
volume of culture medium containing FBS was used to neutralize the trypsin. The 
suspension was collected in a falcon tube and centrifuged at 1500 rpm for 3 minutes. 
The pellet was resuspended in 1 ml of the fresh medium so that the cells could be 
counted. For the counting, the cell suspension was diluted 1:1 with Trypan Blue (0.4% 
T8154, SIGMA) and counted using a TC20™ Automated Cell Counter (Bio-rad). The 
appropriate number of cells was then plated accordingly or cryopreserved. The day 
after plating, the medium was replaced to eliminate dead cells and debris and 
subsequently changed every two days. Cell densities used in this thesis are listed in 
Table 2.1. 
TABLE 2.1 DENSITIES USED FOR THE HUMAN CELLS WHEN PLATED 
Plate Number of cells 
10 cm dish 200.000 cells 
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6 cm dish 70.000 cells 
2.1.3 CRYOPRESERVATION AND RECOVERY OF THE CELLS 
When the cells were at 80%-90% confluence, they were trypsinized and counted 
using a TC20™ Automated Cell Counter (Biorad) to assess viability and resuspended in 
freezing medium (12648-010, Life-technologies) at a density of 106 cells per ml of 
medium. The cell suspension was stored in cryovials (1 or 2 ml each) and frozen using 
a freezing container filled with 2-propanol (P/7507/17, Fisher Chemical) stored at -
80˚C for 24 hours before long-term storage in the liquid nitrogen tank.  
When needed, the vial was quickly thawed in a water bath at 37˚C and thawed 
drop-wise in 10 ml of pre-warmed medium. The suspension was centrifuged at 1500 
rpm for 3 min, and the supernatant was discarded. The cells were resuspended in the 
appropriate culture medium and maintained according to Section 2.1.2. 
2.1.4 MAINTENANCE OF CONDITIONALLY IMMORTALIZED PODOCYTES 
The conditionally immortalized Podocytes (ciPodo) were obtained from Professor 
Moin Saleem (University of Bristol, UK) (Saleem et al., 2002). The cells were 
maintained at 33°C for expansion purposes in a dedicated incubator or at 37°C for at 
least nine days for differentiation purposes. When needed to be trypsinized, the cells 
were passaged at a ratio 1:3.  
2.1.5 ISOLATION OF PRIMARY PODOCYTES 
hK6 was used to isolate human podocytes. Upon reception of the sample, the 
nephrectomy was bluntly dissected using surgical blades under sterile conditions, 
using a modified procedure described in (Koitabashi et al., 2011). Briefly, the pieces 
were passed through a metallic 200 µm sieve inserted in a 50 ml falcon. The resultant 
suspension was made of both tubules and glomeruli, was centrifuged and 
resuspended in fresh medium and passed through a 40 µm sieve inserted in a 50 ml 
falcon. In this step, the glomeruli are withheld in the sieve and the rest of the tissue is 
collected at the bottom of the tube. The 40 µm sieve was then turned upside-down, 
and the glomeruli collected and plated. Several glomeruli were obtained, either with 
of without Bowman’s capsule. The glomeruli were plated in the primary podocyte 
medium. Outgrowths were observed after 8 days in culture. Five days after the 
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outgrowth was observed, the cells were trypsinized and sieved through a 40 µm sieve 
to remove the glomeruli. 
2.1.6 POPULATION DOUBLINGS TIME CALCULATIONS 
To calculate the Population Doubling Time, the software Doubling Time was used 
(http://www.doubling-time.com/). The following equation was used to compute the  
doubling time: 
 𝑇 = 𝑡 ×
ln 2
ln 𝑁1 − ln 𝑁0
 
Where 
𝑇 = Population Doubling Time 
𝑡 = time of culture 
𝑁1 = number of cells at the end of the culture period 
𝑁2 = number of cells at the beginning of the culture period 
At each passage, the number of cells obtained was recorded, and the cells were 
always plated at the same density, according to Table 2.1. 
2.1.7 TRANSDUCTION OF HK2 CELLS WITH GFP LENTIVIRAL PARTICLE 
The hK2 cells were labelled using the lentiviral expression vector pHIV-eGFP 
plasmid (3rd generation, Addgene, 21373), kindly prepared in HEK293 cells by Dr. Sofia 
Pereira or Dr. Arthur Taylor (University of Liverpool). An MOI (multiplicity of infection) 
of 5 was used to transfect the cells to have >90% labelling efficiency. Typically, 2x105 
cells were plated 8 hours before transfection in a 10 cm dish. Once attached, their 
medium was replaced by the complete medium containing the appropriate amount of 
lentiviral particles (depending on the batch of the titration) containing 8 µg/ml of 
Polybrene (Sigma, H9268). The cells were incubated in these conditions for 16 hours. 
The medium was then appropriately discarded, and the cells were grown in normal 
medium.  
2.1.8 CLONOGENIC ASSAY AND GIEMSA STAINING 
For the clonogenic assay, 100 and 200 sorted hK2 CD133+ or CD133- cells were 
seeded in a 6 cm dish in presence of fresh medium and conditioned medium (1:1). 
After three weeks in the incubator, the dishes were washed once with PBS and fixed in 
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Methanol (100%, Sigma), and stained in a solution of Giemsa (Sigma) in PBS (1:10) for 
25 minutes. The dishes were then washed three times in PBS and once in dH2O before 
letting them dry overnight. Once dry, the dishes were observed under the inverted 
microscope and the number of colonies was recorded.  
2.1.9 PODOCYTE DIFFERENTIATION ASSAY 
To verify the differentiation potential of the primary human renal cells , the hK2 
sorted populations, CD133+ and CD133- cells, were induced to differentiate in vitrointo 
podocytes. The protocol used for the differentiation was adapted from (Okamura et 
al., 2009).  
Human CD133+ and CD133- at passage 2 or 3 were seeded at a density of 1x104 
cells per well in a 6-well plate and left to attach overnight in HRPC medium. The 
following morning, the medium was replaced with podocyte differentiation medium 
(VRAD) or control medium. The media were changed every 2 days, and the assay 
lasted for 7 days in total (2 changes of the medium in total). In some dedicated wells, 
coverslips were used for immunofluorescence purposes. At day 7, the coverslips were 
fixed in 4% (v/v) PFA solution and the immunofluorescence was performed according 
to paragraph 2.3. Three wells per condition per experiment were used for cell cycle 
analysis. The assay was repeated 2 times successfully, and a number a time without 
success.   
2.2 FIXATION AND IMMUNOHISTOCHEMISTRY OF SAMPLES 
Upon collection, part of the renal biopsies was collected in a 50 ml falcon and 
incubated in 4% PFA (28908, Thermo Scientific) for 2 hours at room temperature, 
washed with PBS three times, and incubated in 30% Sucrose (w/v) in PBS (S7903, 
Sigma) overnight or until the tissue sunk to the bottom of the falcon. The tissue was 
then washed 3 times with PBS and embedded in cryo-embedding solution 
(CryomatrixTM, 6769006, Thermo Scientific) in cryo-embedding moulds (Polysciences 
Europe GmbH, Germany). The mould was placed in liquid nitrogen-chilled isopentane 
(154911, Sigma) until frozen, and stored in -80°C freezer.  
6 µm thick sections were cut on a Cryostat HM 505 using a microtome blade 
(MX35 ULTRA, Thermo Scientific). The sections were placed on microscope slides 
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Superfrost (10149870, Fisher Scientific,) and stored at -80˚C if not immediately 
stained.  
2.3 IMMUNOFLUORESCENCE ON CELLS 
The immunofluorescence experiments on cells were performed on 8-wells 
chamber slides (354108, Corning). The primary renal cells were plated at passage 0 
without counting the cells and grown until confluent; the cells at any other passage 
were seeded at 50,000 cells per well and grown overnight. When appropriate, the 
cells were washed with PBS once and fixed in 4% PFA in PBS for 10 minutes at room 
temperature. The cells were then washed and blocked with blocking buffer [2% (w/v) 
BSA (Bovine Serum Albumin, A1470, Sigma) in PBS, 0.1% (v/v) Triton-X 100 (T-8787, 
Sigma)] for one hour at room temperature. A list of all antibodies used in this thesis is 
provided in Table 2.2 and Table 2.3. The primary and secondary antibodies were 
diluted in blocking buffer. The cells were incubated with primary antibody solution 
overnight at 4°C in a humidified chamber. The day after, the cells were washed 3 times 
with PBS and incubated for 2 hours in secondary antibody solutions at room 
temperature in the dark in a humidified chamber. At the end of the incubation period, 
the cells were washed with PBS three times and incubated in DAPI (4’, 6-diamidino-2-
phenylindole, dihydrochloride, D1306, Invitrogen)  solution (1:100,000 in PBS or 
blocking solution) for 10 minutes in the dark. Negative controls were included to test 
the secondary specificity, by omitting the primary antibodies and replacing it with 
blocking buffer. After the DAPI staining, the cells were washed with PBS three times; 
the plastic grid was removed, and the slides were mounted with Fluorogel with Tris 
buffer (17985-10, EMS) and sealed with nail polish. All fluorescence micrographs of 
cells shown in chapter 3 were obtained using the epifluorescence Leica DM2500 
microscope coupled to a Leica DFC420C camera, except the figures 3.1 and 3.2, taken 
using a spinning disk confocal microscope CSU-X1 coupled to a digital camera (CMOS, 
Hamamatsu, C11440). 
The immunofluorescence experiment to evaluate the colocalization of CD133 and 
CD24 in chamber slides was performed using the Antibody Labeling Kit Zenon®Alexa 
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Fluor® Mouse IgG1 (ThermoFisher Scientific, Z-25002), according to the manufacturer 
instructions. 
The immunofluorescence experiments on cells in VRAD or control medium shown 
in chapter 4 were performed on coverslips. Coverslips of the diameter of 13-19 mm 
were placed in 6 well plates, and the cells were seeded on top. The staining procedure 
is as explained in the previous paragraph, but the coverslips were mounted on 
microscope slides.  
2.4 IMMUNOFLUORESCENCE ON TISSUES 
6 µm thick frozen sections were removed from the -80°C freezer and left for 30 
minutes at room temperature to defrost. The slides were washed once in PBS for 5 
minutes and the area occupied by the tissue was delineated with a hydrophobic pen 
(S2002, DAKO). The human tissues were blocked for one hour at room temperature 
with 0.1% (v/v) Triton-X 100 and 10% (v/v) Goat serum (G9023, Sigma) in PBS; the rat 
tissues were blocked in 2% (w/v) BSA with 0.1% (v/v) Triton-X 100 in PBS. This blocking 
solution was used to dilute primary, secondary antibodies and DAPI. After one hour, 
the sections were incubated with the primary antibody solution and incubated 
overnight at 4°C in a humidified chamber. The next day, the sections were washed 3 
times with PBS and incubated with a secondary antibody solution for two hours at 
room temperature in the dark in a humidified chamber. Finally, the sections were 
incubated with DAPI solution for 10 minutes at room temperature in the dark, washed 
with PBS three times, mounted and sealed using nail polish. Negative controls were 
included to test the secondary specificity, by omitting the primary antibodies and 
replacing it with blocking buffer. All fluorescence micrographs of human tissues shown 
in chapter 3 were obtained using the spinning disk confocal microscope CSU-X1 
coupled to a digital camera (CMOS, Hamamatsu, C11440).  
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TABLE 2.2 LIST OF PRIMARY ANTIBODIES USED FOR IMMUNOFLUORESCENCE ON CELLS, TISSUES AND 
RUDIMENTS 
Type Description 
Host  
Isotype 
Dilution Company Cat. Num. 
P
ri
m
ar
y 
A
n
ti
b
o
d
ie
s 
CD133/1 M IgG1 1:50 Miltenyi, 130-090-422 
CD24 M IgG1 1:75 Santa Cruz, sc-19585 
CD44 M IgG2a 1:200 Abcam, ab6124 
Pax2 Rb 1:200 Abcam, ab37129 
Wt1 M IgG1 1:200 Millipore, 05-753 
Vimentin Gt 1:200 ICN, 647401 
Podocin Rb 1:200 Abcam, ab50339 
Nephrin Rb 1:200 Abcam, ab72908 
Megalin M IgG1 1:200 Acris, DM3613P 
Laminin Rb 1:1000 Sigma, L2020 
Synaptopodin M IgG1 1:2 Acris, BM5086 
GFP Rb 1:5000 Abcam, ab6556 
CD68 M IgG1 1:500 Abcam, ab31630 
CD206 Rb 1:500 Abcam, ab64693 
Ki67 Rb 1:500 Abcam, ab15580 
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TABLE 2.3 LIST OF SECONDARY ANTIBODIES USED FOR IMMUNOFLUORESCENCE ON CELLS, TISSUES AND 
RUDIMENTS *NOW THERMO FISHER 
Type Description 
Host  
Isotype 
Dilution Company Cat. Num. 
Se
co
n
d
ar
y 
an
ti
b
o
d
ie
s 
AF® 488nm 
Gt α Ms 
IgG1 
1:1000 Life Technologies* A-21121 
AF® 633nm 
Gt α Ms 
IgG1 
1:1000 Life Technologies* A-21126 
AF® 488nm 
Gt α Ms 
IgG2a 
1:1000 Life Technologies* A-21131 
AF® 594nm 
Gt α Rb 
IgG (H+L) 
1:1000 Life Technologies* A-11012 
AF® 488nm 
Gt α Rb 
IgG(H+L) 
1:1000 Life Technologies* A-11034 
AF® 594nm 
Gt α Gt 
IgG (H+L) 
1:1000 Life Technologies* R37117 
AF® 594nm 
Ck α Gt 
IgG (H+L) 
1:1000 Life Technologies* A-11058 
2.5 FLUORESCENCE ACTIVATED CELL SORTING (FACS) 
The human renal cells were analysed by FACS for the expression of several surface 
markers, listed in Table 2.4. The FACS characterization experiments were performed 
with single or dual labeling, according to the excitation and emission spectra of the 
antibody used, using a BD FACSCalibur (BD Biosciences). All steps were performed on 
ice. 2x105-1x106 cells were aliquoted in a 1.5 ml Eppendorf and washed once with PBS. 
The cells were then washed once with 1 ml of FACS buffer, composed of 0.1% (w/v) 
NaAzide (S2002, Sigma) and 1% (w/v) BSA in PBS. After 5 minutes of centrifugation at 
500xg, the cells were resuspended in 50 µl of FACS buffer and the appropriate 
antibodies were added. The samples were incubated, according to the manufacturer 
instructions, for 10 minutes at 4°C in the dark. At the end of the incubation period, 
950µl of FACS buffer were added, and the sample was centrifuged for 5 minutes at 
300g. The samples were then resuspended in approximately 1 ml of FACS buffer of in 
1% (v/v) FBS in PBS and analysed using the FACSCalibur. When possible, isotype-
matched control antibodies were used to confirm the specificity of the antibody used. 
Unlabeled cells were used as baseline control, to set the threshold of SSC, FSC and the 
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fluorescence channels (FL) in use. The peak of the unlabeled control during acquisition 
and analysis was set to be in the 100-101 regions of the FL axis. At least 10,000 events 
per sample were recorded. The .fcs (flow cytometry standard) files were analysed 
using Flowing software (Cell Imaging Core, Turku Centre for Biotechnology, Finland) 
and FlowJoV10 (Ashland, USA).  
For the sorting of the cells, the BD FACSAria (BD Biosciences) was used. The cells were 
labeled with the appropriate antibodies according to the procedure explained in the 
previous paragraph. The FACS sorting buffer was different: for the actual sorting, the 
cells were resuspended in PBS containing 1% (v/v) FBS at a concentration of 5-7.5x106 
cells/ml. 5x105 of unlabeled or labeled cells were provided to set the gates correctly. 
The sorting was performed by specialized personnel after the discussion of the gatings 
that were to be applied to the sortings. To increase the viability of the sample after 
sorting and to increase the recovery of the cells, the tubes were coated with 100% FBS 
for at least 30 minutes before the sorting. 1 ml of FBS was left in the tube of the sort. 
In the end, the sorted populations were re-analysed to define the purity of the sorting 
and, once in the lab, resuspended in growth medium, counted and plated accordingly. 
The FACSAria was used to sort single cells of CD133+ or CD133- into each well of the 96 
well plate (2 plates each cell type).   
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TABLE 2.4 LIST OF ANTIBODIES USED FOR FACS 
Description 
Fluorescence 
channel 
Dilution Company Cat. Num. 
CD133/1-PE FL2 1:10 Miltenyi, 130-098-826 
CD133/2-APC FL4 1:10 Miltenyi, 130-090-854 
CD24-FITC FL1 1:10 Miltenyi, 130-099-118 
CD45-PerCP FL3 1:10 Miltenyi, 130-098-145 
CD31-PE FL2 1:5 BD Bioscienc 555446 
CD326-FITC FL1 1:10 Miltenyi, 130-098-115 
CD324-APC FL4 1:10 Miltenyi, 130-099-723 
CD13 - FITC FL1 1:10 Abcam, ab46882 
CD90 - FITC FL1 1:10 Miltenyi, 130-097-930 
CD73 - PE FL2 1:10 Miltenyi, 130-097-943 
CD56 - PE FL2 1:10 Miltenyi, 130-098-137 
Tra-1-60 - PE FL2 1:10 Miltenyi, 130-100-350 
Control IgG1 FITC FL1 1:10 Miltenyi, 130-098-847 
Control IgG1 PE FL2 1:10 Miltenyi, 130-098-845 
Control IgG1 APC FL4 1:10 Miltenyi, 130-098-846 
Control IgG2b APC FL4 1:10 Miltenyi, 130-098-890 
2.6 MAGNETIC ACTIVATED CELL SORTING (MACS) 
The MAC sorting of hK2 cells for CD133 was performed by labeling the cells with 
the CD133/1-PE antibody (Table 2.2) according to the procedure described in the 
previous paragraph. After labeling, the cells were washed with ice-cold MACS buffer, 
consisting of 0.5% (w/v) BSA, 2 mM EDTA (E4884, Sigma) in PBS (pH 7.2) and 
centrifuged at 300g for 5 minutes. The supernatant was aspirated completely, and the 
pellet was resuspended in 60 µl of MACS buffer and 40 µl of Anti-PE Microbeads (130-
048-801, Miltenyi) (double the quantity recommended by the manufacturer). The 
 56 
 
suspension was then incubated for 15 minutes at 4°C. At the end of the incubation 
period, the cells were washed with MACS buffer and centrifuged at 300xg for 5 
minutes. The supernatant was aspirated completely, and the cells were resuspended 
in 500 µl of MACS buffer. In the meantime, an LD column (130-042-901, Miltenyi) was 
placed on a MidiMACS Separator (130-042-302, Miltenyi) and rinsed twice with 1 ml of 
MACS buffer. Afterwards, the cellular suspension was applied to the column. The 
flowthrough was meant to contain the unlabeled fraction of the cells. No pressure was 
applied to the column while the suspension was passing through. The column was 
then rinsed with 2 ml of MACS buffer, without applying any pressure onto the column. 
The flow-through was collected and analysed using the FACSCalibur for the number of 
PE+ cells, which represent the CD133+ cells (FL2). After rinsing twice with MACS buffer, 
the column was detached from the MACS Separator, 1 ml of MACS buffer was applied 
to the column, and the plunger was used to obtain the purified labeled fraction. This 
fraction, which should contain the specifically selected CD133+ cells, was also analysed 
using the FACSCalibur for the number of PE+ cells (CD133+ cells; FL2).  
The MACS efficacy was determined by using the following equation, taken from (Fong 
et al., 2009): 
EQUATION 1 MACS EFFICACY 
𝐸 (𝑒𝑓𝑓𝑖𝑐𝑎𝑐𝑦) = 1 −
% 𝐶𝐷133 + 𝑐𝑒𝑙𝑙𝑠  𝑖𝑛 𝑡ℎ𝑒 ′𝑓𝑙𝑜𝑤 − 𝑡ℎ𝑟𝑜𝑢𝑔ℎ′
% 𝐶𝐷133 + 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑢𝑛𝑠𝑜𝑟𝑡𝑒𝑑 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
 
2.7 CELL CYCLE ANALYSIS 
Each well was processed separately; the cells were trypsinized according to the 
procedure explained in the paragraph 2.1.2, and fixed in 70% (v/v) cold ethanol in 
water: Specifically, the ethanol was added drop-wise to the cell pellet while vortexing 
to avoid cell clumping. The cells were kept on ice for 30 minutes and centrifuged at 
6000rpm for 3 minutes. The ethanol was aspirated, and the cells were washed twice 
with PBS. Ribonuclease A (RNase A, Sigma, R6513, 100µg/ml in PBS) solution was 
firstly added to the pellet and 400 µl of PI solution (Propidium Iodide, P-3566, 
Molecular Probes, 50µg/ml in PBS) was added to the cell solution. The cell solution 
was then incubated for 10 minutes at room temperature in the dark, before analysis 
using the FACSCalibur. At least 10,000 events per sample were recorded. The .fcs (flow 
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cytometry standard) files were analysed using Flowing software (Cell Imaging Core, 
Turku Centre for Biotechnology, Finland) and ModFitLT (Verity Software House, USA).  
2.8 KIDNEY REAGGREGATION ASSAY 
 Pregnant CD-1 mice (Charles River, UK) were sacrificed at embryonic day 13.5 by 
CO2 exposure, followed by cervical dislocation, and the embryos were isolated. The 
kidneys were dissected in kidney dissection medium under the Leica MZ16F dissection 
microscope and collected on ice in a 1.5 ml Eppendorf containing PBS. All following 
steps were performed in a tissue culture cabinet. The kidneys were washed few times 
in PBS and transferred in a 15 ml falcon. 3 ml of Trypsin/EDTA were added directly to 
the kidneys, and the kidneys were incubated for 10 minutes at 37 ˚C, in the incubator. 
After five minutes, the suspension was resuspended gently with a micropipette. After 
the 10 minutes incubation, 10 ml of kidney dissection medium were added to the 
disaggregated kidneys and the falcon was incubated for 5 minutes in a water bath at 
37°C. The suspension was centrifuged at 3000rpm for two minutes and washed once 
in kidney dissection medium. Finally, the cells were resuspended in 1 ml of kidney 
reaggregation medium and counted. The volume corresponding to 1x105 cells (or 
9x104 cells in the chimeric reaggregation experiments) was aliquoted in a 0.5 ml 
Eppendorf and centrifuged at 3000rpm for 2 minutes to obtain a compact pellet. The 
pellet was then collected with a pipette and placed on a 1.2 µm isopore membrane 
(RTTP02500, Millipore) positioned on a stainless steel metal grid inside a 6-well plate. 
Each well contained 1.5-2 ml of kidney reaggregation medium that reached the 
sample by capillarity. The pellets were cultured for 24 hours in kidney reaggregation 
medium supplemented with 20µM of Rho-kinase inhibitor (ROCK, Y27632, 
Calbiochem). On day 1, at least 3 pellets per condition and cell type were fixed in 4% 
(v/v) PFA in PBS for 15 minutes in the dark and washed twice in PBS. For the other 
samples, the medium was the replaced with kidney reaggregation medium and 
cultured at 37°C and 5% CO2. Additional 3 pellets per condition and cell type were 
fixed on day 3 and 6, as described above.  
For the chimeric reaggregation experiments, GFP-mouse mesothelial cells (kindly 
provided by Sumaya Dauleh, University of Liverpool), human GFP-CD133+ and GFP-
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CD133- cells were thawed two days before the assay. On the day of the assay, the cells 
were trypsinized, and 104 cells were added to 9x104 mouse embryonic cells and 
centrifuged at 3000rpm for 2 minutes to obtain a compact pellet. The pellets were 
then processed as explained above. Numbers of biological replicates are indicated in 
Table 2.5. 
TABLE 2.5 OVERVIEW OF ALL THE BIOLOGICAL REPLICATES PER CONDITION. EACH BIOLOGICAL REPLICATE 
WAS MADE OF AT LEAST 3 TECHNICAL REPLICATES.  
 
Replicates 
 
Samples 
Reaggregation 
control 
Positive 
control 
GFP-
CD133+ 
cells 
GFP-
CD133- 
cells 
Biological replicates 6 2 4 3 
2.8.1 IMMUNOFLUORESCENCE OF KIDNEY REAGGREGATED RUDIMENTS 
For the immunofluorescence of the rudiments, the whole membrane was placed 
on a microscope slide and delineated with an hydrophobic pen. The staining 
procedure of the rudiments followed the one explained in paragraph 2.4 for the 
immunofluorescence of the tissues. The GFP cells were imaged without the aid of 
primary antibodies. The primary and secondary antibodies used in the whole study are 
listed in Table 2.2 and Table 2.3. The Laser Scanning Microscope 510 Meta (Zeiss) was 
used to image the samples.  
2.9 FORMATION OF KIDNEY EMBRYONIC SPHEROIDS 
The PDMS (Polydimethylsiloxane) multiwell support was obtained using the 
Sylgard 184 elastomer kit (761036-5EA, Sigma). The prepolymer was mixed with the 
curing agent in a 10:1 ratio. The mixture was then thoroughly mixed and degassed for 
20 minutes. The mixture was finally poured slowly into a 3 cm dish and cured for an 
hour at 70˚C. The final PDMS disc was approximately 5 mm thick, and the wells were 
obtained by punching the disc with a biopsy punch (4 mm, BP-40F, Kai Medical). The 
PDMS multiwell support was autoclaved, the polycarbonate membrane with 1.2 µm 
pores (RTTP02500, Millipore) was applied at the bottom of the multiwell support as 
shown in Figure 4.16. Four PDMS supports were made to prevent the sinking of the 
multiwell in the medium. Once arranged, the dish was filled with 2 ml of Phenol-Free 
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MEM (51200-046, Thermo Fisher) containing 10% of FBS. Each pellet, processed 
according to paragraph 2.8, was transferred to each well after centrifugation and 
grown for six days at 37°C and 5% CO2. On day six, the pellets were transferred to a 96 
well plate with u-bottom using a Wiretrol®II micropipette (5-000-2100, Drummond 
Scientific) and fixed for 15 minutes in 4% (v/v) PFA and washed in PBS twice before 
commencing the immunofluorescence staining, according to the procedure explained 
in paragraph 2.4 using some of the antibodies listed in Table 2.2. On the day of the 
imaging, the fixed spheroids were embedded in 1.5% Low-melt Agarose (A9045, 
Sigma) and 3% gelatin from porcine skin (G9136, Sigma) in a glass Wiretrol®II 
micropipette for imaging. The images were taken by Dr Marie Held on a Z1 Light-sheet 
Microscope (Zeiss), using the  W Plan-Apochromat 20x/1.0 UV-VIS objective lens. 
2.9.1 ANIONIC ORGANIC TRANSPORTER FUNCTIONAL ASSAY  
The functional assay was carried out on live spheroids. At day 5 or 6, the spheroids 
were moved from the multiwell PDMS support to a 96 well plate (U-bottom Costar®, 
3367, Corning Incorporated), washed with PBS twice in sterile conditions and 
incubated with a solution of 1 µM 5(6)-Carboxyfluorescein (6-CF, 21877-1G-F, Sigma), 
20 µg/ml of PNA (B-1075, Vector Laboratories) in PBS with or without 2.5 mM of 
Probenecid (P8761, Sigma) for 1 hour at 25C. The samples not receiving Probenecid 
were designated as control samples, where eventual functional tubuli would be able 
to uptake the 6-CF. At the end of the incubation period, the samples were washed 
with ice-cold PBS for 10 minutes. Both samples received a solution of 10mM 
Probenecid in PBS and were incubated for 15 min at room temperature in the dark. 
Finally, the spheroids were washed with PBS three times and images at the Z1 Light-
sheet Microscope (Zeiss), using an objective lens W Plan-Apochromat 20x/1.0 UV-VIS.  
2.9.2 LIVE IMAGING OF THE SPHEROIDS 
For the live imaging, the spheroids were cultured as described previously for 1 day 
before being embedded in 1.5% Low-melt Agarose (A9045, Sigma,) and 3% gelatin 
from porcine skin (G9136, Sigma) in a glass Wiretrol®II micropipette for imaging. The 
embedding medium was proved to be bio-compatible with the growth of the spheroid 
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over time. Major details about the imaging parameters are provided in the respective 
figure legends.  
2.10 CISPLATIN-INDUCED ACUTE KIDNEY INJURY MODEL 
2.10.1 ANIMAL GROUPS, BLOOD AND URINE COLLECTION 
All in vivo  experiments were conducted at the University of Heidelberg in 
accordance with the German Animal Protection Law and approved by the local 
authority (Regierungspräsidium Nordbaden, Karlsruhe, Germany, in agreement with 
EU guideline 2010/63/EU). Zeneida Herrera Perez performed the injections of 
Cisplatin, FITC-Sinistrin, and cells. 
In this study, immunodeficient athymic nude rats (Crl:NIH-Foxn1rnu, Charles River 
Laboratories), 8-9 weeks old, were used. All animals were housed in pairs in 
individually ventilated cages to maintain sterile conditions and acclimated for 1 week 
before the start of the experiment.  
Plasma samples were collected via ophthalmic venous plexus (orbital sinus) in 
lithium-heparinized tubes (Microvette 500 LH, Sarstedt, Nümbrecht, Germany) using 
capillaries for blood collection (Micropipettes 20µl, Blaubrand, Wertheim, Germany) 
by specialized research technicians. The samples were then centrifuged for 5 minutes 
at 2000xg at 4°C and collected in 1.5 ml tubes (Ratiolab GmbH, Dreieich, Germany) 
and stored at -20°C until analysis. For urine collection, the animals were housed for 16 
hours in individual metabolic cages with free access to water and food. At the end of 
each collection period, the urine volume was recorded, and the samples were 
centrifuged (78g, 5 minutes) to remove precipitates. Centrifuged urine aliquots were 
placed in 2 ml tubes (Eppendorf AG, Hamburg, Germany) and immediately frozen at -
20°C until analysed. 
Routine blood and urine chemistry parameters, including serum creatinine and 
urea, were determined using the Cobas c311 analyzer (Roche Diagnostics GmbH, 
Mannheim, Germany) by the research technicians. Albumin in urine was determined 
by ELISA and osmolarity was analysed using an osmometer (2020 Multi-Sample 
Osmometer, Advanced Instruments Inc., Norwood, MA). Tim-1 and Cystatin-C were 
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measured using the Rat TIM-1/KIM-1/HAVCR Quantikine ELISA kit (MKM100, R&D 
systems) and Mouse/Rat Cystatin C Quantikine ELISA kit (MSCTC0, MKM100, R&D 
systems) respectively at the University of Liverpool by myself. The urine was diluted 4 
and 400 times, respectively and the assay was performed according to the 
manufacturer instructions. The plates were analysed for their optical density using the 
FLUOstar Omega microplate reader (BMG Labtech). 
2.10.2 TRANSCUTANEOUS ASSESSMENT OF RENAL FUNCTION  
For the transcutaneous measurement of renal function, the marker fluorescein 
isothiocyanate (FITC)-sinistrin (Fresenius Kabi, Linz, Austria) was used. After its IV 
administration to the animals, the fluorescence emitted by the marker is measured 
transcutaneously using a miniaturized device (Mannheim Pharma and Diagnostic, 
Mannheim, Germany) shown in Figure 2.1.  
The core components of the device are: 
- Two light-emitting diodes (LEDs), with an emission maximum for FITC at 470 
nm (KPTD-3216QBC Kingbright Electric); 
- One photodiode that detects the fluorescent light with maximum sensitivity at 
525 nm (EPD-525-1-0.9-1; EPIGAP Optoelektronik); 
- Removable Lithium polymer rechargeable battery (voltage of 3.7V and capacity 
of 50 mAh) to supply energy during the measurement. 
For this work, the device was configured to perform a measurement each 1757 ms 
(34.149 samples per minute) with an excitation time of 8 ms. 
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FIGURE 2.1 MINIATURIZED DEVICE USED TO ASSESS THE RENAL FUNCTION IN RATS.  
(A) A miniaturized device utilized in this study. The LEDs and the photodiode represent the 
optical component. (B) The device is small enough to fit on the back of the an RNu rat. For 
the fixation, the animals were under short inhalable anesthesia, to then be awake for the 
rest of the measurement. Image courtesy of Zeneida Herrera Perez. 
The recorded digital data are stored in the internal memory of the device 
(MSP430f2013 Texas Instruments; maximum storage capacity 256 data points). 
On the day of the measurement, the animals were prepared for the 
measurements by depilating a region of the back of approximately 3 cm2 if necessary 
using an electrical shaver for small rodents (Aesculap®). Also, in some cases, a 
depilation cream (Veet® sensitive skin) was applied to the area for 2 minutes to ensure 
that all hair was removed. During the fixation of the device, the rats were kept under 
short inhalable anaesthesia (Isofluorane, Abbott Laboratories, Abbott Park, IL). The 
device was fixed on the depilated area using a double-sided adhesive patch (Lohmann, 
Neuwied, Germany). The measurements started when the battery was connected to 
the device. After the fixation of the device on the back of the animal, a background 
signal was recorded for about 4 minutes before the injection of FITC-Sinistrin. 
5mg/100g body weight (BW) of FITC-Sinistrin was administered into the tail vein. The 
measurements were carried out for at least 2 hours. In this period, the animals were 
placed singularly in the cage in the absence of water and free to move. At the end of 
the measurement, the battery was disconnected, and the device was detached from 
the animal. Figure 2.2 shows typical curved from a healthy and a cisplatin-injured 
animal. 
LED
photodiode
A B
 63 
 
 
FIGURE 2.2 REPRESENTATIVE EXCRETION CURVES OF FITC-SINISTRIN IN A HEALTHY (A) AND INJURED 
(B) RAT. 
The transcutaneous measurements were carried out for two hours. The device was fixed on 
the back of the animal for 5 minutes, before the injection of the FITC-Sinistrin, to establish 
the background reading (B, in image A and B). Once the FITC-Sinistrin was injected (I), the 
fluorescent signal initially increased but then decreased over time, according to the renal 
function of the animal. The Half-Life of FITC-Sinistrin was calculated from the curves using a 
specialized software using a three-compartment model.  
The data were downloaded to a computer through a USB cable. The half-life (t1/2) 
excretion of the administered FITC-sinistrin was computed using a specifically 
designed software for the device. By using the software, the data were analysed with 
a 3-compartment model, which allows calculation of the half-life of the FITC-Sinistrin 
even from abnormal curves due to renal impairment. 
2.10.3 TWO-WEEKS STUDY USING CD133+ AND CD133- CELLS 
A total of 32 male 8-9 weeks old immunodeficient athymic nude rats (Crl:NIH-
Foxn1rnu, Charles River Laboratories) were used for the two-weeks study. Renal 
damage was induced by a bolus injection of Cisplatin (Sigma-Aldrich, Germany) 
intraperitoneally (IP) with a dose of 7mg/100g of BW under short isofluorane 
anaesthesia. Cisplatin solution was prepared freshly in sterile 0.9% saline (AlleMan 
Pharma, Rimbach, Germany) at a concentration of 1 mg/ml. Control animals received 
the same volume of sterile saline as a vehicle. At the start of the experiment, all 
animals were randomly divided in 3 groups, to facilitate the handling and sacrifice of 
the animals, and the measurements and injections. All 32 animals received cisplatin at 
day 0. At day 2, the cell-treated and control groups were determined by a 
randomization of the animals. At least 2 petri dishes containing CD133+GFP+ or CD133-
GFP+ were available, and, after the FITC sinistrin Half-Life measurements, the animals 
B
I
Healthy animal  t1/2 16 min Injured animal  t1/2 78 min 
B
I
A B
 64 
 
that did not show any sign of injury were excluded. The others animals received the 
required amount of cells: animal 1 received CD133+ cells, animal 2 received CD133- 
cells, animal 3 received saline, and so on. 
The renal function was assessed before the induction of the damage (baseline), at 
day 2, 7 and 14 post cisplatin administrations. The day of Cisplatin administration was 
considered as day 0. The day before the measurements, the animals were placed into 
metabolic cages for 16 hours as previously described. The following morning, the urine 
and blood were collected, the animals were weighted, and the renal function was 
assessed by the transcutaneous device, as described at the beginning of the 
paragraph. On day 2 and day 7, the animals that were randomly assigned to cell-
treated groups received 1x106 GFP-CD133+ or GFP-CD133- cells in 500 µl volume of 
sterile PBS. All cells were labeled with PKH26 (PKH26GL-1KT, Sigma-Aldrich, Germany) 
before injection, following manufacturer’s instructions.  
2.10.4 SHORT-TERM STUDY 
For the short-term study, a total of 8 male 8-9 weeks old immunodeficient athymic 
nude rats were used. The renal function was assessed at baseline and day 2. 1x106 
GFP-CD133+ cells were injected in 6 animals at day 2 after the transcutaneous 
measurement. 2 animals were sacrificed 1, 6 and 24 hours after the injection of the 
cells.  
2.10.5 HISTOLOGY: COLLECTION AND ANALYSIS 
On the day of the sacrifice, a complete physical examination was performed, and 
the BW was recorded for all rats. Animals were euthanatized by CO2 exposure and the 
kidneys were weighed. Additionally, 2 portions of lungs, kidney and liver were 
collected for immunohistological analysis and fixed in 4% PFA for 24 hours at 4°C.  
2.10.6 IMMUNOHISTOCHEMISTRY PROCEDURES ON PARAFFIN-EMBEDDED 
TISSUES 
One portion of the fixed tissue was processed for paraffin embedding, cut (3µm) 
and stained with hematoxylin and eosin (H&E) by research technicians. The paraffin 
block was also used to cut 4µm sections to perform the Ki67 staining. Slides were 
deparaffinized and rehydrated by washing the slides twice in Histoclear II (HS-202, 
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National Diagnostics) for 5 minutes each, twice in Absolut Ethanol for 5 minutes each, 
once in 95% Ethanol (5 minutes), once in 70% Ethanol (5 minutes), once in dH2O (5 
minutes) before performing the antigen retrieval procedure (Sodium Citrate 10 mM in 
dH2O, pH 6, C2404, Sigma). After the antigen retrieval, the slides were washed with 
PBS once (5 minutes) and treated with 0.3% H2O2 in MetOH for 30 min (Hydrogen 
Peroxide 30, H1009, Sigma; Methanol, 322415, Sigma). The slides were then washed 
three times (3 minutes) in TBS 0.1% (v/v) Tween (SRE0031, Sigma). After that, the 
procedure follows the one used for immunofluorescence staining in tissue reported in 
paragraph 2.4.  
For Masson Trichrome staining, one slide for each animal was deparaffinized and 
rehydrated as previously described. The slides were then immersed in Weigert’s iron 
hematoxylin working solution (HT1079, Sigma) for 10 minutes, stained with Biebrich 
scarlet-acid fuchsin solution (HT151, Sigma) for 10-15 minutes, differentiated in 
Phosphomolybdic-phosphotungstic acid solution (319279, HT152, Sigma) for 10 
minutes, and stained with aniline blue solution (B8563, Sigma) for 5-10 minutes and 
differentiated in 1% acetic acid solution (695092, Sigma) for 3 minutes. In between all 
steps the slides were rinsed with distilled water before proceeding to the following 
step. Finally, the slides were dehydrated by immersing them twice in 70% ethanol (30 
seconds), three times in 95% ethanol (30 seconds), three times in absolute ethanol 
and twice in Histoclear (30 seconds). The slides were finally mounted with DPX 
(12658646, Thermo Scientific) and left to dry under a chemical hood overnight before 
visualization.  
2.10.7 IMMUNOHISTOCHEMISTRY PROCEDURES ON FROZEN TISSUES 
The other portion of the fixed tissue was washed with PBS three times, and placed 
consecutively in 15% (w/v) sucrose solution in PBS and 30% (w/v) sucrose solution in 
PBS until the sample sank to the bottom of the container due to exchange of water 
with sucrose (approximately 1 day). After three more washes, the samples were 
embedded in Tissue-Tek® O.C.T™ medium and stored at -80 until cut. The frozen 
samples were then cut using the cryostat in 5-6 µm slices and stored at -80 until use. 
For the immunofluorescence stainings, the slides were processed as described in 
paragraph 2.4. 
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2.11 IMAGE PROCESSING 
Count of Pax2+ cells: a total of 10 images were taken for each subpopulation 
(CD133+ and CD133-) for each sample in the red channel (Pax2), green channel (Wt1) 
and blue channel (DAPI). Once at the computer, the images were transformed from 16 
to 8 bit, and the Black and White Threshold was applied. The number of cells Pax2+ 
and DAPI+ was then counted. 
Spheroid area: at least 9 spheroids were imaged every day for 6 days using a Leica 
MZ16F dissection microscope with a DFC420C camera. A black and white threshold 
was applied in the Fiji software and the area of the spheroid was computed.  
Tubular dilation: H&E procedures were performed by research technician at the 
University of Heidelberg. Microphotographs of all the animals were acquired using 
Leica M651 microscope. To study the tubular dilation induced by cisplatin in the three 
groups, 10 random fields of the renal cortex per animal were taken using a 20X 
objective. The images were transformed into black and white and Fiji software was 
used to compute the area of the tubular luminal dilatation, by applying a black and 
white threshold to all images and measuring each black area (Figure 2.3).  
 
FIGURE 2.3 IMAGE PROCESSING PROCEDURE USED TO MEASURE THE TUBULAR DILATATION. 
A random numerical code was assigned to each slide. The images were transformed from 
16 to 8 bit (Image > Type > 8 bit), a black and white threshold was applied (Image > Adjust > 
Threshold). A cut-off was measured in order to count only luminal areas of dilated tubule, 
and the black areas were computed (Analyze> Analyze Particles). The luminal areas on the 
edge of the image were eliminated. At least 12 images per kidney per animals were 
included in the analysis of a total of 480 images. 
 
Original image Processed image (Fiji)A B
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Masson’s Trichrome (MT) staining: Microphotographs of all the animals were 
acquired using Leica. To study the amount of collagen staining per slide, Fiji software 
was used by applying colour threshold (blue) to all images and measuring the blue 
area. Also, 5 MT images per two animals per group were stitched together using the 
‘stitching’ plug-in of the Fiji software. 
Ki67+ cells counting: one paraffin embedded slide per animal was processed 
according to the protocol described in paragraph 2.10.6. Each slide was randomised so 
that the group could not be identified. At least 10 images per slide were randomly 
taken, and the number of positive nuclei for Ki67 was counted by an external observer 
not aware of the group distribution.  
General image processing: routine image processing was performed using the Fiji 
software. 
2.12 STATISTICAL ANALYSIS  
Each figure legend reports which statistical test was applied to that experiment. All 
data are generally represented as mean ± standard error means (SEM), unless stated 
otherwise. The statistical tests were based on the assumption that the data follow a 
Gaussian (normal) distribution. In chapter 3 and 4, the t-test was used to determine 
whether the differences between the means of two independent groups were 
significant. In chapter 5, the ANOVA one-way test was used to determine whether the 
differences between the means of more than two groups were significant. All 
statistical analysis was performed using the GraphPad Prism software. The statistical 
significance is expressed with the p-value (p), considered significant when 
0.05>p>0.01 (*); very significant when 0.01>p>0.001 (**) and extremely significant 
when p<0.001 (***). 
2.13 SUMMARY OF CELL CULTURE MEDIA 
Human renal progenitor cells (HRPC) Cf  Manufacturer, Cat. num. 
FBS      5%  Gibco, 10270-106 
hEGF     10 µg/L  Sigma, E9644 
Hydrocortisone    36 µg/L  Sigma, H0135 
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3,3',5-triiodo-L-thyronine sodium salt 4 ng/L  Sigma, T5516 
ITS (Insulin, Transferrin, Selenium) 1x  Gibco, 41400 - 045 
MycoZapTM    1x  Lonza, VZA-2021 
DMEM/F12    to final volume Lonza, BE12-719F/12 
Conditionally Immortalized Podocytes 
FBS     10%   
RPMI-1640    to final volume Sigma,  R8758 
Primary Podocytes 
FBS     10%   
MycoZapTM    1x   
RPMI-1640    to final volume Sigma, R8758 
 
 
 
Mouse Mesothelial cell 
FBS     10%   
DMEM-High Glucose   to final volume Sigma, D5796 
Kidney Dissection Medium 
FBS     10%   
DMEM     to final volume Sigma, D6546 
Kidney Rudiment Medium 
FBS     10%   
Penicillin/Streptomycin  1%  Sigma, P4333 
MEME     to final volume Sigma, M4655 
Kidney Spheroid Medium 
FBS     10%   
MEM-phenol free   to final volume Gibco, 51200-046 
Podocytes Differentiation Medium (VRAD) 
FBS     10%   
ATRA (in EtOH)    100 µM  Sigma, R2625 
1α, 25- Dihydroxyvitamin D3   100 nM  Sigma, D1530 
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DMEM/F12    to final volume 
Podocytes Differentiation Control Medium (Control) 
FBS     10%   
EtOH Abs    10%  Sigma, E7148 
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3 ISOLATION AND CHARACTERIZATION OF RENAL 
STEM/PROGENITOR CELLS  
3.1 INTRODUCTION AND AIMS 
In the last decade, the field of renal regenerative medicine has blossomed. The 
search for a renal stem or progenitor cell became paramount, in the view of 
formulating a cell therapy as an option for patients with acute and chronic kidney 
diseases to prevent progression to ESRD. In the general introduction, seminal studies 
were introduced, where CD133 was identified as a possible marker of renal 
stem/progenitor cells (Bussolati et al., 2005; Ronconi et al., 2009; Sagrinati et al., 
2006). Notably, these studies made use of tissue nephrectomies derived either from 
the healthy region of a kidney of patients affected by renal cell carcinoma (Angelotti et 
al., 2012; Ronconi et al., 2009; Sagrinati et al., 2006) or elderly deceased donors 
(Angelotti et al., 2012). As healthy as these regions can be, there is always the risk of 
cancerous cells in that region. Consequently, cells isolated from kidneys with tumours 
would not be appropriate for clinical use. On the other side, cells from older kidneys 
are likely to be suboptimal, being more susceptible to ischaemic damage. Therefore, 
there is a need to assess the therapeutic potential of CD133+ cells isolated from young 
potentially healthy kidneys.  
In all previous studies, the CD133+ cells were isolated exclusively using magnetic-
activated cell sorting (MACS) conjugated to CD133 antibodies  (Ronconi et al., 2009; 
Sagrinati et al., 2006). With MACS, the cells are labeled using antibodies conjugated to 
magnetic beads. The bead-labelled cells are then passed through a column within a 
magnetic field. In the column, the labelled cells are retained by the magnetic field 
(positive selection) whereas the cells that are not labelled go through the column 
(negative selection). The whole cell population is passed simultaneously through the 
column, reducing the time of sorting. With FACS (Fluorescence-Activated Cell Sorting) 
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sorting, the cells are labeled using fluorescently-labelled antibodies. FACS is typically 
the method of choice when high purity or the sorting of a very rare population is 
desired (Gross et al., 2015; Jahan-Tigh et al., 2012). How FACS and MACS affect stem 
cell properties is mostly unexplored (Li et al., 2013b).  
In this chapter, the general aim is to investigate the presence of a cell population 
expressing CD133 in tissue biopsies obtained from children and to understand 
whether this population represents the putative progenitor population reported by 
the literature in adult kidneys. It was hypothesised that the expression of CD133 (and 
CD24) in the children’s kidneys would be comparable to the one previously described 
in adult kidneys. In addition, it would be expected that following eventual isolation the 
CD133+ cells would display to a certain extent a proliferation capacity consistent with 
their progenitor status.  
In specific, the following objectives will be investigated: 
I) Analyse the expression of CD133 and CD24 in intact children’s kidneys  
II) Determine if CD133 and CD24 are expressed in renal cells following isolation 
and culture in vitro  
III) Characterize the primary renal cultures in vitro by FACS  
IV) Assess the suitability of MACS or FACS for isolating CD133+ and CD133- cells. 
3.2 RESULTS 
The biopsy tissues were collected at the Alder Hey Hospital (Liverpool) from Mr 
Simon Kenny, a consultant pediatric surgeon, and transported in ice boxes to the 
University of Liverpool. All samples were obtained following informed consent from 
the parents of the patients.  
3.2.1 IDENTIFICATION OF CD133 AND CD24 IN VIVO 
A list of all samples is shown in Table 3.1. Renal tissue was obtained from biopsy 
tissue samples obtained from children, age between 15 months and 15 years. hK2 was 
the only healthy sample in the cohort, obtained from a deceased donor. All the other 
samples were obtained from patients hospitalized mainly for recurrent infections. 
Four of these patients presented a duplex kidney. Duplex kidneys represent the most 
 73 
 
common congenital abnormality of  renal development, where a duplication of the 
pelvicalyceal system of the kidney results in the presence of two ureters, called upper 
and lower moiety ureters. The anomaly is asymptomatic in most cases but carries 
several complications, such as  vesicoureteral urinary reflux (VUR). VUR is defined as 
the retrograde flow of urine from the bladder to the ureter and kidney and causes 
acute infections, renal scarring and nephropathy (Doery et al., 2015). No additional 
information about the renal condition of the patients was obtained after their 
hospitalization and reception of the samples. Among all samples, hK6 was processed 
differently (see Material and Methods) and the cells isolated from its glomeruli were 
used as positive control for the differentiation assay (shown in the following chapter). 
TABLE 3.1 LIST OF SAMPLES USED IN THIS THESIS 
All samples (hK1-hK5) were processed according to the protocol reported in the Material and 
Method Section. hK6 was processed differently: the glomeruli were separated from the tubuli 
and plated.  
ID 
Age 
(m/y) 
Condition 
Portion 
received 
hK1 15 m Duplex kidney cortex 
hK2 24 m healthy whole 
hK3 10 y Duplex kidney cortex 
hK4 8 y Recurrent infections cortex 
hK5 8 y 
Duplex kidney + 
recurrent infections 
cortex 
hK6 6 m Duplex kidney cortex 
 
 
As mentioned in the general introduction, the glycosylated isoforms of CD133 are 
reported to be stem cell markers, and two monoclonal antibodies are commercially 
available to detect the glycosylated epitopes, AC133 (CD133/1) and 293C2 (CD133/2) 
(Angelotti et al., 2010).  
CD133/1 was used to evaluate the expression of CD133 on frozen sections. CD133 
was expressed in the glomeruli of all samples, specifically on the parietal epithelial 
cells of the Bowman’s capsule (BC), regardless of the age of the patient or the status 
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(healthy vs. not healthy) (Figure 3.1 A-D). Interestingly, few CD133-expressing cells 
were detected inside the glomerulus, as shown in hK4 (Figure 3.1 C). In this sample, 
the staining was not confined to a thin layer of cells. Instead, the images suggested 
that the either the BC is thicker or there were visceral glomerular cells (podocytes) 
that expressed CD133. In hK5, instead, a relative big Bowman’s space was observed. 
However, in the sections belonging to that patient only one glomerulus was spotted, 
so limited conclusion can be drawn. 
 
FIGURE 3.1 EXPRESSION IN VIVO OF CD133 
(A-D) Representative immunofluorescence images showing the cortex of four samples (hK2, 
hK3, hK4, hK5) stained for CD133/1 (green). CD133/1 can be identified on the PEC cells and 
on scattered tubular cells. The glomeruli (g) are annotated and the arrows indicate the cells 
on the BC. The tubuli are highlighted by a dotted line. (E) Immunofluorescence images of hK5 
section stained with CD133/1 at low magnification that shows tubular injury. (F) 
Immunofluorescence images of the medulla of hK2 showed positive staining with CD133/1. 
The inset shows in higher magnification a completely stained tubule. The scale bars represent 
50 µm. 
In addition to the PEC, CD133 staining was found on the luminal surface of 
scattered tubular cells. In hK5, the entire cross-section of some tubuli is stained for 
CD133 (Figure 3.1D-E). Of note, hK5 displayed extensive tubular injury, demonstrated 
by the dilated luminal area of the tubules (Figure 3.1 E). 
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In the case of hK2, the whole kidney was available. Since CD133+ cells were 
previously identified in the inner medulla (Bussolati et al., 2013), the medulla of hK2 
was stained for CD133/1. Cross-sections of most of the tubuli present in the medulla 
(thick segments of the Loops of Henle and Collecting ducts) demonstrated expression 
of CD133 throughout. CD133 was specifically detected on the luminal surface as well 
as on the basolateral surface of the tubular cells, as shown in the small inset in Figure 
3.1 F. 
CD24 was described as marker of putative stem/progenitor cells in adult kidneys, 
together with CD133 (Sagrinati et al., 2006). Its expression, therefore, was assessed on 
frozen sections (Figure 3.2). CD24 was spotted not only on the PEC, but also inside the 
glomerulus, and on some tubular cells (Figure 3.2 A-B). Also, entire tubuli were CD24-
positive. In the medulla, most of the tubular cells expressed CD24 on their entire cell 
surface.  
 
FIGURE 3.2 EXPRESSION IN VIVO OF CD24 
(A-B) Representative immunofluorescence images showing the cortex of two samples (hK2, 
hK3) stained for CD24 (green). CD24 could be identified on the PEC cells, inside the glomeruli 
and on tubular cells. Some tubuli are highlighted by a dotted line. (C) Fluorescence image of 
the medulla of hK2 stained with CD24. The inset shows in higher magnification a completely 
stained tubule. The scale bars represent 50 µm. 
Altogether, the in vivo localization of CD133 and CD24 suggests that both markers 
are expressed in the PECs and in scattered tubular cells, as previously shown (Hansson 
et al., 2014; Sagrinati et al., 2006). However, qualitatively, it appeared as more CD24+ 
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cells were present. For the medulla, limited conclusions can be drawn, since the 
medulla was available for one sample only. 
3.2.2 ISOLATION OF RENAL CELLS FROM HUMAN KIDNEYS AND CHARACTERIZATION 
FOR CD133 AND CD24 
Each human kidney sample went through the isolation procedure, explained in 
detail in the material and methods section (page 45). Five cell lines (hK1-hK5) were 
successfully established in culture. A representative set of bright field images of each 
sample is shown in Figure 3.3. The isolated cells appeared phenotypically highly 
heterogeneous: compact colonies of small, cuboidal, epithelial-like cells were spaced-
out by elongated, mesenchymal-like cells. The images in Figure 3.3 were taken after 
six days in culture, and all isolated cells reached confluence in that time frame, except 
the cells isolated form hK5 that took 12 days. Also, in hK5, less compact colonies were 
visible.  
 
FIGURE 3.3 BRIGHT FIELD IMAGES OF THE FRESHLY ISOLATED CELLS OF ALL SAMPLES 
Bright field images of freshly isolated cells taken six days after the isolation from the tissue. 
Phenotypically, the cells appeared highly heterogeneous, with epithelial -like cells alternating 
with elongated mesenchymal-like cells. Scale bar represents 100 µm. 
The first aim was to assess the expression of CD133 on freshly isolated cells. To 
achieve that, the primary cells were seeded into chamber slide immediately after 
isolation and when confluent, stained with the CD133/2 antibody. As shown in Figure 
3.4 A, a high number of hK2 cells was CD133-positive. 
hK1 hK3
hK4 hK5
hK2hK1
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Consequently, the expression levels of both glycosylated epitopes of CD133 were 
quantitatively evaluated by FACS in all cell lines. All cell lines were cryopreserved at 
passage 1. Upon thawing, the cells were plated, and the expression of CD133 by FACS 
was evaluated at passage 2. At passage 2, the percentage of cells expressing CD133 
was not insignificant. In average, more than 70% of the renal cells isolated expressed 
both CD133/1 and CD133/2. However, some differences were detected in the 
individual samples: hK2 presented significantly more CD133/2-expressing cells 
(p<0.01), whereas hK4 and hK5 presented more CD133/1-expressing cells (hK4: 
p<0.01; hK5: p<0.01).  
Therefore, the FACS analysis at passage 2 showed a notable increase of the cells 
expressing CD133 in one or both isoforms on their surface.  
 
FIGURE 3.4 EXPRESSION OF CD133 IN VITRO 
(A) Immunofluorescence image of freshly isolated cells stained for CD133/2 (red). Most cells 
appeared stained. The scale bar represents 50 µm. (B) FACS analysis showing the amount of 
the two glycosylated epitopes of CD133, CD133/1 and CD133/2, in all samples. The analysis 
was conducted in duplicate, starting from frozen aliquots of the cells at passage 1. The error 
bars represent SEM. A t-test was applied to determine significance, ** p<0.001. 
In the literature, isolation of renal progenitor cells has been reported based on the 
expression of CD133 in combination with CD24 (Romagnani and Remuzzi, 2014). 
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Therefore, the expression of CD24 was evaluated by FACS at passage 2 in the five 
primary cell lines (Figure 3.5). On average, 88% ± 7.8 of the renal cells expressed CD24 
on their surface. Of the CD24+ cells, almost two thirds also expressed CD133/2 
(65.16% ± 13.57). The co-expression of CD133 and CD24 was confirmed by 
immunofluorescence, where some colonies displayed both markers (Figure 3.5 C). 
However, almost a quarter (23.5 ± 8%) of the CD24+ renal cells did not express CD133. 
In comparison, only 4.6 ± 1.4% of the renal cells expressed CD133 but not CD24 
(Figure 3.5 B).  
 
FIGURE 3.5 EXPRESSION OF CD24 IN VITRO 
(A) Representative dot plot, obtained staining the heterogeneous population at passage 2 for 
CD24-FITC and CD133/2-APC. The different quadrants are displayed: Q1, CD133+/CD24-; Q2, 
CD133+/CD24+; Q3, CD133-/CD24+; Q4, CD133-/CD24- (B) Histogram bars summarizing the 
FACS data about the expression of CD24 in the whole population and in conjunction with 
CD133/2. The FACS analysis was performed in duplicate for each sample, starting from 
separate aliquots of frozen cells and for each duplicate a technical replicate was performed. 
The scale bars represent the SEM (C) Representative immunofluorescence image stained for 
CD24 (green) and CD133 (red). The scale bar represents 50 µm. 
Thus, virtually all CD133+ cells expressed CD24, but not all CD24+ cells expressed 
CD133. As a result, we decided to base the isolation of the putative renal progenitor 
cells on the expression of CD133 only (see paragraph 3.2.4).  
 79 
 
3.2.3 CHARACTERIZATION OF THE HETEROGENEOUS POPULATION AT PASSAGE 2 
The heterogeneous population of all samples was characterized by FACS at 
passage 2. Generally, the data are presented separately for each cell line, where 
interesting differences among the samples were found, or pooled together, where all 
samples followed the same trend.  
3.2.3.1 CD31 AND CD45  
At first, the heterogeneous population was characterized by FACS for the 
expression of CD45 and CD31, to rule out the possibility that the heterogeneous 
population obtained is derived from the hematopoietic (CD45) or endothelial (CD31) 
component (Figure 3.6). A small subset of the overall renal population was 
characterised by the CD31 expression, being less than 5% across the five cell lines 
(Figure 3.6 A and C). In regards to CD45, its expression was evaluated in conjunction 
with CD133. An average of 6.18 ± 4.17% cells of CD133-positive cells also expressed 
CD45 (Figure 3.6 B and C). CD45 expression was not detected in the CD133/2-negative 
subset of cells (Data not shown). 
This FACS analysis shows that the isolation procedure did not lead to the 
accumulation of endothelial cells in the bulk population. Also, since CD133 was 
originally identified on hematopoietic stem cells (Yin et al., 1997), it was important to 
exclude an enrichment for hematopoietic cells  expressing CD133. 
 
FIGURE 3.6 EXPRESSION OF CD31 AND CD45 IN VITRO 
(A) Representative FACS histogram showing the distribution of the whole population of renal 
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cells stained with an anti-CD31-PE antibody, to identify the endothelial population. The grey 
histogram represents the control sample (unstained), whereas the blue histogram is a 
representative stained sample. (B) Representative dot plot depicting the heterogeneous 
population at passage 2 after staining for CD45-PerCP and CD133/2-APC. (C) Histogram bars 
showing the mean values of CD31+ cells and CD45+/CD133/2+ cells in all samples. The FACS 
analysis was performed in duplicate for each sample, starting from separate aliquots of frozen 
cells; for each duplicate a technical replicate was performed. The scale bars represent the 
SEM. 
3.2.3.2 MESENCHYMAL MARKERS 
The next aim of the present study was to define the phenotype of the isolated cells 
for mesenchymal markers. CD73 (5’-nucleotidase), CD90 (Thy1.1) and CD44 were 
chosen as indicated by the international society for cellular therapy position 
statement (Dominici et al., 2006).  
All cells from all samples in culture at passage 2 were found to express CD73. 
Therefore, all CD133+ cells were also CD73+ (Figure 3.7A). By contrast, the amount of 
CD90+ cells was below 20% in all samples except hK4, where the number of CD90+ cells 
exceeded 40%. In the CD90+ subpopulations, only in hK1 and hK4 showed significant 
differences between the amount of CD133+/CD90+ and CD133-/CD90+ cells (hK1: 
p<0.05; hK4: p<0.05). Finally, immunofluorescence analysis of CD44 revealed that all 
cell lines expressed this marker (Figure 3.7 C).  
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FIGURE 3.7 EXPRESSION OF MESENCHYMAL MARKERS IN VITRO  
(A) Histogram showing the mean values of all samples for the amount of CD73+ cells in the 
heterogeneous population and in conjunction with CD133. The error bars represent the SEM. 
(B) Histogram showing the amount of CD90+ cells in each sample in relation to the expression 
of CD133. The FACS analysis was performed in duplicate for each sample, starting from 
separate aliquots of frozen cells and for each duplicate a technical replicate was performed. 
The scale bars represent the SEM. A t-test was applied to determine significance, *p<0.05 (C) 
Representative immunofluorescence image stained for CD44 (green) in the heterogeneous 
population. The scale bar represents 50 µm. 
Thus, all cell lines except hK4 expressed CD73 and CD44, but not CD90. hK4, 
instead, had the highest amount of CD90+ cells and most of them were part of the 
CD133- fraction. Although not all recommended mesenchymal markers were tested 
(e.g. CD105), the data suggest that the renal cells show an incomplete mesenchymal 
profile, since they lack CD90. However, CD90 has been also used to identify and purify 
fibroblasts in human primary cell lines (Kisselbach et al., 2009). It is therefore a 
possibility that following the isolation procedure hK4 was enriched for fibroblasts. 
 
  
 82 
 
3.2.3.3 EPITHELIAL MARKERS  
Next, we aimed at characterizing the renal population for epithelial markers. 
Specifically, CD324 (E-Cadherin) and CD326 (EpCam) were chosen (Kalluri and 
Weinberg, 2009; Metsuyanim et al., 2009; Trzpis et al., 2007). Virtually all cells isolated 
in this study expressed both E-Cadherin and EpCam (Figure 3.8 A-D). Thus, all CD133+ 
cells expressed the two epithelial markers. 
CD13 (Aminopeptidase N) was evaluated by FACS as an additional epithelial 
marker on the five cell lines. CD13 is expressed on tubular epithelial cells, specifically 
proximal tubular cells (Van der Hauwaert et al., 2013). Interestingly, at least 50% of 
the cells of each sample expressed CD13 (Figure 3.8 C) and, most importantly, in each 
sample, the number of CD133+CD13+ cells was significantly higher than the 
counterpart (t-test; hK1, hK2, hK3, hK4: p<0.01; hK5: p<0.001). The data indicate that 
a fraction of the CD133+ cells expressed markers of the proximal tubular cells, which 
are fully differentiated cells.  
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FIGURE 3.8 EXPRESSION OF EPITHELIAL MARKERS IN VITRO 
(A-C) Representative FACS histograms showing the distribution of the whole renal cell 
population stained with an anti-CD324-APC (A), anti-CD326-FITC (B) or anti-CD13-FITC 
antibody (C). The grey histograms represent the control sample (unstained), whereas the blue 
histograms are representative stained samples. (D) Histogram showing the mean values of all 
samples for the percentage of CD324+ cells and CD326+ cells in the whole populations or in 
conjunction with CD133. Note that CD324-APC was used with CD133/1-PE and CD326-FITC 
and CD13-FITC were used with CD133/2-APC. The error bars represent the SEM. (E) 
Histogram showing the percentage of CD13+ cells in each sample in relation to the expression 
of CD133. The FACS analysis was performed in duplicate for each sample, starting from 
separate aliquots of frozen cells; for each duplicate a technical replicate was performed. A t-
test was applied to determine significance, ** p<0.001. 
3.2.3.4 RENAL PROGENITOR MARKERS 
To make the phenotypical analysis more thorough, other putative markers of renal 
progenitor cells were evaluated in the heterogeneous population of all cell lines by 
FACS. 
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NCAM1 (CD56) had been identified as marker of progenitor/stem cells in the 
human fetal and adult kidney (Buzhor et al., 2013; Metsuyanim et al., 2009), whereas 
Tra-1-60 had been proposed as marker of progenitor cells in the adult kidneys 
(Fesenko et al., 2010). Very few cells expressed CD56. Similar to the results for CD90, 
all samples presented less than 10% CD56-expressing cells, with the exception of hK4, 
where as many as 40% of the cells expressed CD56. Among the CD56+ cells, there were 
significant differences between the number/percentage of CD56+/CD133+ and 
CD56+/CD133- cells depending on the cell line (Figure 3.9A). The CD133- population of 
hK1 and hK4 contained a higher number of CD56+ cells (hK1, hK4: p<0.01) than the 
CD133+ population, whereas it was the opposite situation for hK3 and hK5 (hK3, hK5: 
p<0.05).  
Tra-1-60 expression showed a more homogeneous trend across the samples: 
approximately 50% of the cells expressed Tra-1-60. Among these, expression of Tra-1-
60 was significantly higher in the CD133+ fraction (Figure 3.9 B).  
 
FIGURE 3.9 EXPRESSION OF RENAL PROGENITOR MARKERS IN VITRO 
(A) Histogram showing the amount of CD56+ cells in each sample in relation to the expression 
of CD133. (B) Histogram showing the mean values of all samples for the amount of Tra-1-60+ 
cells in the whole populations and in conjunction with CD133. The error bars represent the 
SEM. The FACS analysis was performed in duplicate for each sample, starting from separate 
aliquots of frozen cells and for each duplicate a technical replicate was performed. A t-test 
was applied to determine significance, ** p<0.001. 
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In summary, the renal primary cell lines appeared quite heterogeneous, expressing 
mesenchymal markers (CD73 and CD44) and epithelial markers (E-Cad and EpCam). Of 
note, the amount of fully differentiated tubular epithelial cells, detected through the 
expression of CD13, accounted for more than 50% of the population. However, a 
proportion of the CD133+ cells also expressed Tra-1-60, and CD56, even if at very low 
levels. In conclusion, it appeared that even if most of the cells expressed CD133, 
several sub-populations were present.  
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TABLE 3.2 SUMMARY OF THE EXPRESSION OF THE SURFACE MARKERS ANALYSED IN THIS STUDY 
All markers were analysed using the heterogeneous populations of all biological samples 
(hK1-hK5) at passage 2 by FACS in conjunction with the expression of CD133. * hK4 showed 
the highest amount of CD90+ cells (50%) and CD56.  The role of the markers and where they 
are found in mammalian cells is reported. 
Legend: expression levels in the heterogeneous population: +, 0%<X<25%; ++, 25%<X<50%; 
+++, 50%<X<75%; ++++, 75%<X<100%; >10% expression    ; <10% expression   . For 
significance levels, consult the respective section in the results.  
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3.2.4 SORTING OF CD133+ AND CD133- CELLS 
In order to analyse the CD133+ and CD133- populations separately in further 
experiments, the heterogeneous population was sorted based on the expression of 
CD133. The feasibility and efficacy of MACS and FACS in separating the two 
populations was compared using the hK2-derived heterogeneous population. 
The FACS sorting strategy of the heterogeneous population is shown in Figure 3.10 
A-D: 
- The entire population, defined Parental (P1), was gated by excluding cells at 
high Forward Scatter – Area (FSC-A) and Side Scatter – Area (FSC-A). Higher 
SSC-A signals indicate increased granularity and therefore dying cells; high FSC-
A signals denote the presence of doublets in the cell suspension. The P1 gate 
contained an average of 85.5% ± 5.3 cells (Figure 3.10 A) 
- The doublet content in the population was further characterized by looking at 
the FCS-Weight. Cells at high FCS-W were gated out for the actual sorting 
(Figure 3.10 B), 
- Finally, a histogram and a dot plot were generated to define the amount of 
CD133+ and CD133- cells to be sorted (Figure 3.10 D).  
The distribution of CD133-labelled cells did not allow a clear distinction between 
CD133+ and CD133- cells, since no distinct peaks were observed (Figure 3.10 C). Thus, 
in order to insure high purity for both populations, a relatively large gap was 
maintained between the two populations to sort (21.1% ± 8.5) (Figure 3.10 C).  
The graph in Figure 3.10 E shows the content of CD133+ cells analysed before the 
sortings using the FACS counter (for the MACS sorting), and the FACS sorter (for the 
FACS sorting). The starting amount of CD133+ cells in the bulk population (hK2) was 
the same for both techniques. The amount of CD133+ cells that could be retrieved at 
the end of the both sortings was different. The difference depended on the necessity 
to keep the gap (between CD133+ and CD133- cells) wider during the FACS sorting, so 
that the purity of both populations could be increased. By doing so, there was a 
significant loss of CD133+ cells that could be obtained at the end of FACS sorting 
compared to the MACS sorting (p<0.05) (Figure 3.10 E).  
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The MACS sorting was carried out using an antibody against CD133/2 labelled with 
PE. Microbeads that recognized the PE fluorochrome, and LD columns specifically 
designed for negative selections, were used. However, the MACS system proved to be 
inconsistent and highly variable with respect to purity, specifically of the CD133- 
population (Figure 3.10 F). The MACS efficacy calculated according to Equation 1 
(Material and Methods, page 56) was 0.49, leading to a purity for the CD133- 
population of 50.8% ± 33.1. Both CD133+ and CD133- populations, when sorted by 
FACS, displayed a higher purity compared to the populations isolated by MACS (p<0.05 
for both populations) (Figure 3.10 F). This data suggest that the LD columns worked 
well to obtain a pure CD133+ population, but not to get a pure CD133- population. 
Therefore, it appeared that the number of CD133+ cells that needed to be depleted 
from the total population was too high for the columns to work efficiently (Miltenyi 
technical support, personal communication).  
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FIGURE 3.10 FACS SORTING STRATEGY EMPLOYED IN THE STUDY AND COMPARISON WITH MACS 
(A-D) Sorting strategy used to sort the heterogeneous population in CD133+ and CD133-  
cells. The strategy is detailed in the results section. (E) Histogram showing the expression of 
CD133 before MACS and before FACS. 6 independent sortings for both techniques were 
performed on hK2. For the MACS sortings, the FACS Calibur was used, whereas for the FACS 
sorting, the FACS Aria was used. A t-test was applied to determine significance, * p<0.05 (F) 
Histogram showing the purity obtained for both populations after FACS and MACS (n=6). An 
ANOVA one-way with Dunnet Post Hoc was used to establish significance, * p<0.05. 
Based on these results, it was decided to use FACS sorting as the method of choice 
to separate the entire cell population of the other biological samples into CD133+ and 
CD133- sub-populations. A summary of the sortings of all samples is shown in Figure 
3.11. Higher variability between biological samples was observed due to the 
differences in the actual amount of CD133+ cells. The purity of the CD133-based sub-
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populations, however, remained considerably high (CD133+: 90.7 ± 4.6% vs CD133-: 
87.6 ± 9.8%). 
To sum up, FACS sorting was chosen to sort CD133+ and CD133- cells, because of 
the consistently high purity (~90%) that could be achieved for all biological samples. 
However, by using the FACS, less CD133+ could be obtained because of the technical 
requirements of the FACS sorter machine.  
 
FIGURE 3.11 SUMMARY OF THE SORTING FOR ALL SAMPLES (HK1-HK5) 
(A) Histogram showing the average distribution of CD133+ and CD133-  cells of all samples 
according to the FACS analysis showed in Figure 3.10. hK1 and hK3 were sorted twice, hK4 
and hK5 were sorted once, hK2 was sorted eight times. The error bars represent the SEM. (B) 
Histogram showing the mean values of purity of CD133+ and CD133- cells for all samples 
obtained. The error bars represent the SEM. 
3.2.5 CHARACTERIZATION OF CD133+ AND CD133- POPULATIONS BY 
IMMUNOFLUORESCENCE 
The putative renal progenitor population expressing CD133 and the CD133- 
subpopulation were further characterised for renal progenitor markers, in line with 
previous studies (Bussolati et al., 2005). Specifically, the expression of the two 
transcription factors Pax2 and Wt1 was evaluated by immunofluorescence. Pax2 is not 
expressed in adult kidneys, but it has been shown to co-localize with CD133 (Bussolati 
et al., 2005; Ye et al., 2011). Wt1 is expressed in the developing kidneys and, in the 
adult kidneys, by podocytes and parietal epithelial cells (Kabgani et al., 2012). Analyses 
of both populations were performed by seeding the cells both CD133+ and CD133- 
populations of all biological samples (hK1, hK2, hK3, hK4, hK5) immediately after 
sorting, and letting them attach overnight before fixing and staining. Representative 
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fluorescence images are shown in Figure 3.12. Wt1 was expressed by all cells of the 
CD133+ and CD133- populations. Pax2, instead, was expressed by 95.7% ± 4.2 of the 
CD133+ cells and by 57.3% ± 9.8 of the CD133- cells.  
 
FIGURE 3.12 EXPRESSION OF RENAL PROGENITOR TRANSCRIPTION FACTORS (WT1, PAX2) AND 
VIMENTIN 
Representative immunofluorescence images stained for (A) Pax2 (red) and Wt1 (green) in 
CD133+ and CD133- cells. Notably, 57.3% ± 9.8 of the CD133-  cells expressed Pax2. For each 
cell line, 10 random images were taken and the number of Pax2+ cells was counted for each 
of them, together with the number of DAPI+ cells, to get the total amount of cells (B) 
Representative immunofluorescence image stained for Vimentin (red) in CD133+ and CD133-  
cells.  
Vimentin, a marker of mesenchymal cells, was found to be expressed in the 
regenerating epithelium after acute damage and by the scattered tubular cells 
(Smeets et al., 2013; Witzgall et al., 1994). Here, Vimentin was expressed by all CD133+ 
cells (Figure 3.12 B), consistently with previous reports in the literature (Bussolati et 
al., 2013; Lindgren et al., 2011; Smeets et al., 2013). However, also all CD133- cells 
expressed Vimentin, indicating that the marker is expressed in vitro by all renal cells 
regardless CD133 expression. 
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3.2.6 CHARACTERIZATION OF THE CD133+ AND CD133- POPULATIONS IN 
CULTURE 
The results presented so far showed that a population of CD133+ cells could be 
efficiently isolated from the chilren’s kidneys. However, the number of CD133+ cells in 
culture greatly exceeded that of CD133- cells already at passage 2 (Figure 3.13), 
suggesting that the CD133+ cells may proliferate and take over in the primary cultures 
or that most renal cells start expressing CD133 de novo.  
Since one of aims of this project was to isolate a CD133+ population for cell 
therapies, it was essential to assess whether the cells were expandable from every 
donor, and whether the expression of CD133 was maintained during expansion. 
Therefore, after isolation, the population doubling time for the CD133+ population for 
each sample from passage 2 to passage 3 was recorded (Figure 3.13 A). Interestingly, 
the CD133+ population from hK5 could not be expanded after sorting. For all the other 
samples, PD times are shown in Figure 3.15 A. The healthy sample (hK2) gave rise to a 
CD133+ population with the lowest PD time of approximately 30 hours. The 
correlation between the age of the patients and the population doubling time did not 
give any significant result (Data not shown; p-value 0.4541). However, the differences 
among the biological samples were significant (Figure 3.13 A) and this might be 
explained by the different disease status of the patients. However, information about 
the patients was not available. 
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FIGURE 3.13 CHARACTERIZATION OF CD133+  POPULATION IN CULTURE 
(A) Population Doubling time (PD time) of four samples (hK1, hK2, hK3, hK4) calculated from 
passage 2 to passage 3 using the Doubling Time software. An ANOVA test with Dunnets Post 
Hoc was applied and the p-values of all combinations are listed in (B). (C) PD time of all CD133+ 
populations calculated from passage 2 to passage 5. One data point of hK4 was eliminated 
from the graph since it was too far out from the other samples (1125 hours).  
Next, the PD time evaluations were carried out during expansion of the cell 
populations. The CD133+ cells were monitored for up to 25 days and counted at every 
passaging step to obtain the PD time for each passage for each cell line (Figure 3.13 B). 
For all cell lines, an increase in the PD time was observed at higher passages, 
indicating that the cells might become senescent over passages. For hK4, the last time 
point greatly exceeded the PD time of the other samples, reaching 1125 hours . 
Therefore, hK4 was excluded from further characterizations.  
During the sorting process, both CD133+ and CD133- cells were isolated. Figure 
3.14 shows representative micrographs of both CD133+ and CD133- cells belonging to 
hK2 and hK3 five days in culture after sorting. In hK2, the vast majority of the CD133+ 
cells maintained a small cuboidal, epithelial-like morphology. By contrast, the CD133- 
cells appeared mainly enlarged and elongated. For hK3, instead, both populations 
appeared to be quite slow-cycling and did not reach confluency after five days in 
culture. In the CD133+ fraction, there were not only small epithelial-like cells but also 
occasional enlarged cells, also which were also present in the CD133- fraction. Small, 
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compact colonies of epithelial cells, (Fig. 3.14 B) were not unusual to spot in CD133- 
cultures. These colonies may originate from CD133+ cells, hence representing a 
contamination of the CD133+ cells within the CD133- population. 
 
FIGURE 3.14 BRIGHT FIELD IMAGES OF CD133+ AND CD133- CELLS AT PASSAGE 2 
Bright field images of freshly isolated cells taken five days after the FACS sorting. The dotted 
line represents a compact colony of epithelial cells, presumably CD133+ cells. Scale bar 
represents 50 µm. 
3.2.7 CLONOGENIC POTENTIAL OF CD133+ AND CD133- CELLS  
In order to define a progenitor/stem cell as such, it is important to test its 
potential to self-renew, giving rise to an entire population starting from a single cell. 
Following this requirement, two methods were used to investigate the clonogenic 
potential of both populations: Giemsa assay and FACS.  
For the Giemsa assay, 100 and 200 CD133+ or CD133- cells at passage two after 
FACS sorting were seeded in a 6 cm dish (Figure 3.15 A-B). After three weeks in 
culture, several colonies were observed, each presumably originated from a single cell. 
The dishes were stained using the Giemsa staining, so that the colonies could be 
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counted under an inverted microscope. When 100 cells were seeded, both CD133+ 
and CD133- cells gave rise to around 40 colonies, corresponding to a cloning efficiency 
of 40%. When 200 cells were seeded, the CD133- cells gave rise to almost 80 colonies 
(cloning efficiency 40%), whereas the CD133+ cells to about 65 colonies (cloning 
efficiency 32.5%; t-test, p=0.0198). However, the assay is not entirely reliable, since it 
is not possible to exclude that two cells in close proximity gave rise to one colony only. 
Also, some colonies could be found so close to be virtually undistinguishable, and it is 
not possible to isolate the clones to characterize them further.  
 
FIGURE 3.15 CLONOGENIC ASSAY 
(A-B) Giemsa staining. 100 and 200 CD133+ or CD133-  cells were seeded in a 6 cm dish after 
sorting from the heterogeneous population. The dishes contained fresh medium and 
conditioned medium (1:1) and the cells were left in the incubator for 3 weeks, without a 
change of medium. After the culture period, the cells were fixed in Methanol, and stained 
with Giemsa dye, to highlight the cell body. The colonies were scored under an inverted 
microscope. A un paired t-test was used to establish significance between the CD133+ and 
CD133-  samples, * p=0.0198, n=3. (C) Sorting on single cells into a 96 well plate from the 
heterogeneous population. The wells contained fresh medium and conditioned medium (1:1) 
and the wells were scored for the presence or absence of single cells on day 1. Subsequently, 
the wells were observed every week until the presence of a confluent well was identified. 
From the 96 well plate, the colonies were then trypsinized and transferred subsequently to a 
48 well plate, 24 well plate, 12 well plate, 6 well plate and 6 cm dish. 
To overcome this issue, the CD133+ and CD133- populations were seeded straight 
after sorting in two 96 well plates at the density of 1 cell per well. Each well contained 
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a mixture of fresh medium with conditioned medium from the heterogeneous 
population to better support the growth of the eventual clones. Figure 3.15 shows 
that both populations were able to give rise to clones. Interestingly, the CD133+ and 
CD133- cells showed a cloning efficiency of 20% (20 colonies out of 96 wells), and 25% 
(24 colonies out of 96 wells), respectively (Figure 3.15 C). Most of the clones were 
found to not expand following the passaging, and only few could be expanded. Having 
obtained few colonies, the study and the use of clones for following experiments was 
not pursued further. 
Overall, the clonogenic assays performed on both populations do not show any 
major difference. However, the data suggest that the cell-cell interaction in the 6 cm 
dish, as for the Giemsa assay, facilitated the growth of colonies.  
3.2.8 EVALUATION OF THE CD133  EXPRESSION IN BOTH SORTED POPULATIONS 
DURING EXPANSION 
To ensure that the expression of CD133 was maintained by the whole positive 
population over passages, and not acquired by the negative population, both CD133+ 
and CD133- populations from three cell lines (hK1, hK2, and hK3) were monitored for 
the CD133 expression by FACS over six passages (Figure 3.16 A). After sorting, the 
number of CD133-expressing cells in the CD133+ population accounted for more than 
95% up to passage 4 to then reach circa 80% at passage 5 and nearly 60% at passage 
6. In the CD133- population, instead, after sorting, an increase in the number of cells 
expressing CD133 was reported. From the sorting to passage 3, the number of CD133+ 
cells reaches approximately 30% of the whole population, and decreased from 
passage 5 (Figure 3.16 A). These data can be explained through two mechanisms: the 
CD133+ cells proliferated faster than the counterpart or a fraction of the CD133- cells 
started expressing CD133 de novo.  
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FIGURE 3.16 CHARACTERIZATION OF CD133+ AND CD133- CELLS DURING EXPANSION 
(A) FACS analysis over 6 passages of changes in CD133 (CD133/2) expression in the CD133+ 
and CD133- populations of the biological samples hK1, hK2, hK3. (B) FACS analysis over 6 
passages of changes in CD13 expression in the CD133+ population of biological samples hK1, 
hK2, hK3. CD13 was evaluated alone and together with CD133/2 APC. (C) FACS analysis over 6 
passages of changes in CD13 expression in the CD133- population of biological samples 
samples hK1, hK2, hK3. CD13 was evaluated alone and together with CD133/2 APC. The 
sorted populations from each sample were expanded twice and the FACS analysis for CD133 
was performed in duplicate at each passage. The bars show the SEM. 
In addition to the expression of CD133, the two populations were evaluated for 
the expression of CD13, since it was expressed by a significant portion of the CD133+ 
population at passage 2 (Figure 3.8 and Figure 3.16 B-C).  
In the CD133+ population, the amount of the CD13+ cells increased from passage 
two onwards, reaching 80% at passage 4. Interestingly, all CD13+ cells are also CD133+. 
Notably, at passage 5 there is a sudden drop in the expression of CD13, which might 
reflect a dedifferentiation of the population (Figure 3.16 B). In the CD133- population, 
an exponential increase of the CD13+ subpopulation was observed. Also in this case, all 
CD133+ cells were CD13+, but not all CD13+ cells were CD133+ positive (Figure 3.16 C).  
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In summary, the data from the expansion of the cells showed that the positive 
population maintained the expression of CD133 up to passage 5. In the negative 
population, it was noted an upregulation of CD133 expression in culture. Importantly, 
both populations contained a significant fraction of fully-differentiated tubular cells.  
Due to these findings, it was decided that in the in vivo experiments the cells 
would be expanded for not more than 4 passages and injected at passage 5, in order 
to use a relatively pure CD133+ population. For the negative population a different 
strategy was chosen: the CD133- population was sorted after every passage to remove 
as many CD133+ cells as possible. Since the amount of CD133+ cells did not exceed the 
40% of the total number of cells, MACS could be successfully used to achieve a good 
purity (Data not shown). 
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3.3 DISCUSSION 
At the moment, the alternatives for ESRD patients are limited to transplantation 
and dialysis. However, the shortage of kidneys and the demanding costs of dialysis 
make it necessary to explore alternative therapies. Cellular therapies might represent 
this alternative, given that any pure population chosen is tested to be efficaceous to 
ameliorate or slow down the progression of kidney injuries. The beneficial effects of 
mesenchymal stem cells in preclinical models of kidney injuries are quite established 
(Grange et al., 2014b). Nevertheless, several groups investigated whether a progenitor 
population exists in the adult kidney. In 2005, the surface protein CD133, a hallmark of 
several stem cells and cancer stem cells, was suggested as marker of a putative 
progenitor population in the adult kidneys, even though its role has not been 
completely elucidated (Angelotti et al., 2012; Bussolati et al., 2005; Sagrinati et al., 
2006).  
In the current study, the isolation and characterisation of CD133+ renal 
stem/progenitor cells was performed using kidneys biopsies obtained from children. 
The age range of the samples used was quite wide (6 months to 10 years old) and 
most patients were hospitalized for recurrent infections, in some cases a consequence 
of having a duplex kidney. Nevertheless, the CD133+ population was shown to lie on 
the Bowman’s capsule (BC), and in scattered tubular cells consistent with previous 
studies (Hansson et al., 2014; Ronconi et al., 2009). In the outer stripe of the medulla, 
the whole cross-section of the tubuli of the loop of Henle was shown to express 
CD133. This population may represent the papillary renal stem cells identified in mice 
(Oliver et al., 2004) and in humans (Bussolati et al., 2013). Therefore, our results show 
that in children’s kidneys, localisation of CD133 expression is consistent with that 
previously described in adult kidneys, and regardless of the underlying renal disease 
(Bussolati et al., 2005; Hansson et al., 2014). Interestingly, sporadic CD133+ cells were 
spotted inside the glomerulus, especially in hK4 (Figure 3.1). In previous studies, it was 
hypothesized that human CD133+ cells migrate from the luminal pole of the BC 
towards the tuft of the glomerulus to differentiate into podocytes  (Ronconi et al., 
2009), as it was shown for PEC cells in mice during adolescence (Appel et al., 2009). In 
the samples of this study, the staining observed inside the glomerulus was more likely 
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to represent the contribution of parietal epithelial cells to a glomerular lesion, as in 
the case of glomerulosclerosis, or the dedifferentiation of fully differentiated 
podocytes in response to glomerular damage (Smeets et al., 2009; Smeets et al., 
2011). Since the information about the renal damage of the patients of this study is 
not available, it is hard to rule out one or the other possibility.  
Previously published studies reported that, consistently with the notion of 
representing stem/progenitor cells in the kidney, CD133+ cells account for 
approximately the 0.5-4% of the total number of cells isolated from adult kidneys 
(Sagrinati et al., 2006). Those evaluations were carried out on freshly isolated cells 
before plating. In this chapter we have described the isolation and characterisation of 
five cell lines from 5 biological samples (kidney biopsies). In the cell populations of all 
biological samples at passage two (P2), after five-to-seven days in culture, the content 
of CD133+ cells ranged from 40% (hK4) to over 90% (hK3) (Figure 3.4). The FACS data 
at P2 suggested that once in culture the CD133+ cells proliferated quicker than the 
CD133- counterpart. Alternatively, it can be hypothesized that the cells acquired 
CD133 expression as an adaptation to the culture conditions. It is possible that the 
medium used in this study, which has been reported to maintain fetal metanephric 
cells in culture (Price et al., 2007), can eventually play a role in the selective expansion 
of the CD133+ population. Initially, the two monoclonal CD133 antibodies CD133/1 
(AC133) and CD133/2 (293C3) were used to characterize the isolated populations 
(Angelotti et al., 2010). It was interesting to notice that there were differences  in the 
number of cells that expressed the two specific epitopes. This finding has never been 
reported before and it is difficult to explain. The role of CD133/prominin or its 
glycosilated epitopes in maintaining or defining the stem cell phenotype is still unclear 
(Fargeas, 2006).  
Once in culture, all cell lines looked highly heterogeneous and displayed both 
compact epithelial colonies and mesenchymal-like cells. A comprehensive analysis of 
the surface marker profile was performed to characterise the isolated cells. Firstly, the 
expression of CD24 was assessed, since all CD133+ have been described to express 
CD24 (Figure 3.5) (Romagnani and Remuzzi, 2014). Our analysis revealed that virtually 
all CD133+ cells in culture expressed CD24, but not all CD24+ cells expressed CD133. 
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CD24 has been described as a marker of stem cells and cancer stem cells, restricted to 
metabolically active cells and progenitor cells and not present on fully differentiated 
cells (Fang et al., 2010). Similarly to CD133, its role in the context of stem cell 
properties has not been elucidated. It has been identified on epithelial cells in many 
organs and is therefore often regarded as an epithelial marker (Fang et al., 2010). 
Based on our findings and the known characteristics of CD24, we decided to carry out 
our further studies based on the expression of CD133 only (Bussolati et al., 2005; 
Ronconi et al., 2009; Sagrinati et al., 2006). 
The bulk population was interrogated for a series of markers that would elucidate 
their phenotype (see Table 3.2). We looked at canonical markers of mesenchymal 
stem cells (Figure 3.7). CD73 and CD44 were previously shown to be expressed on 
renal progenitor CD133+ cells (Bussolati et al., 2005; Bussolati et al., 2013). Conversely, 
the cells do not express high levels of CD90. The expression of CD90 seems quite 
controversial in the literature, where in one study CD90 was found in the majority of 
the cells isolated from adult kidneys (Bussolati et al., 2005), whereas in another study 
CD90 is expressed in less than 30% of the isolated cells (Metsuyanim et al., 2009). The 
difference can be explained by different culture conditions used. However, CD90 has 
also been used to identify and purify fibroblasts in human primary cell lines 
(Kisselbach et al., 2009). It is therefore a possibility that following the isolation 
procedure no fibroblasts were isolated in all samples except hK4, which would be 
consistent with the cell morphology of hK4, where more spindle-like cells were 
observed (Figure 3.3). 
In our analysis, the epithelial markers CD326 (EpCam, Epithelial Cell Adhesion 
Molecule) and CD324 (E-Cadherin) were present in virtually 100% of the population 
(Figure 3.8). In particular, EpCam-positive cells displayed considerable homogeneity in 
the staining intensity, in contrast to analysis performed on human fetal kidney cells by 
Metsuyanim and colleagues (Metsuyanim et al., 2009). They argued that the presence 
of EpCambright and EpCamdim populations was indicative of the presence of 
differentiated cells and progenitor cells, respectively. Their conclusion was based on 
the observation that during fetal development EpCam is expressed in the ureteric bud, 
comma-shaped and S-shaped bodies, but not in the metanephric mesenchyme (MM) 
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which contains the renal multipotent progenitor population (Metsuyanim et al., 2009). 
Thus, according to the hypothesis by Metsuyanim and colleagues, the cell populations 
isolated in this study would be fully differentiated. Interestingly, EpCam was identified 
on the surface of regenerating epithelia (Trzpis et al., 2008). 
CD13 (aminopeptidase N) is a marker of fully differentiated proximal tubular cells 
(Baer et al., 1997). Our analysis is the first of its kind to characterize a primary renal 
population for the expression of CD13 (Figure 3.8). However, recently, the expression 
of CD13 was shown on CD133+/NCAM- fetal-derived cells (Pode-Shakked et al., 2016). 
Here, the results can be interpreted in different ways: If CD133 is a true marker of 
putative progenitor cells, then CD13 identified a sub-population of progenitor cells 
already committed towards the tubular fate. Alternatively, if CD133 is acquired in 
culture as an adaptation to the in vitro conditions, then all tubular cells that proliferate 
in culture would acquire CD133. It needs to be pointed out that the medium used to 
isolate the cells might play an important role here. Despite its use to culture fetal 
progenitor cells (Price et al., 2007), the same protocol was retrieved in studies that 
isolated and cultured proximal tubular cells (Van der Hauwaert et al., 2013). It might 
be possible, therefore, that the culture conditions used in this study either promote 
the expansion of progenitor cells with tubular commitment or the upregulation of 
CD133 expression in cells with tubular commitment. 
To obtain a deeper understanding of the heterogeneous status of the primary 
cultures we had isolated, the putative renal progenitor markers NCAM1 and Tra-1-60 
were evaluated (Figure 3.9). NCAM1 (CD56) has been identified in the nephrogenic 
zone of the developing kidney, and it was also found on a small percentage of adult 
kidney epithelial cells (Buzhor et al., 2013). Our analysis showed that only a small 
percentage of CD56+ cells was detected (with the exception of hK4) in primary cultures 
of all biological samples, which is consistent with what has been previously described 
(Metsuyanim et al., 2009).  
Tra-1-60, an isoform of the proteoglycan podocalyxin, is expressed in the 
Bowman’s capsule and has been linked to renal epithelial cell polarization and 
tubulogenesis. However, podocalyxin is also expressed in mature podocytes (Fesenko 
et al., 2010). Interestingly, in our primary cell populations at least half the cells 
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expressed Tra-1-60, and in addition, the majority of them also co-expressed CD133. 
However, the investigation of the features of Tra-1-60+ cells was not done in vitro, so 
its function in context of progenitor cells remains elusive (Fesenko et al., 2010). It is 
possible that CD133+/Tra-1-60+ cells represent a progenitor population committed 
towards podocytes, but there is no evidence in the literature to support this 
hypothesis.  
It should be mentioned as well that it was attempted to generate clonal 
populations at the start of the project. However, the clones proved to be difficult to 
expand and characterize (Figure 3.15). Therefore, it was decided to study the bulk 
population. Further research to dissect even further the heterogeneity observed could 
involve molecular profiling  of a large pool of single CD133+ cell to exactly determine 
its phenotypical composition.  
The aim of the study was to isolate CD133+ cells and test their potential in an in 
vivo model of acute kidney injury (chapter 5). As a negative cell population, we 
envisaged to use CD133- cells. Therefore, the samples were sorted for the expression 
of CD133. Both MACS and FACS technologies were compared to assess which 
techniques achieved the highest purity in both CD133+ and CD133- cell populations 
(Figure 3.10). MACS gave a higher yield in terms of cell numbers but a lower purity 
than FACS. This is in contrast to what has been shown in the literature, where MACS 
were used to isolate the CD133+ population (Angelotti et al., 2012; Bussolati et al., 
2005; Ronconi et al., 2009; Sagrinati et al., 2006). However, in all these studies, the 
CD133+ cells were isolated soon after the dissociation of cells from the tissue, when 
1%-4% of the cells are CD133+ (Bussolati et al., 2005; Sagrinati et al., 2006). Therefore, 
our inability to isolate a highly pure CD133- cell population using MACS was attributed 
to the high number of CD133+ cells in the population to sort. Importantly, how FACS 
and MACS can affect specific stem cell function still remains largely unknown.  
Once sorted, the CD133+ and CD133- populations were further characterized by 
immunofluorescence for the expression of Pax2 and Wt1, two transcription factors 
expressed in the metanephric mesenchyme (Reidy and Rosenblum, 2009), and 
Vimentin, a marker for mesenchymal cells which has been also associated with de-
differentiation and regenerating epithelia (Smeets et al., 2013). Our analysis showed 
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that both the CD133+ and CD133- populations expressed Wt1. Since Wt1 is expressed 
in both PEC and podocytes in mouse and humans (Bussolati et al., 2005; Kabgani et al., 
2012),  our results are not surprising. Our results also showed that all CD133+ cells and 
approximately 60% of the CD133- cells expressed Pax2. Pax2 expression had been 
previously identified in vitro in CD133+ cells by Bussolati and colleagues (Bussolati et 
al., 2005). Pax2 is not expressed in adult tissues in vivo, but was shown to be re-
expressed after acute injury on tubular cells  (Ye et al., 2011). Here, we observe its 
expression in the majority of the cells, including CD133- cells. Also, both populations 
also expressed Vimentin, regardless of CD133 expression. 
Taken together, the characterization data demonstrated high levels of 
heterogeneity in the primary cultures, which needs to be further analysed. In vitro, the 
cells express markers that have been identified in vivo on regenerating epithelia, 
including Pax2, EpCam, Vimentin, CD44, Tra-1-60, regardless of the CD133 expression 
(Asselman et al., 2003; Fesenko et al., 2010; Smeets et al., 2013; Trzpis et al., 2008; 
Witzgall et al., 1994; Ye et al., 2011). By plating the bulk population, we might be 
therefore expanding what it would be the population responsible for the regeneration 
of the tubular epithelium in vivo. Whether this population is the PEC or the STC 
population it cannot be determined, since the marker CD106, that distinguishes 
between the two putative progenitor populations, was not utilized in this study. Also, 
since the sorting of the CD133+ cells was carried out on cells cultured for one or even 
two passages, it is possible that the CD133+ cells obtained do not represent the 
previously reported population (Ronconi et al., 2009; Sagrinati et al., 2006), and were 
phenotypically altered by the culture conditions. In addition, since the whole kidney 
was available for one of the patients (hK2), it could have been feasible to separate the 
tubular and glomerular compartments, and then sort for CD133, to investigate 
different progenitor potentials in the two renal compartments.  
Morphologically, the two isolated populations showed marked differences, since 
the CD133+ cells had predominantly a polygonal epithelial-like phenotype, whereas 
the CD133- cells appeared mostly enlarged and elongated. However, even in the 
CD133- fraction, it was not unusual to find small epithelial colonies. Indeed, a further 
characterization by FACS of both CD133+ and CD133- cells over few passages in culture 
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showed that there is an increase of the CD133+ fraction in the CD133- population. 
Importantly, most of the CD133+ cells were CD13+ until P5, when a substantial drop in 
the expression of CD13 was observed. This drop is consistent with the loss of markers 
specific for the fully differentiated cells, as it was documented for primary proximal 
tubule cells and podocytes (Okamura et al., 2009; Wilmer et al., 2010). Take together, 
this data can be interpreted in two ways: i) the progenitor population pre-committed 
to a tubular fate expands over time, or ii) the CD133+ cells acquire the CD13 
expression in culture, probably fostered by the culture medium. 
Finally, the CD133+ populations were analysed for their population doubling time 
(PD time) in culture. There were significant differences between the PD times of all 
samples, which probably reflected the renal health of the patients. Interestingly, one 
sample (hK5) could not be expanded. The possible differences between samples in 
terms of expandability have never been investigated, but it should be of great 
importance when considering autologous cellular therapies. 
In summary, in this chapter, it was shown that putative progenitor cells could be 
isolated from young kidneys. The phenotypical analysis of the samples proved that the 
progenitor populations were heterogeneous, having both epithelial and mesenchymal 
characteristics. It would be expected that a progenitor population, isolated through 
the expression of a bona fide marker, such as CD133, would be quite homogeneous. 
Instead, other subpopulations were identified, carrying fully differentiated markers 
(CD13) or other putative progenitor markers (CD56 and Tra-1-60). Interestingly, 
markers associated with the dedifferentiation/regeneration of tubular cells, such as 
Pax2, Vimentin, and EpCam were also expressed in vitro. It is, therefore, possible that 
the population isolated is the one that had been described to proliferate in response 
to injury in the tubular compartment. The isolated cells will be tested for 
differentiation capacity and ability to integrate into an ex vivo chimeric assay in the 
next chapter and for their amelioration potential in vivo in chapter 5. 
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4 INVESTIGATING THE ABILITY OF CD133+ AND CD133- CELLS 
TO DIFFERENTIATE INTO PODOCYTES AND TO INTEGRATE IN A 
CHIMERIC RUDIMENT 
4.1 INTRODUCTION AND AIMS 
In the previous chapter, the isolation of a renal cell population from biopsy tissues 
obtained from children was reported. Upon isolation, most of the renal cells expressed 
CD133, marker of renal progenitor cells. The nature of the isolated cells was 
characterized and compared to the CD133- counterpart. The CD133+ population 
appeared quite heterogeneous and expressing markers of both epithelial and 
mesenchymal cells. Importantly, the vast majority of CD133+ cells expressed CD13, a 
marker of fully differentiated proximal tubular cells. The CD133+ population could be 
expanded in culture for up to 6 passages, but it started losing the expression of the 
marker by passage 5. Instead, in the CD133- fraction, an increase of CD133-expressing 
cells was observed. It would appear as the CD133+ population has proliferative 
potential in vitro.  
In this chapter, two aspects of the CD133+ and CD133- cells described in chapter 3 
will be investigated, in order to demonstrate their renal progenitor potential: (i) the 
differentiation potential towards a specialized renal cell type; and (ii) the ability of the 
progenitors to integrate into developing structures of a chimeric rudiment. The first 
aspect has been used in previous studies to test the putative progenitor population. 
The second feature is relatively unexplored for the CD133+ population. In both cases, 
the CD133- will be used as negative control. 
If the CD133+ truly represents a population of renal progenitor cells, it can be 
expected that they might somehow contribute to the formation of de novo tubuli 
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during the reorganization of the mouse embryonic renal cells. In contrast, the CD133 - 
population would rather occupy the stromal space within the chimera without any 
sign of integration.  
Specifically, the following objectives will be addressed: 
1. Investigate the differentiation potential of CD133+ and CD133- cells isolated from 
young adults kidneys, specifically towards podocytes; 
2. Analyse the nephrogenic potential of CD133+ and CD133- cells in the chimeric 
kidney rudiment assay, in comparison to control reaggregated rudiments and 
chimeric rudiments using a positive control cell line; 
3. Modify the kidney rudiment assay to make it suitable for the LSFM. 
4.2 RESULTS 
4.2.1 PREPARATION OF CD133+ AND CD133--GFP-LABELLED 
The heterogeneous population of cells isolated from hK2 had been cryopreserved 
at passage 1 (see chapter 3). In preparation for the reaggregation assay and the in vivo 
study, cells were thawed, and upon attachment, transduced with a pHIV-GFP viral 
vector using an MOI (Multiplicity of Infection) of 5. The transduced cells were 
expanded for one passage before sorting for the expression of CD133 using the FACS 
Aria. The efficiency of transduction was qualitatively confirmed under the 
fluorescence microscope (Figure 4.1) and quantitatively assessed during the sorting, 
yielding to 88.3% ± 6.5 of the cell population, over three independent sortings.  
The following sorting strategy was pursued to achieve two populations, of either 
CD133+ or CD133- cells, as shown in Figure 4.2: 
- Cells with an FSC-A lower than 70 were considered dead cells and excluded by 
gating. Higher and SSC-A signals indicated increased granularity and therefore 
likely dying cells. Therefore, the population of healthy cells, defined as Parental 
(P1) was considered for further analysis (Figure 4.2 A). 
- The doublet content in the population was further characterized using the 
Forward Scatter-Width (FSC-W) parameter. Cells with high FCS-W were gated 
out of the actual sorting (Figure 4.2 B). 
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- Finally, a density plot was generated to define the amount of cells that were 
either CD133+/GFP+, CD133+/GFP-, CD133-/GFP+, or CD133+/GFP-. It should be 
noted that a small fraction of CD133+ cells is not efficiently transfected with the 
vector pHIV-GFP, shown in Figure 4.2 C, Q1.  
Due to the overall high labelling efficiency, the sortings were based only on the 
expression of CD133/2 (APC-labelled, FL4). The purity immediately after the sortings 
was comparable for the two cell types (94.9 ± 3.7 % vs. 92.0 ± 1.8 %, CD133+ vs. 
CD133-). 
 
 
 
 
FIGURE 4.1 MICROGRAPHS OF CD133+GFP+ AND CD133-GFP- CELLS AT P3 
Representative pictures of CD133+GFP+ cells and CD133-GFP+ cells at P3.  All green 
fluorescence pictures were taken with the same exposure conditions (5 seconds). Scale bars 
correspond to 50 µm. 
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FIGURE 4.2 SORTING STRATEGY USED TO SORT CD133+GFP+ AND CD133-GFP+ 
(A) Dot Plot showing Forward Scatter-Area (FSC-A) and Side Scatter –Area (SSC-A) used to 
discriminate healthy and damaged or dying cells. (B) Dot plot of SSC-A and Forward Scatter-
Width (FSC-W) used to discriminate doublets, which might represent a false positive signal. (C) 
Density plot obtained plotting the signal from the excitation of cells with the 488-nm laser 
(GFP FITC-A, log scale) against the signal from the FL4 laser (APC-A, log scale). Due to the high 
efficiency of GFP labelling, the CD133+GFP- population was neglected, and the sorting was 
based only on the expression of CD133 (Q1+Q2 vs. Q3+Q4) (D) The lentiviral transduction and 
the sortings were performed three times on independent cryopreserved hK2 cells. The table 
summarizes the percentages of cells obtained during the three independent sortings, reported 
according to the quadrants they belonged to. 
4.2.2 ANALYSING THE POTENTIAL OF CD133+/- RENAL PROGENITOR CELLS TO 
DIFFERENTIATE INTO PODOCYTES 
The first aim of this part of the study was to assess the differentiation potential of 
the isolated CD133+ and CD133- cells. Both sorted populations, derived from hK2, 
were seeded at passage 2 or 3 at low density (10.000 cells/well in a 6 well plate) and 
treated for seven days with VRAD medium, containing 100 µM of All-Trans-Retinoic 
Acid (ATRA) and 100 nM Vitamin D3. In parallel, both CD133+ and CD133- cells were 
treated with VRAD control medium. After seven days, both VRAD-treated populations 
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showed a drastic change in the proliferation rate and morphology when compared to 
the populations treated with the VRAD control medium (Figure 4.3). Specifically, both 
CD133+ and CD133- cells treated with the VRAD medium stopped proliferating and, 
most importantly, showed an enlarged and arborized cell body, typical of podocytes.  
 
FIGURE 4.3 REPRESENTATIVE BRIGHT FIELD IMAGES OF CD133+ AND CD133- CELLS CULTURED IN 
VRAD CONTROL OR FULL VRAD MEDIUM FOR SEVEN DAYS.  
104 CD133+ or CD133- cells were seeded in a 6 well plate in HPRC medium overnight. The 
following day, the medium was changed for either VRAD or control medium and refreshed 
every two-three days. After 7 days, the cells appeared as in the figure above. The cells in 
control medium grew as normal. Following treatment with VRAD medium, instead, the cells 
stopped proliferating, their cell body became enlarged (*) and arborized cells appeared 
(indicated by arrowheads). Scale bars represent 50 µm.  
To compare the differentiated cells, conditionally immortalized podocytes (ciPodo) 
and primary podocytes were used. ciPodo is an immortalized cell line consisting of 
proliferative immature podocytes when grown at the permissive temperature of 33°C 
while when cultured at 37°C for 14 days the cells undergo complete differentiation 
(Saleem et al., 2002). ciPodo cells grown under differentiating conditions at 37°C had 
enlarged cell bodies, and some of them were binucleated (Figure 4.4). In addition, 
primary human podocytes were isolated from hK6 by isolating and plating the 
glomeruli with or without Bowman’s capsule (inset in Figure 4.4 B). After several days 
in culture, outgrowths of cells could be observed. The outgrowths were passaged for 
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up to 5 passages. The cells display features of podocytes, including enlarged and 
arborized cell body and occasional binucleated cells. 
 
FIGURE 4.4 REPRESENTATIVE BRIGHT FIELD IMAGES OF DIFFERENTIATED CIPODOCYTES AND PRIMARY 
HUMAN PODOCYTES IN CULTURE 
(A) ciPodocytes were grown at 33°C until 60% confluence and then grown at 37°C for at least 7 
seven days to induce differentiation. Binucleated arborized cells (arrows) were not unusual to 
spot in culture. (B) Primary podocytes were obtained by plating entire glomeruli with or 
without Bowman’s capsule (BC), as shown in the inset. After at least seven days in RPMI+10% 
FCS, cells were growing out of the glomeruli. The outgrowths were then passaged for up to 5 
passages. Here, P5 hK6 glomerular outgrowths are shown. Arborized, binucleated cells 
(arrows) can be observed. Scale bars represent 50 µm 
4.2.2.1 EXPRESSION OF MARKERS OF PODOCYTES 
VRAD- and control-treated CD133+ and CD133- cells were tested for the expression 
of two podocyte-specific markers: podocin and nephrin. Both proteins are essential 
for the maintenance of the slit diaphragms in podocytes. Interestingly, following seven 
days of culture in VRAD medium, both CD133+ and CD133- cells showed the expression 
of podocin and nephrin (Figure 4.6 A and B). Immunofluorescence for podocin 
revealed a distribution which overlaps with the cytoskeleton, with occasional stronger 
staining in the foot processes of some cells. By contrast, nephrin was concentrated on 
the cortical ring of the cytoskeleton of the cells, especially in the CD133 - population. 
Conversely, the cells cultured in control medium for seven days failed to show any 
staining for Nephrin or Podocin, suggesting that the VRAD medium induced the 
expression of podocyte-specific markers.   
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For comparison, immunofluorescence stainings for nephrin and podocin were also 
performed on primary human podocytes at passage 4 and ciPodo grown at 37°C for 
ten days. In the ciPodo, podocin displayed the same distribution as the VRAD-treated 
human cells, closely resembling the pattern previously shown in the literature (Saleem 
et al., 2002). In the primary human podocytes, instead, podocin appeared not only 
overlapping with the cytoskeleton, but also or accumulated in the periphery of the 
cells (Figure 4.6 C).  
The nephrin staining in the primary podocytes and ciPodo, instead, was 
comparable to the staining obtained for the human cells with a diffused distribution in 
the cytoskeleton and concentrated localization at the cell periphery.  
To summarize, it seems that the following stimulation with VRAD medium, both 
CD133+ and CD133- cells do express markers that are physiologically expressed in 
podocytes.  
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FIGURE 4.5 EXPRESSION OF PODOCIN AND NEPHRIN IN HUMAN CD133+ AND CD133- CELLS AFTER SEVEN DAYS IN VRAD OR CONTROL MEDIUM 
Representative immunofluorescence images showing (A-D) CD133+ and (E-H) CD133- cells cultured in VRAD or control medium stained for podocin and 
nephrin (red). 104 CD133+ and CD133-  cells were seeded in a 6 well plate and let to attach overnight in renal progenitor medium. The day after the medium 
was changed for VRAD medium or control medium. The assay lasted in total seven days, with two changes of medium. The VRAD medium, but not the 
control medium, induced the expression of podocin and nephrin. Insets show high magnification images. Arrowheads point towards the accumulation of 
podocin on the edges of the cells. White arrows indicate the accumulation of nephrin into the cortical ring of the cytoskeleton. Scale bars represent 50 µm. 
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FIGURE 4.6 REPRESENTATIVE IMMUNOFLUORESCENCE IMAGES SHOWING HK6-DERIVED PRIMARY 
PODOCYTES AND CIPODOCYTES STAINED FOR PODOCIN AND NEPHRIN  
(A-B) hK6-derived podocytes at passage 4 and (C-D) ciPodocytes grown at 37˚C were stained 
for podocin (red) and nephrin (red). The insets show high magnification images. Arrowheads 
point towards the accumulation of podocin on the edges of the cells. White arrows indicate 
the accumulation of nephrin into the cortical ring of the cytoskeleton. Scale bars represent 50 
µm. 
4.2.2.2 CELL CYCLE ANALYSIS OF DIFFERENTIATED PODOCYTES 
In the previous paragraph, it was reported that the VRAD medium was able to 
induce the expression of podocin and nephrin in both CD133+ and CD133- cells. 
Podocytes are fully differentiated post-mitotic cells, with a typical arborized 
morphology and, often, binucleated. With the aim to provide a more comprehensive 
characterization, the cell cycle of both cell types was analysed by FACS after seven 
days in either VRAD or control medium. 
To start, the ploidy of the cells was taken into account, hypothesising that 
binucleated cells would be tetraploids.   
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Upon treatment with VRAD, both cell types presented a significantly higher 
number of tetraploid cells compared to the control groups (CD133+: Ctrl 3.48% ± 1.14 
vs VRAD 13.77% ± 1.83 p<0.0001, unpaired t-test; CD133-: Ctrl 2.45% ± 1.07 vs VRAD 
11.62% ± 1.99 p=0.0116, unpaired t-test) (Figure 4.7 A and B). This increase in 
tetraploid cells may indicate that following treatment with VRAD medium the number 
of binucleated cells increased as a consequence of the cells being unable to complete 
mitosis.  
Next, the distribution of the phases of the cell cycle was investigated. Figure 4.7 C 
shows representative cell cycle histograms obtained by FACS of the CD133+ cells 
treated with control medium or VRAD. The results showed that the VRAD treatment 
significantly increased the population of cells arrested in the G2/M phase of the cell 
cycle (CD133+: Ctrl 6.92% ± 0.98 vs VRAD 18.55% ± 1.78, p=0.0014, unpaired t-test; 
CD133-: Ctrl 6.55% ± 0.75 vs VRAD 18.68% ± 3.13, p=0.0243, unpaired t-test; Figure 4.7 
D and E). Interestingly, a significant increase in the population of cells in S phase was 
also observed in both the CD133+ and CD133- population upon treatment (CD133+: 
Ctrl 7.53% ± 0.71 vs VRAD 14.05% ± 1.58, p=0.0159, unpaired t-test; CD133-: Ctrl 
6.30% ± 0.79 vs VRAD 16.82% ± 2.22, p=0.0216, unpaired t-test). These results suggest 
that the retinoic acid also potentiated the DNA synthesis in both CD133+ and CD133- 
populations. 
Taken together, these findings indicate that the VRAD medium is responsible for 
an arrest of the proliferation and a morphological change of the cells. This is 
supported by the observation that the cells displayed an arborized phenotype, with 
occasional binucleated cells upon treatment. According to the immunofluorescence 
data, both treated cell types expressed nephrin and podocin, similarly to primary 
podocytes and conditionally immortalized podocytes. The analysis of the cell cycle 
indicated that the retinoic acid slightly stimulated the proliferation of some cells while 
inducing aberrant mitosis in others. 
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FIGURE 4.7 CELL CYCLE ANALYSIS OF CD133+ AND CD133- CELLS IN CONTROL AND VRAD MEDIUM 
(A-B) Number of diploid and tetraploid cells in both CD133+ and CD133- cells after seven 
days in control and VRAD medium. (C) Representative histograms showing the distribution 
of the cells in the different phases of the cell cycle. (D-E) Distribution of both CD133+ and 
CD133- cells in the various phases of the cell cycle.  
For the generation of the data, at least 15000 events per sample were recorded using a 
FACS Calibur and the analysis of diploids/tetraploid cells and distribution of the phases  of 
the cell cycle was performed using ModFit LT software. Each dataset comprises two 
experimental replicates, with three technical replicates per experiment. The t-test was used 
to determine statistical differences among the treatments. * p<.05; ** .05<p<.01; *** p<.01 
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As a next step, I had planned to analyse the gene expression profile of the treated 
cells, specifically with respect to podocyte-specific markers. However, subsequent to 
the analysis described above, the VRAD assay failed to provide consistent results. In 
particular, when it was repeated, using the same cell populations isolated from hK2 or 
different cell lines at various passages, the cells displayed vacuoles inside the cell body 
and started dying within two days after the start of the assay (Figure 4.8). Although 
several conditions were tested, and all reagents changed and carefully diluted, it was 
not possible to observe the same pattern of differentiation in the populations. 
Therefore, further analysis of the cells involving the VRAD assay was abandoned. 
 
FIGURE 4.8 REPRESENTATIVE BRIGHT FIELD IMAGES OF HUMAN CELLS TREATED WITH VRAD MEDIUM 
UNDERGOING CELL DEATH 
The differentiation assay was repeated with several cel l types, belongings to hK2 or other 
samples at passage 1 or passage 5. After the first two successful experiments, the VRAD 
medium induced cell death in the cells, highlighted by white arrows in the images here, as 
soon as 2 days after the beginning of the assay. Scale bars represent 50 µm. 
4.2.3 THE KIDNEY REAGGREGATION ASSAY AS A TOOL TO EVALUATE THE 
NEPHROGENIC POTENTIAL OF CD133+ HUMAN RENAL PROGENITOR CELLS 
CELLS 
The nephrogenic potential of the sorted CD133+ and CD133- populations was 
tested using the reaggregation assay described by Unbekandt and Davies in 2010, 
from now on defined as kidney reaggregation assay (KRA) (Unbekandt and Davies, 
2010). It was decided to start from embryonic kidneys at a developmental stage of 
13.5 days post fertilization (E13.5). The detailed methods are described in section 2.8 
of material and methods (page 57). Figure 4.8 A and B show a schematic 
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representation and a photograph of a kidney rudiment in culture. For the successful 
organotypic development of the kidney rudiments, it is essential that the cell pellet is 
positioned at the interface between medium and air.  
 
FIGURE 4.9 KIDNEY REAGGREGATION ASSAY 
The reaggregated rudiment is assembled using embryonic kidney cells isolated from E13.5 
embryos. Schematic (A) and image (B) of the set-up of the kidney reaggregation assay. All 
rudiments are placed on a polycarbonate membrane (1.2 µm pores), which in turn is 
positioned on top of a metallic grid at the air-medium interface. The ROCK inhibitor is added 
for the first 24 hours of culture, in order to increase the viability of the mouse cells.  
In a typical reaggregated, a total of one hundred thousand cells was used. The 
following controls were included in the experimental set-up: 
- Reaggregated control rudiments: mouse embryonic kidney cells at E13.5 were 
disaggregated and reaggregated, to verify that following reaggregation there 
was a recapitulation of the development and the formation of de novo 
structures;  
- Positive control chimeric rudiments: mouse embryonic kidney cells at E13.5 
were reaggregated with GFP-labelled mouse mesothelial cells mixed in at a 
ratio of 1:10 (see below for more details). 
All chimeric rudiments and the controls were grown up to six days, fixed and 
stained for Laminin, a marker of basement membrane to highlight renal structures, 
and Megalin, a marker of proximal tubule cells, or Wt1, a marker of the podocytes in 
the nephron. Some additional pellets for each experimental group were fixed one and 
three days after reaggregation, to monitor the development of the structures.  
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4.2.3.1  CONTROL REAGGREGATED RUDIMENTS 
Figure 4.10 shows the reaggregated control rudiments at day 1, 3 and 6.  
The staining at day 1 was performed to confirm that there were no remnant 
structures after the disaggregation at day 0. In fact, at day 1 (Figure 4.10 A), no 
structures were observed, besides some cysts that show Megalin staining. At day 3, 
the rudiments contained tubuli as highlighted by the presence of both Laminin at the 
basement membrane, and Megalin on the luminal side (Figure 4.10 B). These 
structures became even more convoluted at day 6 (Figure 4.10 C).  
Thus, analysis of the control reaggregated rudiments showed that the mouse 
embryonic cells recapitulated the development of renal structures that start as cysts 
at day 1 and elongate and get convoluted over the culture period.  
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FIGURE 4.10 CONTROL REAGGREGATED RUDIMENTS AT DAY 1, 3 AND 6 
Representative confocal images of single focal planes of reaggregated rudiments stained for 
Laminin (red) and Megalin (white) at day 1 (A), 3 (B) and 6 (C). Laminin was used to highlight 
epithelial structures, whereas Megalin was used to highlight the luminal surface of tubuli. 
Over time, it is possible to appreciate an increased complexity of the convoluted tubuli. Scale 
bars represent 50 µm. 
Once the technique was established, GFP-labelled mouse mesothelial cells were 
used as positive control and re-aggregated in a 1:10 ratio (Figure 4.11). In independent 
studies performed in my laboratory by Sumaya Dauleh (University of Liverpool), 
mouse mesothelial cells were efficiently used in the rudiment. The chimeric rudiments 
were analysed six to seven days after reaggregation. At the end point, the cells were 
found alive and interspersed in the chimera. Therefore, these cells were used as 
positive control.  
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The chimeric rudiments were monitored at the day 1, 3 and 6 by confocal 
microscopy and by fluorescence dissection microscopy. At day 1, the GFP-positive cells 
were randomly interspersed among the mouse cells, as shown by the single focal 
plane confocal image (Figure 4.11 A) and by the low magnification fluorescence 
images using a dissection microscope (Figure 4.11 B). At day 3 and day 6, tubules 
expressing Megalin were observed, and the GFP-positive cells were interspersed 
around the crescent tubuli. Figure 4.11 G shows a high magnification confocal image 
of a chimeric rudiment at day 6. There was no evidence at any time point of an 
integration of the mesothelial cells into the renal structures. Instead, the cells were 
often observed in the interstitium, lying on the laminin layer surrounding the tubuli. It 
cannot be excluded that the mouse mesothelial cells support the growth of the mouse 
tubuli. While no specific advantage in the tubular growth was observed in the chimeric 
rudiments in relation to the control rudiments, importantly, the mouse mesothelial 
cells integrated and spread throughout the chimeric organoid without hindering its 
development or the formation renal structures. A loss of the mouse mesothelial cells 
over time was not qualitatively observed (Figure 4.11 B, D, F).  
 
   
 123 
 
 
FIGURE 4.11 CHIMERIC RUDIMENT USING MOUSE MESOTHELIAL CELLS, MONITORED AT 1, 3 AND 6 
DAYS 
Representative merged confocal images of single focal planes of chimeric rudiments 
containing GFP-labelled mouse mesothelial cells stained for Laminin (red) and Megalin 
(white) at day 1 (A), 3 (C) and 6 (E). Representative fluorescence images taken under the 
dissection microscope at day 1 (B), 3 (D) and 6 (F). (G) Representative high magnification 
confocal image of a chimeric rudiment using mouse mesothelial cells. Scale bars represent 
50 µm. 
 124 
 
4.2.3.2 REAGGREGATED RUDIMENTS USING GFP-LABELLED CD133- AND CD133+ 
CELLS 
Next, human GFP-labelled CD133- and CD133+ cells were tested for their 
nephrogenic potential in the KRA at a ratio of 1:10 (Figure 4.12).  
At day 1, the CD133- cells were randomly interspersed with Laminin-expressing 
mouse cells (Figure 4.12 A and B). From day 1 to day 3, there was a striking decrease in 
the number of GFP-positive cells in the rudiment. Figure 4.12 B, D and F show the 
same chimera imaged at different time points. It appeared that most of the human 
cells had died in the time frame of two days. Nevertheless, the dying human CD133 - 
cells failed to disrupt the development of the renal structures. Both at day 3 and at 
day 6, most of the GFP-positive cells were detected in the interstitial space outside the 
developing epithelial structures (Figure 4.12 C and E). A series of focal planes of a z-
stack in Figure 4.13 reveals a dying GFP-positive cell. Interestingly, fragments of the 
dying GFP-expressing CD133- cells were detected outside of the renal tubular 
structures, while one cell could be seen inside the tubule. Of note, this was the only 
cell spotted inside renal tubular structures in the entire set of experiments. Also, in 
the z-stack, two cells appeared to be attached to the tubuli, thus colocalizing with the 
Laminin signal. 
The results so far indicate that the human CD133- cells died within 2 days after the 
start of the KRA. The death of considerable numbers of cells failed to prevent the 
formation of the developmental renal structures. However, given the high rate of cell 
death in such a short time frame and the observation of only one case of integration, 
it can be concluded that the latter was a a stochastic event rather than active 
participation of the human cell in the formation of renal structures. 
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FIGURE 4.12 CHIMERIC RUDIMENTS USING CD133- CELLS, MONITORED AT DAY 1, 3 AND 6 
(A-C-E) Representative merged confocal images of single focal planes of chimeric rudiments 
containing GFP-labelled human CD133- cells stained for Laminin (red) at day 1 (A) and 3 (C) 
and for both Laminin (red) and Megalin (white) at day 6 (E). (B-D-F) Representative 
fluorescence images taken under the dissection microscope at day 1 (B), 3 (D) and 6 (F). 
Scale bars represent 50 µm. 
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FIGURE 4.13 CONFOCAL IMAGES SERIES OF A Z-STACK SHOWING A DETAIL OF A CHIMERIC RUDIMENT 
USING CD133- CELLS AT DAY 3 
Detail of a chimeric rudiment with GFP-labelled CD133- cells stained for Laminin (red) and 
Megalin (white). The z-stack has a z-step of 5 µm. Scale bar represents 10 µm. From the 
images, it is possible to observe 2 cells aligned with the Laminin+ tubuli, a cell that is inside 
the cross-section of a tubule, and a dead cell in proximity of a cell. The cell inside the tubule 
was a rare observation.  
Finally, human GFP-labelled CD133+ cells were tested at a ratio of 1:10 (Figure 
4.14). At day 1, the CD133+ cells were interspersed among the mouse embryonic cells 
in the chimera. However, by day 6, substantial cell death of the GFP-positive human 
cells could be observed (Figure 4.14 B, D and F). The surviving cells grouped in the 
middle of the chimera and failed to integrate into any of the developing renal 
structures. Furthermore, at day 3, no structures were detected in proximity of the 
clump of human cells (Figure 4.14 C), and at day 6, a few cysts expressing Wt1 were 
found close to the human cells (Figure 4.14 E). This observation was consistent 
throughout all experiments (see page x of M&M). Interestingly, Figure 4.15the area of 
the rudiment that did not contain human cells showed a complex network of tubuli. 
Few isolated cells were spotted in the area containing structures, but not inside the 
tubuli (see 1 in Figure 4.15).  
These results suggest that the human CD133+ cells grouped together inside the 
kidney rudiment instead of interspersing, and that these CD133+ clumps prevented or 
slowed down the development of renal structures in their direct vicinity, without 
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disrupting the overall formation of the renal structures in more distant regions of the 
rudiment. 
 
FIGURE 4.14 CHIMERIC RUDIMENTS USING CD133+ CELLS, MONITORED AT DAY 1, 3 AND 6 
(A-C-E) Representative merged confocal images of single focal planes of chimeric rudiments 
containing GFP-labelled human CD133+ cells stained for Laminin (red) at day 1 (A) and 3 (C) 
and for both Laminin (red) and Wt1 (white) at day 6 (E). White arrows indicate the presence 
of small structures stained for Wt1. (B-D-F) Representative fluorescence images taken 
under the dissection microscope at day 1 (B), 3 (D) and 6 (F). Scale bars represent 50 µm 
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FIGURE 4.15 SINGLE FOCAL PLANE CONFOCAL IMAGE OF A CHIMERIC RUDIMENT USING CD133+ 
CELLS ON DAY 6 
Additional representative images of single focal plane of a chimeric rudiment containing 
GFP-labelled human CD133+ cells stained for Laminin (red) and Megalin (red) at day 6. (A-B-
C) Low magnification image showing the chimeric rudiment. The images suggest that there 
are no developed tubuli in the area where there is the cluster of human cells. (1-2) Two 
areas of the chimera were imaged at higher magnification. Very few cells were detected 
interspersed in the rest of the chimera. The arrows indicate 3 human cells close to 
convoluted tubuli expressing Laminin and Megalin. The diameter of the rudiment was 
calculated to be 536 µm. The scale bar represents 50 µm. 
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Given the inability of the cells of interest to survive in the chimera and to 
contribute to the formation of renal structure, it was decided to not stain the chimera 
for additional nephrogenic genes, such as Pax2 or Six2. Instead, the formation of renal 
embryonic spheroids was pursued, in order to eliminate the membrane as support 
and image the spheroids in the Light Sheet Fluorescent Microscope (LSFM). 
4.2.4 A REFINED KIDNEY REAGGREGATION ASSAY FOR LIGHT SHEET MICROSCOPY 
The KRA as presented in the last section followed the method described by 
Unbekandt (Unbekandt and Davies, 2010). Being grown on a support, the kidney 
organoid was partially three dimensional with a dome-like shape. Also, as a result of 
the technique which requires careful handling of the delicate reaggregated kidney 
organoids at several critical steps, consistency in the outcome may not be achieved 
every time. One important drawback of the technique is that rudiments need to be 
fixed at specific time points for detailed monitoring and analysis of the development 
of the renal structures. Therefore, the aim was to generate spheroids that could be 
imaged using the Light-sheet fluorescent microscope, allowing live imaging to track 
the behaviour of fluorescently labelled cells, in addition to end point high resolution 
imaging. 
To obtain spheroids, a different set-up was devised. A multi-well support disk of 
approximately 3 cm diameter was shaped from PDMS (Polydimethylsiloxane), a 
hydrophobic material. A polycarbonate membrane (same as the one used in the 
conventional assay) was placed underneath the PDMS disk. The multi-well disk was 
placed in a culture dish and maintained at the medium/air interface by PDMS spacers 
(Figure 4.16 A). The KRA protocol was followed to the step where mouse embryonic 
kidney cells were reaggregated. The pellet was composed of one hundred thousand 
cell, as in the assay involving the membrane. Each pellet was positioned inside one of 
the wells in the multi-well disk and grown for up to six days. Figure 4.16 B and C shows 
the arrangement of the PDMS multi-well disk at day 0 and day 6. For endpoint imaging 
at day 6, the spheroids were fixed and embedded in 1.5% agarose inside a glass 
capillary (Figure 4.16 D) and imaged using the LSFM. The experiments with the LSFM 
were performed in collaboration with Dr. Marie Held, Post Doc at the University of 
Liverpool, who operated the LSFM.  
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FIGURE 4.16 MODIFIED KRA, DEVISED TO PRODUCE SPHEROIDS TO IMAGE IN THE LSFM 
(A-B) The multi-well support disk is made of PDMS, a hydrophobic material, and a 
polycarbonate membrane placed underneath; PDMS spacers (SP) allow the membrane to be 
at the air-medium interface. This set-up offers the right environment for the spheroid to 
receive nutrients from the medium in the bottom of the dish without attaching to the 
membrane. (C) Image of the dish taken at the dissection microscope displaying the spheroids 
inside the PDMS support in medium after 6 days in culture. (D) Glass capillary containing the 
spheroid that for imaging in the LSFM. The pellet is embedded in 1.5% agarose/3% gelatine 
and, for the imaging, the embedded spheroid is pushed out of the capillary using a plunger.  
During the six days in culture, the spheroids were imaged every day using a 
dissection microscope. To follow their development and potential growth, the 
spheroid area was measured daily, assessed with the Fiji software and normalized to 
the area of the spheroids at day 1. By day 3, the area of the spheroids declined 
significantly by 30%, to then increase steadily until day 6 (Figure 4.17). These 
fluctuations in the spheroid area could possibly reflect an initial compaction of the 
cells that might lead to the development of the structures, followed by an increase in 
the number of cells over time. In general, at day 6, the diameter of the spheroids was 
approximately 450 µm. 
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FIGURE 4.17 COMPACTION OVER TIME OF THE SPHEROIDS  
The graph summarizes the mean and SD of the area measurements for six days of culture 
(n=8). The area occupied by the spheroids was measured using the Fiji software. The values 
were normalized to the area of the spheroids at day 1. Each day was compared to day 1 by 
using a t-test, and only the spheroids at day 3 are statistically smaller in relation to day 1. * 
p<0.05 
At day 6, the spheroids were fixed and stained using immunofluorescence to 
investigate the presence of developing renal structures (Figure 4.18). The presence of 
epithelial structures was confirmed by the presence of Laminin. Inside some of these 
structures, also Megalin was identified, suggesting the presence of proximal tubuli 
(Figure 4.18 A). The lectin peanut agglutinin (PNA) was used to stain ureteric bud, 
collecting duct, and proximal tubules, in cases of primary antibody incompatibility 
(Phillips et al., 2001). Pax2 was detected in the condensed mesenchyme around the 
tips of the ureteric buds and inside some ureteric trunks, as indicated in Figure 4.18 B. 
It appeared that more than one ureteric bud underwent branching. Furthermore, 
Synaptopodin staining at the tip of the tubuli highlighted the presence of fully 
developed nephrons (Figure 4.18 C). Altogether, the images point towards the co-
presence of different developmental stages in the same spheroid. 
Of note, the LSFM is equipped with two illumination objectives positioned at 180 
degrees to another. The images showed in Figure 4.18 were taken with a single 
illumination objective, either from the left (A) or the right (B) side. The illumination 
source explains why the images appear faded out on one side. Because the spheroids 
 132 
 
are quite large and compact, it is difficult to image the light-scattering core of the 
spheroid.  
 
FIGURE 4.18 REPRESENTATIVE LSFM IMAGES OF THE SPHEROIDS CULTURED FOR SIX DAYS 
Immunofluorescence images taken with the LSFM of a spheroid made of one hundred 
thousand mouse embryonic cells cultured for six days and fixed in 4% PFA. (A) Spheroid 
stained for Megalin (white) and Laminin (red) (B) Spheroid stained for Pax2 (green) and PNA 
(red) The asterisks indicate tubular structures where Pax2 is expressed inside the tubuli, so 
likely to be the ureteric buds. The white arrows indicate the accumulation of Pax2 in the cap 
mesenchymes. Dashed lines indicate the branching of two different ureteric buds. (C) Detail of 
a spheroid showing a nephron stained for Synaptopodin (yellow) and Laminin (red). The 
stainings highly reflect the physiological localization of the markers. All images are MIPs 
obtained imaging the spheroid with a single illumination lens. Scale bar represents 50 µm, 
unless stated otherwise. 
4.2.5 FUNCTIONALITY OF THE TUBULI IN THE SPHEROIDS 
It had been shown that serially-reaggregated engineered kidneys can transport 
organic anions and cations into and out of the renal tubuli (Lawrence et al., 2015). To 
test the functionality of the spheroids obtained in this study, an organic anion uptake 
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assay was set up by using the anionic 5(6)-carboxyfluorescein (6-CF). 6-CF is 
transported by the family of organic anion transporters (OATs) through the basolateral 
and apical surface of the tubular cells.  
In this assay, the spheroids were treated at day 5 or 6 with 6-CF, either with or 
without Probenecid (2.5 mM), an inhibitor of the OAT family and the Mrp efflux 
pumps. Subsequently, spheroids from both treatment groups were incubated with 
Probenecid at high concentration (10 mM). In the samples without probenecid 
treatment at the beginning and high Probenecid at the end, 6-CF was transported into 
the tubuli, while the inhibitor was expected to prevent the efflux of 6-CF (Lawrence et 
al., 2015; Rak-Raszewska et al., 2012). 
Imaging of the spheroids after the functional uptake assay by LSFM showed that 
spheroids treated with Probenecid at the beginning and the end of the assay 
contained no 6-CF inside the tubuli (Figure 4.19). By contrast, in the samples treated 
with probenecid only at the end, 6-CF was found inside the tubuli. The orthogonal 
views XZ and YZ demonstrate at a single cell level the occurred uptake of 6-CF by the 
tubular cells. In conclusion, the PDMS multi-well culture system allowed the culture of 
spheroids, which developed appropriate renal structures, and gained functional 
physiological properties over time. 
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FIGURE 4.19 ANIONIC UPTAKE ASSAY ON REAGGREGATED CONTROL SPHEROIDS 
Functional anionic uptake assay on spheroids cultured for 5 or 6 days. (A) The samples ‘w/ 
Probenecid’ were initially incubated for 1 hour with Probenecid (2.5 mM), 6-CF (1 µM, 
green) and PNA (20 µg/Ml, red). (B) The control samples (w/o Probenecid) were incubated 
only with 6-CF and PNA. After the incubation period, both sample groups were incubated 
with a higher concentration of Probenedid (10 mM), washed and imaged. The images 
represent MIPs of fused single illumination images. (B’) MIP of a detail of a control 
spheroid. Orthogonal views in XZ and YZ show the fluorescence inside the tubuli in single 
cells. The assay was repeated 4 times with independent samples. Scale bars represent 100 
µm.  
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4.2.6 IN VIVO IMAGING OF KIDNEY SPHEROIDS 
So far, it was shown that the kidney rudiment assay could be adapted to culture 
conditions that led to the formation of spheroids. Therefore, the final aim of this part 
of the study was to image live the reaggregation process of mouse embryonic cells 
and any fluorescently labelled cell of interest. This would serve as a proof of concept 
experiment, demonstrating that it is possible to observe the developing renal 
structures in the spheroids in real time using the Light sheet microscope.  
Initially, a spheroid consisting only of mouse embryonic cells was embedded in 
1.5% agarose and 3% gelatine, which had been previously tested as a compatible 
combination for the growth of the spheroid (data not shown). The spheroid was 
imaged from day two every 30 mins for 10 hours using dual illumination to increase 
the axial and lateral resolution. The embedded spheroid was immersed in a chamber 
connected to a reservoir continuously supplying fresh medium, to counteract eventual 
evaporation, and PNA as a vital dye to highlight the developing renal structures. The 
montage in Figure 4.20 shows a summary of the MIP images every two hours of the 
spheroid. From the series, it is possible to appreciate the compaction of the spheroid 
over time and the organization of the cells into small structures, appearing between 6 
and 8 hours after the beginning of the imaging. 
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FIGURE 4.20 SERIES OF LSFM IMAGES OBTAINED DURING THE LIVE IMAGING OF A REAGGREGATED 
SPHEROID FOR TEN HOURS 
Montage summarizing MIP images of reaggregated rudiments generated using mouse 
embryonic cells. The spheroid was imaged over a period of 12 hours (0.5 days) at intervals of 
30 min with a single illumination. In total, 26 3D stacks in the red fluorescence channel (PNA) 
were recorded. Each 3D stack contained 247 single frames spaced 0.65 µm along the z-axis. 
In the montage, a summary of all images is presented. A continuous supply of medium 
containing diluted PNA (red) was necessary to keep the spheroid alive and stain developing 
structures over time. The spheroid compacted over time, passing from 232 µm at t=0h to 205 
µm at t=10h. Scale bar represented 100 µm. 
Next, a reaggregated rudiment containing GFP-labelled mouse mesothelial cells 
was imaged every 30 mins from day 1 over the course of 72 hours. The sample was 
embedded in 1.5% agarose and 3% gelatine. The montage in Figure 4.21 shows a 
summary of MIP images of the spheroid every three hours. As previously observed, 
the spheroid compacted over time. An interesting finding was the high mobility of the 
GFP-labelled cells in the spheroid, which end-point imaging fails to reveal (Figure 
4.21). However, we could observe a number of mitosis events (Figure 4.22). Three 
problems were identified by imaging this spheroid over a long time period: i) due to 
the high compaction over time, the core of the spheroid could not be imaged; ii) the 
imaging chamber can easily get contaminated and the contaminated medium 
impeded proper light scattering; iii) the spheroid moves in the capillary and after 45 
hours of imaging it could not be visualized anymore. 
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FIGURE 4.21 SERIES OF LSFM IMAGES OBTAINED DURING THE LIVE IMAGING OF A CHIMERIC 
SPHEROID CONTAINING MOUSE MESOTHELIAL CELLS FOR FORTY-FIVE HOURS 
Montage reporting MIP images of reaggregated chimeric rudiments generated using mouse 
embryonic cells. The spheroid was imaged over a period of 63 hours (2.6 days) at intervals 
of 30 min with a dual illumination. However, the spheroid was visible up to 45 hours. In the 
first 45 hours, 182 3D stacks with one channel (green channel –GFP mouse mesothelial 
cells) were recorded. Each 3D stack contained an average of 350 single frames spaced 0.81 
µm along the z-axis. A continuous supply of medium was necessary to keep the spheroid 
alive. The spheroid compacted over time, being around 421µm at t=0 and reaching 323 µm 
at t=45h. Scale bar represented 100 µm. 
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FIGURE 4.22 SERIES OF LSFM IMAGES OF A DETAIL OF THE CHIMERIC RUDIMENT CONTAINING MOUSE 
MESOTHELIAL CELLS 
Montage of 4 images belonging to the time series shown in the previous figure. In this image, 
a cell undergoing mitosis is indicated by the white arrow. This is just one example of several 
episodes of mitosis happening in the spheroid, suggesting that the environment does not 
impede cell division.  
In the last three paragraphs, a novel approach for the formation of spheroids was 
presented. The process to form spheroid is very simple and by-passes the critical step 
of transferring the pellet on top of the membrane, that can easily result in the 
spreading of the pellet on the membrane. The size of the spheroid is quite consistent 
(~400 µm) as opposed to the size in the conventional KRA that can be very variable. 
Also, another advantage of the spheroid set-up is given by the lack of contact of the 
spheroid with the membrane. Last, but not least, the possibility of using the gentle 
imaging of the LSFM will permit to gather more information compared to the 
conventional assay. And, in line of principle, the use of a continuous supply of PNA 
coupled with the use of fluorescently labelled cells can potentially be used to infer live 
dynamics of the cells in the spheroid at a single cell level and help understand whether 
the cells actively migrate towards the structures or if their presence inside structures 
is due to stochastic events. However, a number of optimizations are needed to 
improve the antibody penetration and, therefore, the imaging of the core, and to  
prevent contamination of the medium during live experiments.   
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4.3 DISCUSSION 
In this chapter, the main aim was to provide a proof that the isolated CD133+ cells 
are progenitors. In order to do that, their ability to differentiate into podocytes was 
tested by culturing the cells in vitro with VRAD medium. Alongside, the cells were used 
in an ex vivo kidney reaggregation assay, to assess whether either CD133+ and CD133- 
cells could integrate into developing structure into the rudiment.   
Differentiation is an important parameter for the potency of putative 
progenitor/stem cells. In the literature, CD133+ cells were defined multipotent for 
their ability to differentiate into a broad range of cell types, from renal lineage, like 
tubular and podocytic, to extra-renal lineages, such as endothelial, neurogenic, 
osteogenic and adipogenic (Bussolati et al., 2005; Ronconi et al., 2009; Sagrinati et al., 
2006). This wider plasticity of the renal CD133+ cells could be considered an important 
incentive for clinical applications, specifically for their use in regenerative medicine 
therapies. However, since the kidney has only limited regenerative potential, it seems 
unlikely that CD133+ renal progenitor cells may be able to differentiate into cells not 
even close in terms of anatomical localization. The unexpected reports of trans -
differentiation could therefore be the consequences of the use of specific culture 
media and their cocktails of growth factors. Thus, the observed morphology would be 
a result of adaptation to the “new” culture conditions.  
Vitamin A (All-trans retinoic acid, ATRA) is a signaling molecule that exerts multiple 
effects during embryogenesis, by directly or indirectly regulating a broad range of 
cellular processes, from proliferation to differentiation (Gudas and Wagner, 2011). 
Many of the primary target genes regulated by ATRA present Retinoic Acid Responsive 
Elements (RARE) on their promoters. In the glomerulus, nephrin is one of the genes 
transcriptionally activated by ATRA (Okamura et al., 2009; Suzuki et al., 2003). Retinoic 
acid and Vitamin D3, another proven activator of nephrin gene expression, were 
indeed used to induce the differentiation of renal progenitor cells in podocytes in 
several studies (Arcolino et al., 2016; Bombelli et al., 2013; Kietzmann et al., 2015; 
Ronconi et al., 2009; Sagrinati et al., 2006). The process was being partially elucidated, 
and miRNA-193a appeared as a powerful regulator of this differentiation process 
(Kietzmann et al., 2015). Recently, BIO (6-bromo-indirubin-3’-oxime), an inhibitor of 
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the glycogen synthase kinases 3 (GS3Ks) was used to enhance further the 
differentiation ability exerted by the ATRA on hRPC. Besides an upregulation of the 
nephrin gene and protein, BIO led to an increase in the percentage of quiescent cells 
in G0/G1 accompanied by a reduction of the proportion of the cells in S phase (Lasagni 
et al., 2015). This redistribution of the phases of the cell cycle is in line with the dogma 
that podocytes are quiescent post-mitotic cells. However, this is in contrast to the 
findings from this study. Here, primary human CD133+ and CD133- cells isolated from 
young adults kidneys were tested for their ability to differentiate into podocytes by 
culturing them in ATRA and Vitamin D3. An increase in the percentage of cells in the 
G2/M phase of the cell cycle was observed, together with a slight, but significant 
increase in the proportion of the cells in the S phase. This finding would support the 
possibility that ATRA induced aberrant mitosis in the cells used in my experiments. In 
chapter 3, it was reported that the vast majority of the isolated human cells cultured 
in fetal progenitor medium (Price et al., 2007) expressed a marker of fully 
differentiated proximal tubular cells (CD13). It can be hypothesized that the cells, 
being mostly proximal tubule cells-like are not able to fully differentiate into 
podocytes and, following VRAD treatment they arrest in the G2/M phase of the cell 
cycle. Nevertheless, the expression of nephrin and podocin was confirmed by 
immunofluorescence and showed to be comparable to the conditionally-immortalized 
and primary podocytes. Unfortunately, due to subsequent technical problems with the 
assay, these preliminary findings could not be corroborated.  
Despite the impossibility to consistently reproduce the differentiation assay, the 
assessment of functionality of the differentiated cells is key to confirm the 
differentiation. Previous reports that exploited the VRAD medium to differentiate 
putative progenitor cells into podocytes simply relied on immunofluorescence and 
gene expression to define the cells as fully differentiated podocytes (Angelotti et al., 
2012; Bombelli et al., 2013; Ronconi et al., 2009). Alongside with immunofluorescence 
and gene expression, Arcolino and colleagues (Arcolino et al., 2016) examined the 
functionality of the neonatal urine progenitors-derived podocytes using the albumin 
endocytosis assay, generic functional assay for proximal tubular cells and podocytes, 
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and testing the activity of the podocytes-specific transient receptor potential cation 
channel (TRPC6) in the presence of Ca2+.  
Alongside with the differentiation assay, the nephrogenic potential of both CD133+ 
and CD133- cells was investigated in this study. No definite proof of integration was 
found. All GFP-labelled CD133- cells were found in the interstitial space, in parts 
closely aligning with the tubular basement membrane. In contrast, most of the GFP-
labelled CD133+ cells were found aggregated on top of the chimeric rudiment, even if 
at day one the cells had been randomly interspersed in the rudiments Figure 4.12 and 
Figure 4.14. The absence of structures in the areas occupied by the cluster of cells, but 
not in the surrounding areas indicates that the human CD133+ cells secreted paracrine 
factors that halted the recapitulation of the developing structures in their close 
proximity.  
To date, this represents the first study where hPSCs were tested for their capacity 
to integrate and potentially contribute to the formation of renal structures in the 
kidney reaggregation assay. A surrogate of the assay was shown by Ward and 
colleagues. They argued that papillar CD133+ cells were able to integrate into 
embryonic kidney rudiments cultured ex vivo for four days (Ward et al., 2011). 
However, the assay used in this study bypassed the disaggregation and reaggregation 
of the mouse cells, and the human CD133+ cells were injected directly into E12.5 
embryonic kidneys in culture. However, due to the experimental design it is possible 
that the integration shown could be instead due to the accumulation of the cells at 
the site of injection. In fact, there is no evidence that the human cells were randomly 
distributed in the embryonic kidney following the injection, but clusters of CD133+ 
cells were detected at day four inside the tubuli (Ward et al., 2011). By contrast, the 
reaggregation assay helps to understand whether exogenous cells actively contribute 
to the formation of the developing renal structures and are capable of specifically 
integrating and differentiating in the correct spatio-temporal fashion.  
Only two studies have so far proved the capacity of iPSC- or ESC-derived nephron 
progenitor cells to engraft into the metanephric mesenchyme or ureteric bud 
(Takasato et al., 2014; Xia et al., 2013). These results cannot be considered as 
unexpected, since both nephron progenitor cell populations were in the ‘right place’ 
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at the ‘right moment' matching in time the developmental stage of the reaggregation 
assay. The need for matching developmental stages between embryonic cells and 
exogenous cells is illustrated by the observation that amniotic fluid stem cells failed to 
integrate into chimeric kidney rudiments unless a genetic modification was 
introduced, such as the induced expression of GDNF (Xinaris et al., 2015). Importantly, 
GDNF (glial cell-line-derived neurotrophic factor 1) is one of the essential growth 
factors expressed by the cells of the metanephric mesenchyme that induce the growth 
of the ureteric bud. Furthermore, the expression of GDNF was shown to be regulated 
by the Pax2-expressing cells in vitro (Vainio and Lin, 2002). In the previous chapter, 
both CD133+ and CD133- kidney-derived primary human cells were found to express 
Pax2. It would be therefore interesting to determine whether the primary renal cells 
secrete GDNF since they express Pax2.  
The reaggregation assay performed in this study failed to show engraftment of the 
CD133+ cells. Instead, the CD133+ cells behaved more similarly to the ESCs used in the 
rudiment experiments by Takasato and colleagues (Takasato et al., 2014), by forming 
cysts on top of the chimeric organoids. Interestingly, no convoluted renal structures 
were identified in the direct vicinity to the cluster of human CD133+ cells. By contrast, 
some of the CD133- cells were found in-between convoluted tubuli in the interstitial 
space. For both cell types, though, a complete disruption of the embryonic kidney 
structures could not be found. If the renal progenitor cells are defined by the 
expression of CD133, as claimed in the literature, then the CD133- cells would more 
likely represent a heterogeneous population of fully differentiated cells. According to 
the phenotyping experiments shown in chapter 3, both populations contain a fully 
differentiated fraction of proximal tubular cells. Yet, despite the observed cell death, 
the CD133- cells were able to remain in the interstitial space of formed structures, 
even if not in the tubuli, whereas the CD133+ could not.  
An important point needs to be raised about the dynamics of the human renal 
cells in the reaggregation assay. Previous studies that reported on the engraftment of 
exogenous cells in the reaggregation rudiments, do not mention any substantial loss 
of exogenous cells; in most cases high-magnification images are shown to 
demonstrate the engraftment, if applicable, of the cells tested (Kuzma-Kuzniarska et 
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al., 2012; Siegel et al., 2010; Song et al., 2012; Xinaris et al., 2012). Xinaris and 
colleagues mentioned that fewer AFSCs were present in the chimeric rudiments at day 
five compared to the initial amount (Xinaris et al., 2012). The results from this chapter 
show a striking difference between day 1 and day 3 in the number of GFP-labelled 
cells (both CD133+ and CD133- cells) detectable in the same chimeric rudiments, even 
though a quantitative assessment was not performed. The use of different media 
combinations failed to prevent the loss of cells over time (data not  shown). Hence, 
one of the conclusions from the KRA experiments is that the mouse embryonic kidney 
environment does not permit the survival of the human cells for more than two days . 
It would be important to thoroughly investigate the causes of the human cell loss that 
was observed in some instances and not in others: is it cell type dependent? An 
interesting experiment to explore the effect of the secreted factors present in the 
organoid environment could include the culture and exposure of human cells to the 
conditioned medium of control reaggregated spheroids: is there an increase in cell 
death in response to the conditioned medium? Subsequently, the factors present in 
the conditioned medium could be further analysed to pinpoint their role in the loss of 
the human cells.  
In this chapter, it was shown that both CD133+ and CD133- cells fail to contribute 
the development of renal structures by using the embryonic kidney reaggregation 
method introduced by Unbekandt in 2010. In this method, the rudiments become 
firmly attached to filter membranes, which can lead to issues with light scattering 
while imaging with the confocal microscope. Also, the imaging of the whole thickness 
of the sample highly depends on the working distance of the objective used. 
Nevertheless, as shown above, high-quality images could be acquired. The rudiment 
formed with the conventional approach is not entirely tri-dimensional; it has more of a 
dome-like shape. The method was therefore adapted in order to form renal 
embryonic spheroids. A direct comparison of some features of both systems is offered 
in Table 4.1. By using the PDMS support, the critical step of transferring the pellet on 
the membrane is abolished. In the conventional method, in fact, at this point the 
pellet can disaggregate and break in multiple points or spread on the membrane, 
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preventing the compaction of the pellet and the recapitulation of the development. By 
increasing its consistency, it is possible to reduce the amount of animals used.  
TABLE 4.1 DIRECT COMPARISON BETWEEN THE CONVENTIONAL AND THE NOVEL METHOD TO 
PERFORM THE KIDNEY REAGGREGATION ASSAY (KRA) 
One of the major differences is connected to the shape of the pellet. In the conventional 
KRA, the pellets assume a dome-like shape, whereas in the novel assay, the pellet becomes 
a spheroid. In the conventional KRA, the critical step is represented by the transfer of the 
pellet from the eppendorf to the membrane, where it can break in multiple pieces or 
spread on the membrane. Losing its compactness, it does not give rise to developing 
structures. That leads to a high variability between experiments and size of the actual 
pellet. All these problems are not relevant in the novel approach, since, once the pellet in 
the hydrophobic environment created by the PDMS and the membrane, it compacts to 
form a spheroid. Nevertheless, both approaches allow formation of functional structures 
and allow live imaging. However, the use of the confocal microscope can lead to photo-
toxicy and photo-bleaching of the sample, whereas the LSFM does not. * functionality 
shown in the literature by (Lawrence et al., 2015; Rak-Raszewska et al., 2012). 
 
The novel reaggregation method combines the hydrophobic material PDMS (poly-
dimethylsiloxane) with a polycarbonate membrane. Due to its low cost, easy 
fabrication and optical transparency, PDMS is the material of choice for microfluidic 
cell culture (Halldorsson et al., 2015). Here, it was used to create a hydrophobic well 
Conventional 
KRA
Novel KRA
Shape
Size Highly variable ~400 µm
Inter-experimental 
consistency
No Yes
Direct contact with 
membrane?
Yes  possible 
cell migration out 
of the pellet
No
Antibody penetration Good Not good
Formation of 
structures?
Yes Yes
Functional tubuli? Yes* Yes
Live imaging?
Yes, by confocal 
 risk of 
bleaching 
Yes, by LSFM 
gentle for long 
term imaging
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that would support the formation and growth of the spheroids made of embryonic 
renal cells without promoting their attachment to the membrane. Elected method of 
the year in 2013 by Nature, the LSFM was chosen to image the spheroids because it 
presents several advantages over the confocal microscopy. High image capture speed, 
low phototoxicity and, therefore, lower photobleaching of the samples permit gentle 
imaging of live organisms that are fluorescently labeled or transparent, e.g. 
Caenorhabditis elegans. The LSFM is affirming itself in many fields, from plant biology 
to developmental biology, from neuroscience to the histological analysis of tissues 
(Pampaloni et al., 2015).  
Due to the physical arrangement of the microscope, it is possible to rotate the 
sample and image it from different angles. The optical sections recorded are suitable 
for imaging reconstruction software such as Fiji or Imaris, which will allow detailed 
volume rendering of the sample. The amount of additional information that can be 
gathered using the LSFM is remarkable.  
The embryonic renal spheroids that were created using the modified 
reaggregation method, presented a good distribution of epithelial structures at day six 
as shown by the expression of Laminin and Megalin. Pax2 was detected in an 
appropriate spatial arrangement, in both the MM and the UB. Not only so, in some 
spheroids nephrons expressing Synaptopodin at the tip of Laminin-positive structures 
were observed, suggesting that all stages of nephron development might be 
represented. This finding resonates with the lack of the presence and branching of one 
ureteric bud, which orchestrates the correct series of events during nephrogenesis 
(Vainio and Lin, 2002). The major drawback of the system was related to the 
impossibility to image the centre of the spheroid. Compact spheroids like these are 
difficult to image in their cores, due to antibodies not reaching the centre after 
fixation at end-point analysis, or due to increased light scattering in the case of live 
imaging. By comparison, tumor spheres of 1000-3000 cells are routinely imaged using 
the LSFM (Pampaloni et al., 2013). An alternative method would be the optical 
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clearing of the spheroid at end points, using one of the several protocols available3, 
whose aim is the reduction of the light scattering and the increase of the optical 
distance that can be imaged. CLARITY, for example, was used to image large samples 
(e.g. mouse brains) and showed a high structural resolution and molecular details 
(Chung and Deisseroth, 2013).  
The assessment of the functionality of their renal tubuli was an important quality 
control for the reaggregated kidney spheroids formed following the novel method. 
The tubuli of the renal spheroids were able to uptake 6-CF and to be blocked by the 
OAT inhibitor, Probenecid. This feature implies that the tubuli are functional, as 
previously shown in the KRA rudiments (Lawrence et al., 2015; Rak-Raszewska et al., 
2012). However, not all tubuli in the spheroid control samples appeared stained. This 
can be explained by two factors: i) the brightness of the tubuli in the front of the 
spheroid impedes the imaging of the tubuli in the core; ii) some tubuli might be more 
immature than others and in different developmental stages, as discussed above. 
However, the OAT family transporters start being expressed from E11.5 in the renal 
vesicles (Lawrence et al., 2015) and, in the spheroids, the condensed metanephric 
mesenchyme was observed. Hence, the spheroids represent developmental stages 
from E10.5-E11.5 onwards. Therefore, the lack of fluorescence in all tubuli might be 
due to an artifact in imaging. 
Finally, live imaging of spheroids without and with GFP-labelled cells was 
performed. To achieve this, the microscope was combined with a biocompatible 
sample holder immersed in a perfusion chamber that is supplied continuously with 
medium and nutrients by dedicated reservoirs, connected to a peristaltic pump 
(Pampaloni et al., 2014). The GFP-labelled cells were highly active in the spheroid and 
underwent mitosis, showing that the arrangement supported normal cellular 
processes to take place. This allowed the live imaging sequence to capture cellular 
events as they were taking place in real-time. However, as already mentioned for the 
imaging of fixed spheroids, the core could not be imaged, and it was impossible to 
                                                 
3 Clearing Procedures for Deep Tissue Imaging – Science Lab - Leica Microsystem website 
https://www.leica-microsystems.com/science-lab/clarity/clearing-procedures-for-deep-tissue-
imaging/ 
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determine whether GFP-labelled cells would be in the core as well. However, it is 
important to note that the live imaging experiments described in this thesis represent 
proof-of-principle studies, and more in-depth experiments are needed to fully explore 
the capabilities of the novel reaggregation method in combination with the LSFM. 
Generally, the LSFM could be used to image spheroids made of stem cells, where 
the core harbors the quiescent stem cells. The encouraging results above show that 
mitosis can be detected, and exogenous cells be tracked, widening the type of 
questions that can be answered.  
The versatility of the reaggregation spheroids in combination with the capabilities 
of the LSFM will open a myriad of possibilities to study cell behaviour in various 
different applications. Recently, iPSC-derived Six2+Sall1+Wt1+Pax2+ nephron 
progenitor cells were plated on low-attachment plates and grown for ten additional 
days in order to obtain renal organoids that could be used for nephrotoxicity studies 
(Freedman et al., 2015; Morizane et al., 2015). Importantly, since organoids with sizes 
in the range of 400µm are ideal for the formation of a hypoxic core, the system may 
become highly relevant for the study of growth delays or regeneration after drug 
exposure (Ranga et al., 2014). Alternatively, the cross-talk between different cell types 
(e.g. tubular and immune cells) could be analysed in great detail. Finally, the LSFM has 
been proposed for use of in the clinic, to directly address the need for histological 
analysis of the biopsies of cancer patients (Pampaloni et al., 2015). 
The LSFM will facilitate the analysis of organoids in studies on 
pharmacodynamics/pharmacokinetics, embryonic development, regenerative 
medicine applications, and tissue engineering. The applications are innumerable and 
will bring together scientists with a wide range of backgrounds.  
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 AMELIORATION POTENTIAL OF HUMAN CD133+ AND CD133- IN 5
A CISPLATIN-INDUCED RAT MODEL OF ACUTE KIDNEY INJURY 
5.1 INTRODUCTION AND AIMS 
Given its central role in the detoxification and excretion of toxic compounds , the 
kidney is the major target of exogenous toxicants. Circa 20% of nephrotoxicity is 
caused by drugs, and this percentage increases with age, to reach up to 66% in the 
elderly. Nephrotoxicity is one of the key limiting factors of chemotherapeutics for 
various types of hyperplasia (Perazella, 2012).  
In this chapter, a preclinical model of cisplatin-induced acute kidney injury was 
used to test the potential of human primary CD133+ and CD133- cells to be used as 
cellular therapeutics. Athymic rats lacking only T cells were used in order to facilitate 
the survival of the human cells into the rat environment. Renal function was 
monitored using a novel transcutaneous device that does not require continuous 
blood or urine samplings as for conventional plasma clearance techniques. Instead, it 
measures the excretion of the renal marker FITC-Sinistrin after intravenous injection. 
The excellent safety profile of Sinistrin combined to the successful use of the device in 
preclinical models make the device a promising tool for the clinic (Scarfe et al., 2015; 
Schock-Kusch et al., 2009; Schock-Kusch et al., 2011; Steinbach et al., 2014).  
The intravenous administration was the chosen route of administration. An 
important obstacle of this route is represented by the possible entrapment of the cells 
into the lung capillary bed. From the tail vein, the blood travels through the inferior 
vena cava all the way to the right ventricle of the hearth. From there, the venous 
blood is distributed to both lungs where the carbon dioxide (CO2) is removed. The 
alveoli are responsible for the oxygenation of the blood that will then be diverted to 
the rest of the body. The diameter of the interior pulmonary capillaries was measured 
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to be 5.15 ± 1.3 µm in SD rats. Therefore, IV-injected cells larger than the pulmonary 
capillaries, risk to get trapped in the lungs (Kutscher et al., 2010; Leibacher and 
Henschler, 2016). For instance, Fischer and colleagues demonstrated that the majority 
of intravenously administered stem cells [mesenchymal stromal cells (MSC), 
multipotent adult progenitor cells (MAPC), bone marrow-derived mononuclear cells 
(BMMC) and neural stem cells (NSC)] in rats did not reach the arteriosus system, but 
were trapped in the pulmonary system and cleared there. The size of the cells made a 
difference in the pulmonary passage: the smallest cells in the set [BMMC (diameter of 
7 µm)] showed a pulmonary passage 30-fold higher than MSCs (d=~18µm), followed 
by MAPC and NSC (d=15 and 16 µm, respectively) that had a 2-fold increase compared 
to MSCs. The adhesion properties of the injected cells played a role too: MSCs treated 
with CD49d (that inactivates VCAM-1) showed a 2-fold increase of pulmonary passage. 
VCAM-1, adhesion molecule expressed by endothelial cells, might promote the 
entrapment of the MSCs in the endothelial capillaries in the lungs, impeding the 
pulmonary passage (Fischer et al., 2009).  
Given the previous studies that use CD133+ and CD133- cells in acute kidney injury 
models (introduced extensively in the introduction), it was speculated that the CD133+ 
cells would exert a positive impact on the development of the acute injury induced by 
cisplatin. On the contrary, CD133- cells serve as a negative control, since their efficacy 
has never been shown before. The transcutaneous device can be effective in reducing 
the number of animals used for the experimentation, allowing the longitudinal 
monitoring of the renal function without the need of sacrificing the animals. It was 
also hypothesised that, following IV administration, the cells identified by GFP would 
get trapped in the lungs, and never reach the kidney. In the kidneys, instead, it would 
be expected to observe PKH26 staining, used to co-stain the cells, as a sign of the 
release of extracellular vesicles that help the amelioration process. 
In this chapter, the main aims that will be addressed in this chapter encompass: 
I) Assess the therapeutic effect of human-derived CD133+ and CD133- cells on 
renal function in a model of acute kidney injury induced in 
immunodeficient rats (RNu) after cisplatin administration.  
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II) Investigate the biodistribution pattern and evaluate the engraftment of the 
intravenously injected human-derived CD133+ and CD133- cells into the 
damaged kidney. 
III) Study the role of the innate immune system following the administration of 
the human renal CD133+ and CD133- cells, to establish possible 
mechanisms of action of the human cells in the model. 
5.2 RESULTS 
The in vivo experiments presented in this chapter were carried out during my 
secondment in the lab of Prof. Norbert Gretz (Centre for Medical Research, University 
of Heidelberg, Mannheim, Germany), where I worked in collaboration with Zeneida 
Herrera Perez (University of Heidelberg) who developed the Cisplatin Rat model.  
The cells were transduced and sorted at the University of Liverpool and cultured at 
the University of Heidelberg for one passage before the injection. Zeneida Herrera 
Perez performed the injections. The GFP-containing lentivirus (pHIV-GFP) was kindly 
supplied by Dr. Arthur Taylor (University of Liverpool). The Hematoxylin and Eosin 
stainings were performed by technical personnel at the University of Heidelberg. The 
paraffin blocks for other staining procedures were kindly cut by Angela Platt-Higgins, 
research technician at the University of Liverpool. 
5.2.1 PREPARATION OF CD133+ AND CD133--GFP-LABELLED 
The heterogeneous population was labelled with GFP lentivirus and sorted for the 
expression of CD133 only, as shown in paragraph 4.2.1 in chapter 4. For the in vivo 
experiments, it was decided to inject the cells (CD133+ and CD133-) at passage 5, right 
after the trypsinization at passage 4, when the CD133 expression was expected to be 
above 90%. According to Figure 3.16, CD133+ cells start losing considerably the 
expression of CD133 after 5 days in culture at passage 5 (~80%). The FACS analysis 
confirmed that 91.36% ± 9.17 of the CD133+ cells expressed CD133/2  However, based 
on the finding that CD133 expression increased in the CD133- population during 
expansion, immunodepletion of CD133+ cells by MACS was employed to maintain a 
pure negative population when necessary (Data not shown). Before injection, 7.01% ± 
6.00 of the CD133- cells expressed CD133/2 (Figure 5.1). 
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To include an additional cell labelling method, consistent with previous studies in 
the literature (Gupta et al., 2015; Qi and Wu, 2013; Ronconi et al., 2009), both cell 
populations were incubated before the injection with PKH26. PKH26 is a lipophilic dye 
with an excitation wavelength of 551 nm and an emission wavelength of 567 nm, 
which is diluted out upon cell division and can be transferred to the host cells via 
extracellular vesicles (Li et al., 2013a).  
Therefore, all cells were GFP-positive and PKH26-positive and either CD133+ or 
CD133-. From now on, they will be referred as CD133+ and CD133- cells only.  
5.2.2 TWO-WEEK STUDY  
The experimental design of the two-week study is shown in Figure 5.2. Cisplatin 
was injected intraperitoneally (IP) at a dose of 7mg/100g BW and the day of cisplatin 
administration was defined as day 0. Renal function was monitored throughout the 
study using the GFR transcutaneous device, and measurements were performed 
before the induction of the damage (baseline) and on days 2, 7 and 14 after Cisplatin 
injection. Also, blood and urine samples were collected at baseline and days 7 and 14 
after the induction of the damage. Day 7 represents the peak of damage (Zeneida 
Herrera-Perez, personal communication). Three experimental groups were used in this 
study. The control group received cisplatin on day 0 and saline on day 2 and 7, the 
 
FIGURE 5.1 CONFIRMATION OF THE PURITY OF BOTH POPULATION AT P5 BEFORE INJECTION IN VIVO 
FACS analysis of the expression of CD133/2 APC in both CD133+ and CD133- populations at P5, 
the passage of the injection in vivo. Mean values ± SEM of three independent sortings and 
expansions.  
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CD133+-treated group received cisplatin on day 0 and 1 million CD133+ cells on day 2 
and 7 and the CD133--treated group received cisplatin on day 0 and 1 million CD133- 
cells injected on day 2 and 7. It is important to mention that the GFR measurements 
on days 2 and 7, and urine and blood collection on day 7 were performed before the 
injection of a single dose of 1 million CD133+ or CD133- cells. 
 
FIGURE 5.2 EXPERIMENTAL SET-UP OF THE TWO-WEEK STUDY 
5.2.2.1 MONITORING THE RENAL FUNCTION USING THE TRANSCUTANEOUS DEVICE 
The overview of the GFR measurements over the length of the study is presented 
in Figure 5.3. The results of FITC-Sinistrin half-life (HL-Sin), serum creatinine and serum 
urea are reported in Figure 5.3.  
At baseline, all rats had comparable HL-Sin, while on day 2 the renal injury was 
already apparent, as shown by the modest, but not significant increase in HL-Sin. In 
fact, the measurements on day 2 were used to corroborate the presence of the 
damage and avoid the injection of cells into animals that did not develop the damage. 
In fact, 37.5% (12 out of 32 rats) of the animals did not show any increase in HL-Sin at 
day 2 and were therefore eliminated from the study. 
On day 7, both cell-treated groups showed a reduction of the HL-Sin, of 59.1% 
(CD133+ cells) and 46.8% (CD133- cells), when compared to the control group. 
Interestingly, there is no significant difference between the groups that received 
CD133+ or CD133-. These data suggest that the reduction in HL-Sin observed was a 
consequence of the cell injection. Furthermore, the results indicate that CD133 might 
not be the exclusive factor responsible for the amelioration of the renal function.  
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By day 14, a decrease in the HL-Sin was observed in the control group, 
corroborating the acute type of damage induced by Cisplatin. As mentioned in the 
introduction, the tubular compartment triggers an offsetting response; the residual 
proximal tubule cells start proliferating to replace the neighbours lost upon injury, 
leading to the improvement of the renal function. In the cell-treated groups, the HL-
Sin remained at similar levels as on day 7, suggesting that the second injection of 
CD133+ or CD133- cells did not further ameliorate the renal function.  
Altogether, these results suggest that one injection of either CD133+ or CD133- 
cells two days after the induction of the damage was beneficial in reducing the HL-Sin, 
and, as a consequence, improving the renal function. Nevertheless, the HL-Sin of each 
group failed to return to the baseline levels after 14 days (Figure 5.3).  
 
FIGURE 5.3 HALF-LIFE VALUES OF FITC-SINISTRIN OVER THE TWO WEEKS STUDY OBTAINED USING THE 
GFR DEVICES  
Mean values ± SEM of the HL-Sin over the whole length of the study (CD133+ group n=6, 
CD133-  group n=6, Control group n=7). An ANOVA one-way statistical test with Dunnet Post 
Hoc analysis was applied for each time point to compare the groups ** p=0.0026; ** 
p=0.0095.  
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TABLE 5.1 MEAN VALUES OF HL-SIN, SERUM CREATININE, AND SERUM UREA ± SEM FOR ALL 
GROUPS AT ALL TIME-POINTS EVALUATED 
An ANOVA one-way statistical test with Dunnet Post Hoc analysis was applied for group to 
compare baseline values and values at day 14.  
HL-Sin p-values: Control: Base vs. 14D p <0.0001; CD133+: Base vs. 14D p=0.0237; CD133-: 
Base vs. 14D p=0.0032;  
Serum Creatinine p-values: Control: baseline vs. d14 p<0.0001; CD133+: baseline vs. d14 
p=0.0008; CD133-: baseline vs. d14 p<0.0001;  
Serum urea p-values: Control: baseline vs. d14 p=0005; CD133+: baseline vs. d14 p=ns; 
CD133-: baseline vs. d14 p=ns. 
 
5.2.3 MONITORING SERUM CREATININE AND UREA TO ASSESS FUNCTIONAL RENAL 
DAMAGE  
The magnitude of the renal damage was also evaluated through the measurement 
of conventional renal biomarkers, such as creatinine and urea in serum and urine 
(Figure 5.4).  
The animals that had received CD133+ or CD133- cells showed a reduction in the 
serum levels of creatinine and urea when compared to the control animals at day 7  
(Figure 5.4 A). Despite similar values for both the CD133+ and CD133--treated groups, 
statistical significance in the difference for serum creatinine and for serum urea was 
only observed in animals that received CD133+ cells. At day 14, all groups showed 
comparable values of serum creatinine. However, the serum creatinine levels at day 
14 failed to return to baseline levels (Table 5.1). 
Cisplatin CD133+ CD133-
HL-Sin (min)
± SEM
B 16.41 ± 1.78 17.36 ± 1.54 13.38 ± 1.68
D2 40.3 ±12.51 30.63 ± 2.08 27.25 ± 2.07
D7 81.27 ± 11.01 33.21 ± 4.47 43.18 ± 4.96
D14 50.83 ± 7.47 35.07 ± 5.38 37.60 ± 5.17
SCr (mg/dL) 
± SEM
B 0.16 ± 0.00 0.17 ± 0.00 0.16 ± 0.00
D7 1.59 ± 0.55 0.44 ± 0.04 0.56 ± 0.05
D14 0.59 ± 0.08 0.39 ± 0.04 0.46 ± 0.02
SUrea (mg/dL) 
± SEM
B 39.64 ± 2.09 31.8 ± 1.33 35.23 ± 1.80
D7 294.7  ± 94.87 75.84  ± 10.97 107.3  ± 24.82
D14 122.1 ± 29.23 63.7 ± 10.4 76.42 ± 12.32
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
nsns
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The results for the serum urea revealed that at day 7 rats from both cell-treated 
groups had much lower values than control animals, but only in the group that 
received CD133+ cells was the difference significant (Figure 5.4 B). However, at day 14 
the serum urea levels of the cell-treated groups, but not the control group returned to 
baseline levels (Table 5.1). 
Altogether, the renal serum markers supported the data obtained through the GFR 
device, revealing an acute phase of the injury in the control animals that was 
attenuated in both groups of animals after treatment with the cells. 
Creatinine and urea were also analysed in the urine of the animals of each 
experimental group (Figure 5.4 C-D). An increase of urinary creatinine or a decrease in 
urinary urea would be symptomatic of kidney disease. In the cisplatin model, however, 
there were no significant differences in the urinary injury markers between groups , 
with the exception for the CD133--treated group when compared to control group at 
day 14.  
Altogether, these results suggest that even one single injection of either CD133+ or 
CD133- two days after the initial damage was beneficial in slowing down or even 
arresting the development of the injury. The transcutaneous measurements showed 
an improvement of approximately the 50% of the renal function after treatments with 
both cell types. Serum Creatinine and serum urea were less sensitive, when compared 
to the HL-Sin and significance could be found only for CD133+ cells. Finally, urinary 
Creatinine and Urea failed to highlight any difference in the groups.  
Interestingly, all biomarkers used to assess renal function did not return to 
baseline levels, indicating that the damage is not resolved in 14 days (Table 5.1). The 
cisplatin dose used in these immunodeficient rats surely induced an acute kidney 
injury. However, it can be speculated that the damage could progress to a chronic 
injury in the long-term. An additional set of measurements at a later time point will 
help in defining the long-term effects of the used dose of cisplatin and the role of the 
cellular therapies.  
 157 
 
 
FIGURE 5.4 SERUM CREATININE AND SERUM UREA VALUES OVER THE TWO WEEKS STUDY IN SERUM 
AND URINE 
Mean values ± SEM of serum creatinine (A), serum urea (B), urinary creatinine (E) and urinary 
urea (F) at baseline, day 7 and 14. The urinary values were normalized over a 24 hours period. 
The ANOVA one-way statistical test with Dunnet Post Hoc analysis was applied for each time 
point to compare the groups. (C) and (D) Tables summarizing the p-values of the statistical 
test at day 7 and day 14. The p-values table for urinary creatinine and urea were not included, 
because higher than 0.5. uCr (Day 14; Control vs CD133-) * p=0.0138. 
5.2.3.1 EVALUATING URINARY TIM-1, CYSTATIN C AND ALBUMIN AT D14  
In the last decade, there has been intensive research on developing novel renal 
biomarkers. As explained in the introduction, creatinine and urea are not always 
suitable biomarkers to detect nephrotoxicity. Specifically, Tim-1 (rat homologue of 
Kim-1) and cystatin C (Cys-C) were proposed as excellent biomarkers to monitor renal 
health.  
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Tim-1, Cys-C and the albumin/creatinine ratio (ACR) were evaluated in the urine 
for each experimental group at baseline, day 2 and 7. All values were normalized to 
the amount of urinary creatinine over a 24 hour period (Figure 5.5).  
In healthy animals, Tim-1 is not excreted, as shown by the virtual absence of Tim-1 
from the urine of all animals at baseline. Upon damage, Tim-1 levels raised 
significantly in all groups (One-way ANOVA, Tukey Post Hoc test, p<0.0001 for all 
groups), consistent with the fact that damaged proximal tubule cells shed Tim-1 into 
the luminal area, and, therefore, the urine. At day 7, both cell-treated groups did not 
show any major difference in the levels of Tim-1 when compared to the control group. 
Nevertheless, the urinary concentration of Tim-1 slightly decreased at day 14 for all 
experimental groups. However, this reduction was not significant and, most 
importantly, was comparable for all experimental groups (Figure 5.5 A and Table 5.2).  
Cys-C is produced at a constant rate from every nucleated cell. It is then 
reabsorbed and catabolized from the proximal tubule cells. Therefore, in case of 
tubular damage, the reabsorption capacity of the tubular cells is impaired, and Cys-C is 
released into the urine. In this study, the urinary levels of Cys-C raised equally in all 
three groups at day 7. However, the increase was not significant. At day 14, the Cys-C 
levels remained constant for the CD133- group and rose slightly for the CD133+ and 
control group. No statistical differences were detected among the groups  (Figure 5.5 B 
and Table 5.2).  
Finally, the urinary ACR informs about microalbuminuria. It reflects the status of 
the filtration barrier in the glomerulus; therefore, it can be informative of the onset of 
a chronic type of damage. At day 7, it was observed a slight, but not significant 
increase in the ACR in all groups. At day 14, the control group displayed a significanlty 
higher ACR compared to both cell-treated groups. Importantly, there were no 
differences among the cell-treated groups (Figure 5.5 C and Table 5.2).  
The data relative to the urinary biomarkers Tim-1 and Cys-C were consistent with 
the onset of an acute kidney injury, but not with the trend observed for HL-Sin, serum 
creatinine and serum urea. In the data set presented in this paragraph, the cell 
therapies did not lead to a reduction of the levels of the biomarkers at any time point. 
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Not only so, all groups showed significantly higher levels of urinary markers at day 14 
than at baseline, indicating that some degree of renal damage was still present.  
Instead, the ACR data suggested that the human cells prevented leakage of 
albumin across the filtration barrier in the long term, as shown by the difference at 
day 14 between the two cell-treated groups and the control group. This finding 
corroborates the possibility of the onset of chronic kidney disease.  
 
FIGURE 5.5 URINARY TIM-1, CYS-C AND ALBUMIN OVER THE LENGTH OF THE STUDY 
Mean values ± SEM of urinary Tim-1 (A), Cys-C (B) and albumin (C) at baseline, day 7 and day 
14. To detect the urinary values of Tim-1 and Cys-C, the urine of 5 animals per group was 
randomly used. All urinary values were normalized against urinary creatinine. The ANOVA 
one-way statistical test with Tukey Post Hoc analysis was applied for each time point to 
compare the groups. ACR (Day 14; vs. Control * p=0.215, * p=0.0345) 
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TABLE 5.2 MEAN VALUES ± SEM FOR TIM-1, CYS-C, AND ACR ± SEM FOR ALL GROUPS AT ALL TIME 
POINTS. THE ANOVA ONE-WAY STATISTICAL TEST WITH TUKEY POST HOC ANALYSIS WAS APPLIED FOR 
GROUP TO COMPARE BASELINE VALUES AND VALUES AT DAY 14.  
Tim-1 p-values: Control: Base vs. 14D p=0.0031; CD133+: Base vs. 14D p=0.0381; CD133-: Base 
vs. 14D p=0.0026;  
Cys-C p-values: Control: baseline vs. d14 p=0.0059; CD133+: baseline vs. d14 # p=0.0499; 
CD133-: baseline vs. d14 p=ns;  
ACR p-values: Control: baseline vs. d14 p=0.0217; CD133+: baseline vs. d14 p=ns; CD133-: 
baseline vs. d14 p=ns 
 
5.2.3.2 HISTOLOGICAL EVALUATION OF RENAL INTEGRITY AT DAY 14 
The tissue integrity of the kidneys was analysed after Hematoxylin and Eosin 
staining at day 14. In the control group, several abnormalities , typical of acute tubular 
injury, were observed (Figure 5.6 A): the tubular cells showed features of undergoing 
apoptosis, including pyknotic nuclei, and being shed into the lumen, while the 
remaining epithelium lost the brush border, had a flattened appearance and the 
tubular lumen was disproportionally enlarged. By contrast, in the two cell-treated 
groups, cellular debris in the luminal area and flattened epithelia were rarely 
observed. Instead, regenerating tubuli with almost intact brush borders were 
detectable (Figure 5.6 B-C). In all groups, glomeruli appeared intact and 
morphologically normal.  
In order to quantify the histological damage, the luminal area of the tubuli was 
measured using the imaging software Fiji for each experimental group in a blinded 
fashion. The results are summarized in Figure 5.8 D, showing that the mean luminal 
Cisplatin CD133+ CD133-
Tim-1 
(µg/mg Cr)
± SEM
B 1.10 ± 0.18 0.83 ± 0.08 0.92 ± 0.09
D2 32.63 ± 4.79 26.51 ± 3.09 26.06 ± 2.05
D14 20.11 ± 3.40 15.62 ± 2.90 20.20 ± 3.20
Cys-C 
(µg/mg Cr)
± SEM
B 3.09 ± 1.72 2.56 ± 0.37 2.76 ± 0.69
D7 28.6 ± 8.83 26.18 ± 7.04 27.89 ± 6.49
D14 40.16 ± 5.92 31.98 ± 5.72 26.20 ± 4.58
Alb/uCr
(mg/mg) ±
SEM
B 0.39 ± 0.20 0.11 ± 0.00 0.13 ± 0.02
D7 1.03 ± 0.34 0.28  ± 0.06 0.60  ± 0.10
D14 3.21± 1.15 0.29 ± 0.06 0.31 ± 0.04
*
*
*
*
*
* #
* nsns
*
ns
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area of the groups that received either CD133+ or CD133- cells was significantly smaller 
than the average luminal area of the control group.  
Further correlation analysis revealed a significant coefficient of correlation 
between the computed luminal area and the HL-Sin at day 14 (Table 5.1 E) in the 
control group (p-value <0.05). Also, the CD133+-treated group showed a significant 
correlation coefficient. This correlation indicates that it might be possible to infer the 
actual tissue damage by measuring the renal function through the transcutaneous 
device. Higher animal numbers would be required to fully test this hypothesis.  
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FIGURE 5.6 EVALUATION OF THE RENAL INTEGRITY AT DAY 14 
(A-C) Representative images for each experimental group of H&E-stained paraffin sections of 
the kidney. The scale bars represent 50µm. (D) Mean luminal area ± SEM. The luminal area 
was measured using the imaging software Fiji, applying the black and white threshold to at 
least 10 images per animal. The ANOVA one-way statistical test with Dunnet Post Hoc analysis 
was applied to compare the groups. (E) Pearson correlation between the HL-Sin values at day 
14 and the luminal area at day 14.  
Abbreviations: pn – Pyknotic nuclei, cd – cellular debris, fe – flat epithelium, (d – dilated 
tubuli, rt – regenerating tubuli, surrounded by the black solid line. 
5.2.3.3 CORRELATION OF BIOMARKERS WITH HISTOLOGY AND HL-SIN VALUES 
Since the conventional biomarkers, serum creatinine and urea, still represent the 
gold standard in the clinic to detect acute kidney injury, the correlation between the 
HL-Sin values and the serum biomarkers values was tested (Figure 5.7). None of the 
conventional biomarkers significantly correlated with the HL-Sin values, probably 
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indicating a difference in the accumulation of serum creatinine and urea following 
injury and the excretion rate of FITC-Sinistrin following injury.  
Also, the values of the luminal areas were tested for their correlation with the 
serum biomarkers. However, even in this instance, no significance was found, 
highlighting that both biomarkers might not be sensitive enough to infer the tissue 
integrity in the three experimental groups.  
 
FIGURE 5.7 CORRELATION OF SERUM BIOMARKERS WITH HL-SIN AND LUMINAL AREA VALUES 
(A) Pearson correlation between the HL-Sin values at day 14 and the serum Creatinine values 
at day 14. (B) Pearson correlation between the HL-Sin values at day 14 and the serum Urea 
values at day 14. (C) Pearson correlation between the luminal area at day 14 and the serum 
Creatinine values at day 14. (D) Pearson correlation between the luminal area at day 14 and 
the serum Urea values at day 14. P values are indicated in the insets.  
5.2.3.4 HISTOLOGICAL EVALUATION OF RENAL FIBROSIS AT DAY 14 
Renal fibrosis occurs when there is an excessive accumulation of extracellular 
matrix, specifically collagen, in the tubular-interstitial space. This excessive 
accumulation leads to the formation of scar tissue, with consequent loss of tissue or 
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organ function. In the kidney, progressive loss of function would undoubtedly lead to 
ESRD.  
To measure fibrosis, paraffin sections from kidneys of the three experimental 
groups were stained for Masson’s Trichrome, a histological staining technique efficient 
in detecting early fibrosis where blue staining marks matrix elements, including both 
basement membrane and collagen (Street et al., 2014).  Five images of the cortex 
were stitched together to visualise the differences among the groups throughout a 
larger section of the kidneys including cortex and parts of the medulla  (Figure 5.8 A-C). 
The stitched images show that the cortical epithelium of the control group was 
completely damaged as the most proximal tubular epithelia were flattened, and the 
luminal dilation was high (Figure 5.9 A). By contrast, sections from kidneys of the 
groups that received human cells revealed a more organized cortex, with smaller 
dilated tubuli and regenerating tubular epithelia (Figure 5.9 B, C). Between the two 
cell-treated groups, the CD133- treated group appeared to have tubuli with larger 
lumen that could not be completely appreciated in the H&E single images.  
The blue staining as indicator of matrix deposition was quantified using the colour 
threshold function of the imaging software Fiji, and the results are shown in Figure 5.8 
D. While the mean tissue area identified as fibrotic for all control animals was larger 
than for the cell-treated animal groups, these differences were not significant. 
Examples of staining of the two extremes (highest fibrotic area and lowest fibrotic 
area) are shown in the two insets. Since fibrosis develops slowly in damaged tissue it is 
not surprising that significant differences could not be observed at day 14. The fibrotic 
area was also measured using the histological stain Picrosirius Red where the collagen 
deposition is stained bright red. However, similar results were obtained and no 
differences noted (data not shown).  
In conclusion, the results presented so far demonstrate that the injection of 
CD133+ or CD133- cells have beneficial effects on kidney function and tubular structure 
in cisplatin-injured rats. However, the data fail to show any difference in fibrosis in the 
kidneys between control and cell-treated animals.  
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FIGURE 5.8 EVALUATION OF FIBROSIS AT DAY 14 AFTER CISPLATIN INJURY 
Representative stitched images of Masson’s Trichrome staining of kidney sections from 
control group (A), CD133+-treated group (B), and CD133--treated group (C) animals. (D) 
Quantification of the fibrotic area in histological kidney sections of animals of all groups after 
processing of at least 10 images per animal per group. An ANOVA one-way statistical test with 
Dunnet Post Hoc analysis was applied to compare the groups. The bars represent the SEM. 
The insets show representative images of the animals with the highest and lowest fibrotic 
area. 
5.2.3.5 LOCALIZATION OF PKH26+/GFR+ CELLS AT DAY 14 IN LUNGS AND KIDNEYS 
Once the therapeutic efficacy of the cells has been proved, the following aim was 
to localize the CD133+ or CD133- cells at day 14 in order to assess whether the benefit 
that the cells exert are due to their engraftment in the renal tissue. Given the 
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administration route used in the study, lungs were also collected for analysis. A GFP 
antibody was used to identify unequivocally the human cells, while PKH26 was 
detected due to its fluorescence properties (Excitation maximum 551 nm, Emission 
maximum 567 nm).  
In the lungs, no GFP-positive cells were detectable in the lungs. However, small 
dots of PKH26 stain could be identified in clusters in the lung sections (Figure 5.9 A-B). 
In the kidneys, GFP-positive cells could not be detected; it is important to note that 
strong autofluorescence in the tubuli, especially in the green channel, was visible 
(compare with lung sections). PKH26 staining could be identified in the two cell-
treated groups. As observed in the lungs, the PKH26 staining appeared as red spots 
close to the nuclei of either tubular cells or interstitial cells (Figure 5.9 D-F). 
The results showed in this paragraph provide compelling evidence for the passage 
of the cells through the lungs, where the PKH26 staining is stronger than in the 
kidneys. At the end of the experiment, however, the GFP-positive cells could not be 
identified, suggesting that the expression of GFP or the entire cells might have been 
lost in the two-weeks. It is noteworthy that, especially in the control group, there are 
cells that are autofluorescent in the green and red channel, highlighted in Fig 10 C and 
F with arrowheads. These cells might represent immune cells, such as macrophages 
(Njoroge et al., 2001). 
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FIGURE 5.9 LOCALIZATION OF GFP AND PKH26 IN LUNGS AND KIDNEYS AT DAY 14 
Maximum intensity projection (MIP) confocal images of a representative animal per 
experimental group in lungs (A-C) and kidneys (D-F).  
5.2.4 BIODISTRIBUTION STUDY 
5.2.4.1 LOCALIZATION OF CD133+ PKH26+/GFR+ CELLS IN LUNGS, KIDNEYS  
The two-week study failed to provide a definite answer about the exact 
localization and fate of the cells. It was clearly demonstrated that the cells were not 
present in the kidneys. To elucidate the biodistribution pattern after the injection, a 
short-term study was performed (Figure 5.10). In this study, 1x106 CD133+ 
GFP+/PKH26 labelled cells were injected in 6 animals on day 2. Two animals each were 
then sacrificed at 1, 6 and 24 hours after cell administration, and lungs, kidneys were 
collected for further analysis. Two animals served as vehicle control as they were 
injected with PBS and sacrificed 1 hour after the injection. 
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One hour after the injection, clusters of CD133+ cells were present in the lungs, 
showing both GFP and PKH26 staining. Interestingly, some cells displayed an abnormal 
nucleus. At 6 hours, some human cells appeared fragmentised (Figure 5.11 B), while 
others appeared intact (Figure 5.11 C). Importantly, PKH26 stain was spotted even if 
no intact human cell was found. At 24 hours, no more GFP+ cells could be detected. 
However, positive areas for PKH26 were revealed (Figure 5.11 D).  
In the kidneys, the staining pattern did not differ from what observed at day 14. 
No CD133+ cells were detected in the kidneys at any of the time point analysed, while 
PKH26 appeared as small red dots around the cell nuclei (Figure 5.12C).  Therefore, 
even in the short-term biodistribution study we could exclude the presence of GFP-
positive cells in the kidneys.  
These results suggest that, following intravenous injection, the cells get entrapped 
in the lungs and disappear within 24 hours. Notably, the PKH26 was not confined to 
the GFP labelled cells (see Figure 5.11 B and C) and it was observed even when no GFP 
labelled cells could be stained in the lungs. It can be speculated that extracellular 
vesicles released by the cell body are responsible for this punctuate pattern in both 
lungs and kidneys. On this regard, it has been shown that PKH26 can be released from 
cells bound to extracellular vesicles (Li et al., 2013a). 
 
FIGURE 5.10 EXPERIMENTAL SET-UP OF THE BIODISTRIBUTION STUDY 
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FIGURE 5.12 LOCALIZATION OF HUMAN CD133+ CELLS IN THE KIDNEY 1 HOUR AFTER INJECTION 
Representative MIP confocal image of the kidney cortex of a 1-hour animal showing PKH26 
staining close to the glomerulus. No GFP+ cell was detected.  
5.2.4.2 ROLE OF MACROPHAGES IN THE LUNGS AND KIDNEYS IN THE 
BIODISTRIBUTION STUDY  
The results presented so far would indicate that the human cells  were trapped in 
the lungs after IV administration and disappeared within the following 24 hours. It was 
postulated that macrophages could play a role in the disappearance of the cells in the 
 
FIGURE 5.11 LOCALIZATION OF HUMAN CD133+ CELLS IN THE LUNGS 1, 6 AND 24 HOURS AFTER 
INJECTION 
(A-D) Representative MIP confocal images of the lungs of the animals at the three time points 
showing PKH26 staining and GFP staining. The images were taken by applying the same 
exposure for each channel. (C) Representative confocal image of the kidney cortex of a 1-
hour animal showing PKH26 staining close to the glomerulus. 
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lungs. Therefore, sections were analysed for the expression of macrophage markers, 
specifically CD68, which has been well established as a pan-macrophage marker.  
Resident macrophages are present in most organs, including lungs. In the control 
animals, resident macrophages were seen interspersed throughout the tissue (Figure 
5.13 A). In lungs from animals 1 hour after cell administration, GFP-positive cells were 
surrounded by CD68-positive cells (Figure 5.13 B, E). At 6 hours, this pattern was 
maintained, with clusters of CD68-positive cells surrounding GFP-positive cells (Figure 
5.13 C-F). Interestingly, the PKH26 signal localized with the signal coming from the 
CD68 cells, suggesting that macrophages might be involved in the phagocytosis of 
possible by-products released by the human cells (Supplementary videos 5.1 and 5.2). 
At 24 hours, the clusters of CD68+ cells were still evident in several locations, however, 
GFP positive cells could not be identified (Figure 5.13 D).  
In summary, these results suggest an instrumental role of macrophages in the 
disappearance of the human cells from the lungs. Whether the macrophages observed 
in the lungs were recruited from the circulation or resulted from the proliferation of 
the resident macrophages was not established.  
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In the kidneys, a slight increase in the distribution of infiltrating macrophages was 
observed in the cell treated animals when compared to the control group (Figure 
5.14). However, the differences were not striking. 
 
FIGURE 5.14 MACROPHAGES INFILTRATION IN THE KIDNEYS IN THE BIODISTRIBUTION STUDY 
Representative MIPs confocal images of the lungs of the animals at all time points showing 
GFP (green), CD68 (red) and DAPI (blue). The images were taken with the same exposure for 
the different channels across different samples. The scale bar represents 100 µm.  
 
FIGURE 5.13 MACROPHAGE INFILTRATION IN THE LUNGS  
(A-F) Representative MIPs confocal images of the lungs of the animals at all time points 
showing PKH26 (red), GFP (green) and CD68 (white). The images were taken with the same 
exposure for the different channels across different samples. The scale bar represents 50 
µm. 
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5.2.4.3 EFFECTS OF THE HUMAN CELLS ON THE HOST RENAL EPITHELIUM: 
PROLIFERATION  
The major consequence of the cisplatin uptake into the tubular epithelial cells is 
the apoptosis of the cell. Since the human cells appear to influence the renal function 
and histology of the cisplatin-injured kidneys, it was important to address the 
mechanism through which the cells act on the damaged kidney tissues. To address 
these questions, the kidneys of all animals of the long-term study were analysed for 
markers of proliferation.  
The proliferating cells were identified using the marker Ki67, which is expressed 
during all phases of the cell cycle (G1, S, G2, and mitosis), but is absent from resting 
cells (G0). Quantitatively, a bit less than twice as many proliferative cells were 
detected in the control group than in both cell-treated groups. Of note, rare 
proliferating cells were detected in the Bowman’s capsule, indicated by an arrow in 
the CD133+ image (Figure 5.15 B).  
Therefore, at day 14, the control group showed a significantly higher number of 
proliferative cells. The data might indicate that the cell-treated animals might have 
had a regenerative advantage given by the injection of the cells. Two different 
mechanisms could be taken into account: the cells have the ability to prevent tubular 
apoptosis, or they accelerated the regeneration process. The approach followed in this 
paragraph does not clarify which one might be the actual mechanism. Also, the Ki67+ 
cell in the BC in the CD133+ group might indicate a sort of response of putative 
progenitor cells to the damage induced by cisplatin.  
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FIGURE 5.15 EFFECTS OF THE HUMAN CELLS ON THE PROLIFERATION OF THE HOST EPITHELIUM AT 14 
DAYS 
(A) Histogram bar showing the average amount of KI67+ cells ± SEM per high power field (hpf) 
obtained counting at least 10 random images taken across the whole kidney. The ANOVA 
one-way statistical test with Tukey Post Hoc analysis was applied to compare the groups ** 
p=0.0091 ** p=0.0086 (B) Representative fluorescence images of each experimental group 
showing Ki67 staining (red). In the CD133+ group, the white arrow points to a proliferating cell 
in the Bowman’s capsule. The scale bars represent 50 µm.  
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5.3 DISCUSSION 
One of the final aims of the characterization of progenitor/stem cells is testing 
their capabilities to ameliorate tissue injury by either fostering the regeneration of the 
damaged organ or preventing further damage due to the primary insult. In the 
previous chapters, human renal putative progenitor cells expressing CD133 were 
isolated from children’s kidneys, expanded in culture and phenotypically 
characterized. The isolated cells failed to survive and integrate into developing 
structures of an ex vivo chimeric reaggregation assay. In this chapter, both CD133+ and 
CD133- populations were finally injected in an immunodeficient rat model of acute 
kidney injury, induced by cisplatin, to determine their potential as cellular 
therapeutics. 
On one hand, the beneficial effects of kidney-derived CD133+ cells have been 
reported in different preclinical models of kidney injury, both acute and chronic 
[reviewed in (Bussolati and Camussi, 2015)]. On the other side of the spectrum, the 
efficacy of a broad range of stem cells has been assessed in models of cisplatin-
induced acute kidney injury in rats (summarized in Table 5.4). Regardless of the origin 
of the cells, either rat or human, common results of all those studies include: i) 
amelioration of the renal function, assessed by serum creatinine and/or BUN; ii) 
engraftment of the cells in the damaged kidneys; iii) improvement of the renal 
histology; iv) increase of proliferation markers and/or decrease of apoptotic markers 
in the acute phase of the injury. Also, lipophilic dyes, such as PKH26, were used to 
label the cells before their intravenous administration into the animals.  
In this study, a novel transcutaneous device was used. It was instrumental for two 
reasons. Firstly, it permitted non-invasive measurements of the renal function 
throughout the length of the study. Also, it allowed a pre-screening of the animals so 
that only animals that did develop some sort of damage were used in the control or 
cell-treated group. In the perspective of a preclinical study of regenerative medicine 
therapies, it is paramount to assess the validity of the damage to avoid wasting 
precious human cells and prevent misleading and non-informative results. It is also 
true that the model chosen, being acute, allows this kind of precautions to be put in 
place. In contrast, models of progressive chronic kidney injury do not concede the 
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same freedom, since first signs of damage can be appreciated several days after the 
induction of the damage.  
By using the device, at the peak of damage (day7), an amelioration of the renal 
function of at least 50% in both cell-treated groups compared to controls was 
reported and supported by the concomitant reduction of azotemia (Figure 5.3 and 
Figure 5.4). By day 14, the differences between the control and the cell-treated groups 
were attenuated, corroborating the onset of an offsetting regenerative response in 
the host epithelium in the control animals after damage (Humphreys, 2014; Kusaba et 
al., 2014). To a certain extent, the results provided here are consistent with a number 
of studies that point towards the beneficial effect of human CD133+ cells in vivo [see 
(Bussolati and Camussi, 2015)]. Unexpectedly, CD133- cells provided the same sort of 
functional benefit to the animals, contrary to what has been shown in other models of 
AKI (Angelotti et al., 2012; Sagrinati et al., 2006). Therefore, the lack of CD133 on the 
renal cells did not compromise the success of the cell therapy, posing its relevance 
into question.  
With the aim of extending the panel of non-invasive biomarkers to monitor the 
renal function, Cystatin-C and Tim-1 were measured in the urine. Both biomarkers are 
regarded as promising in clinical practise for a major stability and increased sensitivity 
than serum creatinine (Baxmann et al., 2008). In this study, both markers reflected the 
damaged status of the kidney, rising considerably above the baseline levels upon renal 
impairment. However, the injected cells failed to reduce the levels of both biomarkers 
in the urine at any time point. Urinary Cystatin-C emerged as marker of acute kidney 
injury in the urine (Conti et al., 2006; Herget-Rosenthal et al., 2004; Uchida and Gotoh, 
2002). To date, the dynamics of both Cystatin-C and Tim-1 have been investigated in 
preclinical disease models and in patients with kidney diseases, but not in preclinical 
models of regenerative medicine therapies (Song et al., 2009; Vaidya et al., 2006). 
Only in one study, human renal-derived erythropoietin-containing cells injected in a 
chronic kidney model led to a reduction in the levels of Kim-1 (Yamaleyeva et al., 
2012). Importantly, a sustained expression of Kim-1 has been recently associated with 
renal fibrosis (Humphreys et al., 2013), opening some speculations about the long 
term effects of the high levels of Kim-1 seen in this study.  
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To sum up, at the peak of damage, some markers pointed towards a beneficial 
effect of the cells on renal function (Table 5.3). Most importantly, the two cell types 
did have comparable therapeutic effects on the model. Alongside, the data indicate 
that by day 14 the damage is not completely resolved (Figure 5.1and Table 5.2), not 
even in the cell-treated groups. It can be expected that the cells would have an impact 
on the renal health in the long term, as evidenced by the higher levels of 
microalbuminuria in control animals at day 14 compared to the cell -treated groups. 
Future research would need additional end points to investigate the dynamics of all 
markers, to monitor the eventual progression to chronic disease, and to assess the 
role of the human cells in the long term. 
TABLE 5.3 SUMMARY OF THE THERAPEUTIC EFFECTS EXERTED BY BOTH CELL TYPES (CD133+ AND 
CD133-) COMPARED TO THE CONTROL GROUP.  
All entries are relative to the acute phase of the damage (day 7), making exception for 
Albumin-to-Creatinine ratio (ACR), Histological Damage and Fibrosis.  * difference observed at 
day 14; # difference not significant;       = no difference. 
 
The histology data confirm a major impact of the cells on the renal architecture. 
Typical features of renal damage, including flat epithelia and dilated tubuli, were 
qualitatively and quantitavely reduced in the cell-treated groups (Figure 5.6). Notably, 
the values measured with the transcutaneous device could be correlated with the 
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luminal dilation, suggesting its potential use as predictive tool  to infer the severity of 
the renal damage. Although this finding needs to be supported by a larger number of 
samples, it would be of great value in the clinic.  
Despite the histological improvements, no difference in fibrosis between the 
groups was detected at day 14. Fibrosis is the result of a cascade of events that take 
time to shape the tissue architecture. In fact, Peng and colleagues, reported a 
decrease in the fibrotic area as a consequence of the injection of umbilical cord-
derived MSCs six weeks after cisplatin administration (Peng et al., 2013). However, 
Angelotti and colleagues reported marked differences in renal fibrosis already after 15 
days in a mouse model of rhabdomyolisis (Angelotti et al., 2012). The onset of fibrosis 
is most probably model-dependent and determined by the severity of the model used. 
Having found that both cell types positively impacted on renal health, a crucial 
question was posed about whether the human CD133+ cells homed to the kidneys 
after intravenous administration, as previously reported (Angelotti et al., 2012; 
Grange et al., 2014a; Ronconi et al., 2009). In these studies, exogenous dyes, such as 
PKH26, were used to label and subsequently track the cells. The lipophilic nature of 
the dye implies its retention in extracellular vesicles released from the cells , in 
addition to its loss upon division. In fact, lipophilic dyes have been extensively used to 
label specifically extracellular vesicles before administration (Bruno et al., 2009; 
Cantaluppi et al., 2012; Imai et al., 2015). Once in vivo, the transplanted cells are 
exposed to an incredibly dynamic environment that might stimulate them to deliver 
specific signals (including proteins and miRNAs) through the release of paracrine 
factors, specifically extracellular vesicles (EVs). EVs are vesicles of 40-100 nm of 
diameter released by many types of cells. The vesicles originate from the budding of 
cell membrane and carry protein, lipids, mRNA, miRNA and non-coding RNAs (Raposo 
and Stoorvogel, 2013). mRNAs and miRNAs are particularly important, because 
involved in transcription, cell proliferation and immune regulation, delivering a 
complex set of messages to the target cells. In the kidney, MSCs-derived vesicles 
promoted tubular regeneration and protected tubular cells from apoptosis in AKI 
models, homing to the affected organ (Bruno et al., 2012; Bruno et al., 2009; Gatti et 
al., 2011; Grange et al., 2014b). If the cells are labelled only with these dyes, the EVs 
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might entrap the dye during their biogenesis. In this study, it was preferred to 
accompany the exogenous label PKH26 with a genetic tag (GFP) to track the living cells 
and their by-products. By doing so, it was demonstrated that no living cells were 
present at day 14 in the kidneys or in the lungs. However, PKH26 staining was 
observed in both kidneys and lungs, indicating the passage of the cells through the 
lungs and maybe through the kidneys or the release of paracrine factors released from 
the cells containing PKH26. This study reports conflicting results compared to a broad 
range of studies where lipophilic-like dyes were spotted in the kidneys. A common 
conclusion of all the studies that use PKH26 as only labelling agent is that human cells, 
either CD133+ or not, efficiently homed to the affected organ (Angelotti et al., 2012; 
Gupta et al., 2015; Qi and Wu, 2013; Sagrinati et al., 2006).  
To shed light on the fate of the human cells , rats that received CD133+ cells were 
sacrificed 1, 6 and 24 hours after IV administration. The results unequivocally 
demonstrated the presence of human cells in the lungs 1 hour after the injection, as 
determined by both the GFP and the PKH26 staining (Figure 5.11). The appearance of 
the nuclei leads to believe that the cells are undergoing apoptosis. However, 24 hours 
after the injection, the human cells disappeared. In the kidneys, only some spots of 
PKH26 were visible in the interstitial cells, and no GFP staining was found (Figure 5.11 
and Figure 5.12). It seems plausible to believe that the cells got trapped in the 
network of thin capillaries of the lungs. Since they still showed efficacy in improving 
kidney function and architecture, it can be speculated that EVs were released by the 
human cells while trapped in the lungs. This would explain the presence of PKH26 
staining in the kidneys and lungs in the two-week study. More investigations are 
needed to understand the fate of the cells or their by-products soon after injection. 
On logical grounds, how would a human cell get to the tubuli/glomeruli? Would that 
take place through the interstitial capillaries or through the glomerular filtration 
barrier? In the glomeruli, it might be reasoned that the cells get stuck in the 
glomerular capillaries. However, how the cells might get into the tubuli might be 
physiologically more complicated and need an in-depth investigation. Imaging 
technologies for preclinical models are bridging that gap of knowledge about the in 
vivo biodistribution of the cells after IV injection. Bioluminescence is one of those 
technologies that allow this type of investigations (Heslop et al., 2015). MSCs injected 
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in an AKI model were seen in the lungs after IV injection, and in the kidneys after intra -
arterial injection (Togel et al., 2008). Or, in a mouse model of cerebral hypoxia-
ischemia, it was shown that IV-injected multipotent neural stem cells did not reach the 
brain. Instead, they stopped in the lungs and were cleared within 7 days (Pendharkar 
et al., 2010).  
On the basis of the abnormal morphology of the human cells observed in the lungs 
one hour after injection, we propose that they die. This would explain the paucity in 
GFP signal 6 and 24 hours after the injection, while the PKH26 signal persists. It was 
hypothesised that phagocytic cells, identified through the presence of CD68, might 
play an important role in the disappearance of the human cells  (Ferenbach and 
Hughes, 2008). The analysis revealed that 1 hour after the injection CD68-positive cells 
grouped around the human cells in the lungs, while from 6 hours onwards, clusters of 
CD68 positive cells were observed around remnants of GFP-positive (Figure 5.13). It 
was then speculated that the human cells died and thereby attracted macrophages, 
which in turn phagocytosed the human cells, leaving just GFP-positive fragments 
behind. It cannot be excluded that the injected cells could be susceptible to cisplatin, 
and might die following uptake of cisplatin while in the circulation. This hypothesis, 
however, would imply the presence of cisplatin into the circulation 2 days after the 
induction of the damage. By that time point, the evidence of damage would suggest 
that the drug reached the kidneys, where it exerted its nephrotoxic action during its 
excretion. Nevertheless, the susceptibility of kidney-derived cells has not been tested 
in this study, so it cannot be ruled out completely. 
While dying, apoptotic cells expose phosphatidylserine (PtdSer) on the outer 
surface of the cell membrane. PtdSer is generally recognised as one of the so-called 
“eat me” signals that triggers the engulfment of the dying cell by phagocytosis through 
specific PtdSer receptors, including TIM-4, BAI 1, and Stabilin-2. Macrophages were 
shown to be attracted by PtdSer on the apoptotic cell surface and to secrete anti-
inflammatory cytokines following the phagocytosis (Fadok et al., 1992). In vivo, PtdSer-
carrying liposomes were uptaken by either resident or circulating macrophages after 
IV injection in a rat model of MI (myocardial infarction), attenuating inflammation in 
the infarcted area and improving cardiac function (Harel-Adar et al., 2011). Thum and 
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colleagues postulated the hypothesis that apoptotic cells could be used in myocardial 
infarction models to stimulate macrophages to secrete anti-inflammatory cytokines, 
such as IL-10 and TGF-β. These cytokines would suppress the expression of pro-
inflammatory cytokines, such as TNF-α, IL6 and IL-1β, in the infarcted area (Thum et 
al., 2005). This hypothesis could be applied ideally to any type of tissue, and it might 
explain the functional renal amelioration observed in the model used in this study 
even if a concrete proof of integration of the human cells is missing. A plethora of 
signals might be involved in the cross-talk between the dying cells and the 
macrophages; some of these molecules are on the inner or outer membrane of the 
dying cell while others are released into the circulation (Hochreiter-Hufford and 
Ravichandran, 2013; Poon et al., 2014). 
The fact that both injected cell types in this study reduce the acute phase of the 
damage may indicate that the apoptotic phase induced by cisplatin is prevented or 
quickly remediated. As mentioned, the ability of transplanted cells to foster 
proliferation of the host epithelium was the proposed mechanism of action of several 
types of stem cells injected (see Table 5.4). In this study, the proliferation profile at 
day 14 showed a higher number of dividing cells in the control group than the cell -
treated groups. It can be speculated that the human cells provided an extra help for 
the regeneration of the host epithelium earlier in the timeline, so that by day 14 there 
are less proliferating cells in the cell-treated groups. This speculation would benefit 
from an intermediate end point for the histological analysis. 
To conclude, in this study, the injection of both CD133+ and CD133- cells into the 
tail vein of animals with AKI led to the reduction of the blood levels of functional 
biomarkers (HL-Sin, serum creatinine, BUN) and the preservation of the renal tissue. 
Those features were not accompanied by a conclusive evidence of the engraftment of 
the cells into the renal tissue. Instead, intact human cells were spotted in the lungs 
soon after injection, but not at the end of the study. In contrast, PKH26 signal was 
observed in lungs and kidney in both the biodistribution and two-week study. It is 
therefore proposed that PKH26 is not a reliable marker for the in vivo tracking of 
transplanted cells. In the lungs, CD68-expressing cells were seen in close proximity to 
human cells already 1 hour after cell injection, leading to believe that macrophages 
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might be involved in the phagocytosis of the human cells. It can be postulated that the 
amelioration of the renal function was partially mediated by the extracellular vesicles 
released from the human cells and partially by the release of anti-inflammatory 
cytokines from the macrophages while phagocytising the human cells in the lungs. 
Both hypotheses need further investigations, in the view of their great implications in 
simplifying cellular therapies in the clinical setting.  
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TABLE 5.4 COMPARATIVE TABLE OF ALL STUDIES FOUND IN LITERATURE USING RAT CISPLATIN-INDUCED ACUTE KIDNEY INJURY MODELS. ALL STUDIES REPORTED USE SD RATS.  
Dose 
of Cis 
Cells used Are cells in the 
kidney? 
Are the 
lungs 
analysed
? 
End 
points D 
(D post 
injection
) 
Cell-treated group versus control group Ref 
Type 
(species) 
Num. 
Cell 
label 
Day of 
injection 
post CDP 
Injectio
n route 
sCr and 
BUN 
Attenuation 
of structural 
damage 
Apoptoti
c 
markers 
Proliferatio
n markers 
7 
mg/Kg 
Fetal 
kidney 
stem 
cells (rat) 
2 x 106 
PKH26+ 
D5 IV PKH26 found 
in the kidneys, 
overlays with 
AQP1 
No D5 (0) = vs ctrl N/A N/A N/A (Gupta 
et al., 
2015) No D8 (3) ↓ vs 
ctrl 
Yes ↓ vs ctrl ↑ vs ctrl 
No D12 (7) ↓ vs 
ctrl 
Yes ↓ vs ctrl ↑ vs ctrl 
6 
mg/Kg 
BM MSC 
(rat) 
1 x 106 
PKH26+ 
D4 IV PKH26 found 
in the 
peritubular 
cells 
No D8 (4) ↓ vs 
ctrl 
Yes ↓ vs ctrl ↑ vs ctrl (Qi and 
Wu, 
2013) 
6 
mg/kg 
UC MSC 
(human) 
2 x 106 
CM-Dil 
D1 IV CM-Dil found 
in the kidneys 
4 weeks after 
injection 
No D5 (4) ↓ vs 
ctrl 
Yes ↓ vs ctrl ↑ vs ctrl (Peng et 
al., 2013) 
W6 = vs ctrl Fibrosis 
attenuated 
Anti-
apoptoti
c 
proteins 
↑ vs ctrl 
N/A 
10 
mg/Kg 
Ad-MSC 
(human) 
5 x 105 
BrdU 
D1 IV Yes, in tubular 
epithelial cells 
No D3 (2) ↓ vs 
ctrl 
Yes ↓ vs ctrl N/A (Kim et 
al., 2012) 
Abbreviations: BM-MSC Bone Marrow-derived Mesenchymal Stem cells; UC-MSC Umbelical Cord-derived Mesenchymal Stem Cells; Ad-
MSC Adipose tissue-derived Mesenchymal Stem Cells; BrdU Bromodeoxyuridine; D day; W week; IV intravenous injection; N/A Non Applicable
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6 CONCLUSIONS  
In the past decade, several studies investigated the presence of renal progenitor 
cells in the adult kidney. In most of those studies, CD133 was the marker of choice to 
isolate this population. The CD133+ renal progenitor cells displayed i) a significant 
proliferation and clonogenic potential in vitro, ii) notable plasticity in vitro, being able 
to differentiate in different cell types, both renal and extra-renal, iii) amelioration of 
renal function and tissue structure following injection into preclinical models of kidney 
injury, allegedly led by the engraftment of the cells in the host tissue (Angelotti et al., 
2012; Bussolati et al., 2005; Bussolati et al., 2013; Grange et al., 2014a; Ronconi et al., 
2009; Sagrinati et al., 2006).  
In this chapter, the key findings of each part of this thesis will be summarized and 
put into the context of a possible clinical translation of the cell therapy using CD133+, 
where possible. Figure 6.1 summarizes the key points that emerged from each step of 
the project.  
In this thesis, the general aim was to investigate the presence of CD133+ cells in 
human kidneys obtained from children. In the samples used in this study, the 
localization of CD133 corroborated previous studies where CD133 was expressed by 
the cells of the Bowman’s capsule, defined Parietal Epithelial Cell (PEC), and by 
scattered tubular cells (Angelotti et al., 2012; Ronconi et al., 2009). Once the correct 
anatomical location of the CD133+ cells was confirmed, a population of renal cells was 
isolated and plated, without selecting at passage 0 for the CD133+ cells, as it has been 
reported (Bussolati et al., 2005; Ronconi et al., 2009; Sagrinati et al., 2006).  
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FIGURE 6.1 SCHEMATIC SUMMARY OF THE KEY POINTS IDENTIFIED IN THIS THESIS. 
In this scheme, all relevant phases of this thesis about the use of CD133+ as therapeutics are 
shown.  Each part of the project provided significant insights into possible hurdles of CD133+-
cell based therapies. The drawbacks are particularly evident for the in vitro section, where the 
CD133+ were shown to be heterogeneous in their surface marker profile. When the cells were 
tested for their ex vivo engraftment and in vivo amelioration potential, some congruence was 
observed: the human cells die within few days in the mouse/rat environment. Nevertheless, 
both CD133+ and CD133- cells improved renal function and tissue architecture. This suggests a 
role for paracrine factors or apoptotic cells as modulators of the damage, possibly through 
immunomodulation. It is important to note that these are just speculations and require 
further study. 
The observations of the renal cells in vitro led to key conclusions: 
At passage 1, most of the renal cells expressed CD133, although in vivo the 
amount of CD133+ was reported to be between 0.5% and 4% (Bussolati et al., 2005). 
Whether this extensive expression was determined by a more sustained proliferation 
of the CD133+ cells that quickly took over in culture or by the acquisition of the marker 
as adaptation to the culture conditions could not be established with the experiments 
shown in this thesis.  
A significant proportion of the CD133+ cells expressed CD13, a marker of proximal 
tubule cells. This finding indicates that the isolation protocol and/or the culture 
 185 
 
conditions used in this study led to the differentiation of the renal progenitors 
towards a proximal tubular fate or allowed the enrichment of a population of fully 
differentiated proximal tubule cells that acquired CD133 in culture.  
The CD133+ population is highly heterogeneous. This heterogeneity resonated with 
the presence of several subpopulations, most notably expressing epithelial markers 
(CD24), putative progenitor markers (NCAM/Tra-1-60) or fully differentiated renal cell 
markers (CD13). To provide a more comprehensive characterization, the CD133- cells 
were analysed as negative control population alongside for the same surface markers. 
Interestingly, the two populations failed to show remarkable differences regarding 
surface markers (Table 3.2, Results chapter 3). Once again, the lack of a distinct profile 
for the CD133+ cells might be due to the culture conditions that preconditioned the 
bulk population. The heterogeneity of the CD133+ population could have potentially 
been addressed if the population had been purified after the isolation, as previously 
done by the seminal studies about CD133+. Experimentally, the two approaches 
should be compared to select the method that guarantees the highest purity and 
homogeneity.  
Each CD133+ cell line isolated from a different donor showed different population 
doubling times, possibly reflecting the age or the health status of the donor. 
If the final aim is to devise a cellular therapy using primary CD133+ cells as 
therapeutics, several challenges which could hamper the translation of the therapy in 
clinical settings need to be factored into the risk-benefit analysis of such therapies. 
Firstly, the procedure to obtain a renal biopsy is invasive, and the tissue biopsy is quite 
small. Alternatively, full kidneys can be used to isolate some cells. However, due to the 
shortage of kidneys, autologous therapies as alternative might be quite unrealistic. 
Secondly, the approach used to purify the CD133+ cells, whether directly after 
dissection or after one passage in culture, might assure an adequate number of cells. 
As shown in this study, plating the cells and select for CD133 afterward resulted in a 
high number of CD133+ cells, but the heterogeneity of the population could be a 
drawback. Also, cell lines obtained from patients with underlying renal conditions 
might behave differently in vitro. In this study, for example, CD133+ cells isolated from 
two patients (hK5, hK4) could not be serially expanded. Therefore, a therapy using 
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CD133 cells might require a case-by-case assessment and in some cases a contingency 
plan, such as an allogeneic cell therapy, needs to be readily available.  
Although impressive progress has been made to understand the real potential of 
this population, in vitro as in vivo, the use of these cells as therapeutics and their 
translation to the clinic is still elusive. Some lessons can be learnt from the therapies 
that use mesenchymal stem cells. At the moment, there are no active clinical trials 
where stem cells are used in patients with acute kidney injury (clinicaltrial.gov – April 
2016). Interestingly, one study which is currently recruiting participants, will use 
mesenchymal stromal cells in patients with solid organ cancers  affected by cisplatin-
induced acute renal failure (NCT01275612). This trial would represent an explorative 
dose-finding study to establish safety and efficacy of autologous MSC transplantation. 
Initially, the cells will be isolated, expanded ex vivo and reinfused systemically in the 
patient at a concentration of 106 cells per Kg of Body Weight. From there, the amount 
of injected cells will be escalated accordingly. Serum creatinine and NGAL and NAG 
will be the biomarkers evaluated. The enormous amount of cells needed for in vivo 
human cell therapy at the moment might not be compatible with the amount of 
CD133+ cells that can be isolated from a renal biopsy. More exploratory and 
comprehensive studies need to be performed to understand the scalability of the cell 
therapies from preclinical to clinical settings.  
After phenotyping, the isolated cells were tested for their potential to differentiate 
into a specialized renal cell, such as podocytes. Despite their extensive use in several 
studies, the differentiation conditions failed to provide successful insights into the 
potential of the renal cells in this study. Nevertheless, preliminary results showed the 
upregulation of podocytic markers, such as podocin and nephrin, following stimulation 
of both CD133+ and CD133- cell types with Retinoic Acid. 
The ex vivo reaggregation assay was then used to investigate the engraftment of 
the human CD133+ and CD133- cells into developing embryonic renal structures. Key 
findings from the ex vivo assay include: 
Most of the human cells died over the first three days. The difference between the 
rudiments at day one and day three after the start of the assay is striking and indicates 
that either the human cells failed to have the right conditions to proliferate or even 
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survive in the system, or that there were death signals released by the mouse cells 
that impacted on the human cell survival. 
The few cells that survived at day 3 and 6 failed to show any engraftment, and if 
they did, it would be more plausible to consider it a stochastic integration.  
So far, the reaggregation assay using human cells has been proved successful only 
when using nephron progenitor cells obtained after differentiation of hESCs or hiPSCs 
(Takasato et al., 2014; Xia et al., 2013). Human somatic stem cells, such as 
mesenchymal stem cells or amniotic stem cells, failed to engraft in large number 
unless genetically modified to express GDNF (Kuzma-Kuzniarska et al., 2012; Xinaris et 
al., 2015). This evidence strongly indicates that the main issue is not the species of the 
cell of interest, but the type of cells that are mixed with the mouse cells. Nephron 
progenitor cells or cells expressing GDNF can actively participate in the development 
of the structures, probably because they can release/receive the appropriate signals 
during the shaping of the structures.   
Beyond the isolation of a viable population of CD133+, a significant milestone was 
to test the therapeutic effect of these cells in immunodeficient rats with acute kidney 
injury induced by cisplatin.  
Both CD133+ and CD133- positively impacted on the renal health of the rats. The 
degree of amelioration was comparable for the two cell types and was corroborated 
by conventional serum biomarkers and the half-life of FITC-Sinistrin as a measure of 
GFR using the transcutaneous device. This effects might be explained by two 
mechanisms: i) there is a progenitor population that is common to the CD133+ and 
CD133- populations; or ii) fully differentiated cells are somehow able to improve renal 
function. Clearly, more mechanistic studies are needed to elucidate how the 
amelioration takes place. However, the data indicate that any renal cell type 
independent of CD133 expression shows efficacy, eliminating all problems related to 
purification, phenotyping, and expansion of a specific population.  
The intravenous injection of the human cells led to an accumulation of the cells in 
the lungs and not in the kidneys. It is not surprising that the cells were found in the 
lungs soon following injection. In our group, further experiments were conducted 
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using the primary CD133+ and CD133- cells transduced with a luciferase construct to 
facilitate in vivo bioluminescence imaging. Once injected IV in SCID mice affected by 
Adriamycin-induced nephropathy, the cells accumulated in the lungs (Figure 6.2). 
 
FIGURE 6.2 BIOLUMINESCENCE IMAGING OF HUMAN CD133+ AND CD133- CELLS INJECTED INTO 
SCID MICE AFFECTED BY ADRIAMYCIN-INDUCED CHRONIC KIDNEY INJURY. 
Both CD133+ and CD133- cell populations were transduced with a Luciferase lentivirus after 
sorting and injected at passage five into SCID mice with chronic kidney disease induced by 
Adriamycin. 750 thousand cells were injected into each mouse through the tail vein. The 
bioluminescence was measured 30 minutes after injection. Luciferin was injected 15 minutes 
before the imaging. In this panel, two animals per cell type are shown. Image courtesy of 
Lauren Scarfe (University of Liverpool). 
 Most of the studies that employed renal progenitor cells in vivo did not use any 
imaging technology able to track the cells. Instead, the tracking was often entrusted to 
the PKH26 only. In light of the findings shown in this thesis, all studies that show 
PKH26 labelling in the kidneys after IV injection could be interpreted differently: the 
cells might release extracellular vesicles that entrap PKH26 within the lipidic shell and 
reach the affected organ. In chapter 5, the absence of GFP + cells in the kidney and the 
presence of sporadic PKH26 labelling in the shape of vesicles in the kidneys was 
shown. In the lungs, the release of what can be interpreted as vesicles retaining PKH26 
was even more evident, as the GFP+/PKH26+ cells were clearly identifiable at 1 and 6 
hours after injection, whereas at 24 hours only PKH26 was left. This piece of evidence 
leads the next key finding. 
The cells in the lungs disappeared within 24 hours from the injection. At 24 hours 
after the injection, there was no evidence of intact cells in the lungs or the kidneys. 
However, as already mentioned, the fact the PKH26 was found in the lungs at 24 hours 
might indicate that the cells stayed there at least for some hours; and, since the cells 
CD133+ (IV) CD133- (IV)
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were not retrieved in the kidneys either, it is plausible that they died in the lungs. The 
disappearance of the human cells in less than 24 hours might be determined by the 
phagocytic activity of macrophages, identified through the expression of CD68. The 
distribution of the CD68+ cells appeared to be affected by the distribution of the 
human cells in the lungs. In fact, already after one hour, macrophages were seen in 
close proximity of the human cells. By 24 hours, clusters of CD68+ cells were identified 
in the lungs, where no human cells could be spotted. In vitro co-cultures of intact 
primary cells with macrophages could further elucidate the mechanisms of interaction 
and show if a phagocytosis of the cells takes place. This experiment could be brought 
even a step further by studying co-cultures of primary apoptotic cells with 
macrophages.  
The use of apoptotic cells in therapies is not a new concept. Numerous studies 
have studied the effects of apoptotic cell injections, mainly splenocytes, in cardiac and 
bone marrow transplantation. Apoptotic cells, on one side, down-modulate 
inflammation and immunity, and, on the other hand, modulate the functions of 
antigen presenting cells (dendritic cells and macrophages) and their 
immunoregulatory potential, following phagocytosis (Morelli and Larregina, 2010). 
Overall, the use of apoptotic cells to modulate the renal damage could be an exciting 
avenue for future therapies, once their efficacy is proven.  
To conclude, this study indicated that CD133+ cells might not be the best 
therapeutics for therapies for renal diseases. Instead, the study of systems that 
modulate these cells in vivo would be more appealing as recent studies suggest 
(Lasagni et al., 2015). Also, the present thesis enlightens two possible scenarios for 
future research: the use of extracellular vesicles and their eventual modulatory 
properties, and the use of apoptotic cells to stimulate anti-inflammatory responses 
within the animal. The first scenario appears to be promising, as demonstrated by the 
studies of EVs released from MSCs used in preclinical models of AKI (Bruno et al., 
2012; Bruno et al., 2009).  
While the debate about the existence of renal progenitor cell population will 
continue for a long time to come, one aspect requires  attention now: the patient. 
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